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 Zusammenfassung 
 
 Die m-AAA-Protease ist ein ATP-abhängiger proteolytischer Komplex in der inneren 
Mitochondrienmembran, der eine wichtige Rolle bei der Qualitätskontrolle mitochondrialer 
Proteine und bei der Regulation der Ribosomen-Assemblierung spielt. Mutationen in 
Paraplegin, einer Untereinheit der humanen m-AAA-Protease, führen zu hereditärer 
spastischer Paraplegie (HSP). Diese Krankheit ist durch eine zellspezifische Degeneration von 
Axonen gekennzeichnet, die auch in Paraplegin-defizienten Mäusen auftritt. Es wird 
vermutet, dass Paraplegin die proteolytische Prozessierung von OPA1 vermittelt. OPA1 ist für 
die Aufrechterhaltung der mitochondrialen Morphologie essentiell und wird mit dominanter 
optischer Atrophie, einer weiteren neurodegenerativen Erkrankung, in Verbindung gebracht. 
Paraplegin bildet zusammen mit homologen Afg3l2-Untereinheiten einen heterooligomeren 
Proteinkomplex. Die Auswirkungen eines Verlustes von Paraplegin auf die Assemblierung 
und Funktion der m-AAA-Protease sind jedoch unklar. Des Weiteren wird eine dritte 
mutmaßliche Untereinheit der m-AAA-Protease, Afg3l1, in Mäusen exprimiert, aber ihre 
Rolle für die Aktivität der m-AAA-Protease ist noch nicht bestimmt worden. 
 Der Assemblierungszustand von humanem AFG3L2 wurde in Paraplegin-defizienten 
Mitochondrien aus humanen HSP-Zellen untersucht. Dadurch konnte die Existenz eines 
homooligomeren AFG3L2-Komplexes nachgewiesen werden, der auch bei heterologer 
Expression in Hefe gebildet wurde. Dieser AFG3L2-Komplex ist proteolytisch aktiv, da er die 
m-AAA-Protease der Hefe ersetzen konnte. Weitere Komplementationsstudien in der Hefe 
ergaben, dass die m-AAA-Protease-Untereinheiten der Maus in der inneren Mitochondrien-
membran verschiedene proteolytische Komplexe mit unterschiedlicher Zusammensetzung 
bilden. Homooligomere Afg3l1- und Afg3l2-Komplexe sowie heterooligomere Komplexe 
beider Proteine zusammen mit Paraplegin konnten identifiziert werden. Afg3l1 stellt somit 
eine echte Untereinheit von m-AAA-Proteasen mit proteolytischer Aktivität dar. Alle 
Komplexe weisen konservierte und überlappende Substratspezifitäten auf, da sie 
grundlegende mitochondriale Funktionen aufrechterhalten konnten. Diese Ergebnisse lassen 
vermuten, dass die Abwesenheit von Paraplegin nicht zu einem vollständigen Verlust der m-
AAA-Protease-Aktivität in betroffenen Mitochondrien führt. Stattdessen könnten m-AAA-
Proteasen mit unterschiedlicher Untereinheiten-Zusammensetzung gebildet werden und m-
AAA-Proteasen mit Paraplegin-Beteiligung ersetzen. Durch die Rekonstitution der OPA1-
Prozessierung in Hefezellen, die verschiedene m-AAA-Protease-Komplexe aus Säugetieren 
enthielten, konnten erste Hinweise für unterschiedliche Substratspezifitäten von m-AAA-
 Proteasen mit unterschiedlicher Zusammensetzung erhalten werden. Die Effizienz der OPA1-
Prozessierung war abhängig von der Zusammensetzung der Untereinheiten der Säugetier-m-
AAA-Proteasen. Homooligomere Komplexe bestehend aus murinem Afg3l1, Afg3l2 oder 
humanem AFG3L2 prozessierten OPA1 mit höherer Effizienz als heterooligomere Komplexe, 
die Paraplegin enthielten. Diese Ergebnisse bestätigen, dass OPA1 ein weiteres potentielles 
Substrat der m-AAA-Protease darstellt. Die Befunde dieser Arbeit offenbaren eine 
unerwartete Vielfalt an m-AAA-Proteasen in der inneren Mitochondrienmembran von 
Säugetieren und könnten dazu beitragen, die Pathogenese und Gewebespezifität von HSP zu 
verstehen.
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1 Introduction 
 
1.1 The proteolytic system of mitochondria 
 
 Cell survival critically depends on the integrity and functionality of mitochondria. 
These organelles evolved from an endosymbiontic relationship of aerobic bacteria and 
primordial eukaryotic cells and are the major energy production site in “modern” eukaryotic 
cells (Wallace, 2005). Besides oxidative phosphorylation, crucial activities in intermediary 
metabolism, calcium signalling, and cell death pathways highlight the central role of 
mitochondria for cellular physiology (Chan, 2006a; McBride et al., 2006). In agreement with 
the multitude of cellular functions, mitochondrial dysfunction is thought to contribute to 
cellular ageing and plays an important role in human diseases, such as diabetes, cancer, and 
prevalent neurodegenerative disorders (Chan, 2006a; Kwong et al., 2006; Lin and Beal, 
2006). Moreover, a number of rare genetic diseases are caused by mutations in mitochondrial 
proteins (DiMauro, 2004; Taylor and Turnbull, 2005; Schapira, 2006). 
 It is therefore an important cellular task to ensure correct mitochondrial biogenesis and 
maintain mitochondrial activities under varying physiological conditions. Mitochondria are 
built up of ~1000 proteins (Mootha et al., 2003; Sickmann et al., 2003; Taylor et al., 2003). 
The vast majority of them are nuclearly encoded, synthesised on cytosolic ribosomes, and 
imported into mitochondria. However, a small number of mitochondrial proteins, almost 
exclusively subunits of respiratory chain complexes in the inner membrane, are encoded by 
the mitochondrial genome (Anderson et al., 1981; Foury et al., 1998). They must assemble 
with nuclearly encoded subunits to constitute a functionally active respiratory chain and to 
allow oxidative phosphorylation. Maintenance of mitochondrial activities therefore depends 
on the coordinated expression of two cellular genomes. Moreover, this task is made even 
more difficult by the fact that mitochondria are highly dynamic organelles. They undergo 
constant fusion and fission and frequently change their shape in response to altered 
physiological conditions (Okamoto and Shaw, 2005). 
 Mitochondria must be able to eliminate excess, non-assembled polypeptides to avoid 
potential deleterious effects on organellar functions. Elaborate proteolytic systems which 
conduct the quality surveillance of mitochondrial proteins are present within different 
subcompartments of the organelle. A number of these proteases also exert essential 
housekeeping functions and control crucial steps during mitochondrial biogenesis. Many of 
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them are highly conserved and ubiquitously distributed in eukaryotic cells. They can be 
categorised into several classes according to their main activities (Fig. 1; Tab. 1): 
 
 
Table 1. Mitochondrial peptidases. 
Name Loc. Yeast Function in  
yeast 
Mammals Function in 
mammals 
     
Processing Peptidases
     
MPP  M Mas1 
Mas2 
Presequence cleavage α-MPP 
β-MPP 
See yeast 
MIP  M Oct1 Removal of 
octapeptides 
MIPEP  
(HMIP) 
See yeast 
IMP  IM Imp1 
Imp2 
Presequence cleavage IMMP1L 
IMMP2L 
Unknown 
 IMS Atp23 Atp6 processing and 
assembly 
KUB3 Unknown 
Rhomboid  IM Pcp1 Ccp1 and Mgm1 
processing 
PARL Protection against 
apoptosis 
     
ATP-dependent proteases
     
i-AAA IM Yme1 Quality control YME1L1 Unknown 
m-AAA IM Yta10 
Yta12 
Quality control, 
protein processing, 
membrane dislocation 
paraplegin 
AFG3L1* 
AFG3L2 
Quality control, 
cleavage of MrpL32 
and OPA1 
Lon M Pim1 Quality control, 
mtDNA maintenance 
and gene expression 
LON Quality control, 
mtDNA binding 
ClpXP M    -  ClpP 
ClpX 
Quality control 
      
Oligopeptidases
      
 IMS Mop112 Degradation of pep-
tides and presequences 
PreP** Aβ degradation1
 IMS Prd1 Degradation of pep-
tides and presequences 
Neurolysin Peptide degradation  
 M Lap3 Aminopeptidase, 
protection against 
homocysteine2
Bleomycin 
hydrolase 
See yeast 
      
Other proteases
      
 IM Oma1 Quality control OMA1 Unknown 
 IMS    -  HtrA2 
(Omi) 
Pro-apoptotic, 
cleavage of β-APP 
      
*AFG3L1 is only expressed in mice but encoded by a pseudogene in humans. **Human PreP has been localised 
to the matrix. 1Falkevall et al., 2006. 2Zimny et al., 2006. 
Introduction 9
 
 
Figure 1. Proteolytic pathways within mitochondria of Saccharomyces. cerevisiae. 
Mitochondrial proteases can be functionally classified into processing peptidases, ATP-dependent 
proteases, and oligopeptidases. Proteins residing in the intermembrane space (IMS), the inner 
membrane (IM), or the matrix (M) can be degraded by the consecutive action of ATP-dependent 
proteases and oligopeptidases to amino acids. The oligopeptidases Prd1 and Mop112 have been 
demonstrated to degrade peptides generated by the i-AAA protease. Although oligopeptidases are 
present in the matrix, it remains to be determined which of them act in concert with ATP-dependent 
proteases during protein turnover. See text for details. OM, outer membrane. 
 
1.1.1 Processing peptidases 
 Sorting signals of nuclearly encoded proteins are removed by specific processing 
peptidases present within different subcompartments of mitochondria (Gakh et al., 2002). 
These enzymes generally exhibit rather degenerate sequence specificity and, in case of 
composite targeting sequences, can act sequentially. The mitochondrial processing 
peptidase MPP, a conserved hetero-dimeric metallopeptidase, cleaves off sorting sequences 
in the matrix space (Hawlitschek et al., 1988; Yang et al., 1988; Ou et al., 1989). Some 
mitochondrial precursor proteins are cleaved by a second processing peptidase in the matrix 
space (Kalousek et al., 1988). The mitochondrial intermediate peptidase MIP, a 
monomeric metallopeptidase, removes an octapeptide from preproteins after their processing 
by MPP (Isaya et al., 1991; Isaya et al., 1992; Kalousek et al., 1992). The physiological role 
of MIP cleavage is currently poorly understood; however, severe phenotypes upon gene 
inactivation in yeast and mice suggest important regulatory functions (Isaya et al., 1994; Gakh 
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et al., 2002). The so-called inner membrane peptidase IMP is located within the inner 
membrane but exposes its active sites to the intermembrane space of mitochondria (Gakh et 
al., 2002). This hetero-oligomeric complex is composed of a non-catalytic subunit, Som1, and 
two catalytic subunits containing serine/lysine dyads (Nunnari et al., 1993; Schneider et al., 
1994; Jan et al., 2000). IMP mediates the maturation of intermediate forms of several 
nuclearly encoded proteins generated by MPP in the matrix space (Daum et al., 1982; 
Nunnari et al., 1993; Burri et al., 2005), as well as mitochondrially encoded subunit 2 of 
cytochrome c oxidase (Cox2) (Pratje et al., 1983). 
 In addition to these generic enzymes, several other mitochondrial peptidases can act 
as processing peptidases and regulate the biogenesis of mitochondria. These include energy-
dependent AAA proteases, which are discussed in detail below, but also enzymes with 
apparently more specialised functions. The conserved metallopeptidase Atp23 cleaves off the 
presequence of the mitochondrially encoded subunit Atp6 of the F1FO-ATP synthase complex 
in the intermembrane space after its insertion into the inner membrane (Osman et al., 2007; 
Zeng et al., 2007). Independent of its proteolytic activity, Atp23 acts as a chaperone protein 
and promotes the assembly of Atp6 into the membrane-embedded FO-moiety of the ATP 
synthase complex (Osman et al., 2007; Zeng et al., 2007). A processing peptidase with a 
regulatory role for mitochondrial biogenesis is represented by the rhomboid protease in the 
inner membrane. Rhomboid proteases comprise a conserved family of membrane-embedded 
serine peptidases, which possess catalytic residues within their hydrophobic, membrane-
spanning domains and which generate soluble, biologically active protein fragments by 
cleaving membrane-anchored proteins within transmembrane segments (Urban, 2006). The 
yeast rhomboid Pcp1 cleaves the dynamin-like GTPase Mgm1 (Herlan et al., 2003; 
McQuibban et al., 2003; Sesaki et al., 2003a) and cytochrome c peroxidase (Ccp1), a 
mitochondrial scavenger of reactive oxygen species (ROS) (Esser et al., 2002). Mgm1 is a 
central component of the mitochondrial fusion machinery and accordingly Pcp1-mediated 
processing affects mitochondrial dynamics (Herlan et al., 2003).  
 
1.1.2  ATP-dependent proteases 
 Proteases powered by ATP have been identified in various subcompartments of 
mitochondria. They generally form multimeric protein complexes, which constitute 
sequestered, proteolytic microcompartments, and contain P-loop ATPase domains 
characteristic of the AAA+-family of ATPases (Sauer et al., 2004; Hanson and Whiteheart, 
2005). The energy derived from ATP-hydrolysis is utilised to unfold specific substrate 
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proteins and to transport them into this internal proteolytic cavity (Baker and Sauer, 2006). 
The importance of ATP-dependent proteases for mitochondrial functions is illustrated by 
severe phenotypes associated with the loss of these proteases in yeast (Van Dyck and Langer, 
1999). Although these phenotypes are understood on the molecular level only in a few cases, 
they appear to reflect two activities of the proteases: protein quality surveillance and 
proteolytic control of regulatory steps during mitochondrial biogenesis. Mitochondrial ATP-
dependent proteases are closely related to bacterial enzymes and can be assigned to highly 
conserved protease families, the Lon proteases, the Clp proteases, and FtsH-like AAA 
proteases (Fig. 1; Tab. 1). 
 The Lon protease (or PIM1 protease in yeast) is localised in the mitochondrial matrix 
space (Suzuki et al., 1994; Van Dyck et al., 1994; Wang et al., 1994). This serine protease 
forms homo-oligomeric complexes which, based on cryoelectron microscopy studies on 
purified PIM1 protease, represent flexible, ring-shaped heptamers (Stahlberg et al., 1999). 
The subunits are nuclearly encoded and synthesised in a prepro-form. After import into 
mitochondria, maturation and thereby activation of the subunits occurs in a two-step process: 
the mitochondrial targeting sequence is removed by MPP followed by protease assembly and 
autocatalytic cleavage of the pro-region (Wagner et al., 1997). The PIM1/Lon protease 
conducts protein quality control in the matrix space, a function which is of particular 
importance under stress conditions, when thermally denatured or oxidatively damaged 
proteins accumulate (Bota and Davies, 2002). The protease recognises misfolded or damaged 
proteins, mediates their complete proteolysis, and thereby prevents their accumulation and 
deleterious effects on mitochondrial activities. In addition to its function in protein quality 
control, regulatory functions of the Lon protease during mitochondrial biogenesis are 
suggested by phenotypes associated with the loss of PIM1 protease in yeast. Deletion of the 
PIM1 gene causes the destabilisation of the mitochondrial genome, impairs mitochondrial 
gene expression, and results in respiratory deficiency (Suzuki et al., 1994; Van Dyck et al., 
1994; Van Dyck et al., 1998a). Mitochondrial Lon proteases exhibit a peculiar binding 
affinity for nucleic acids pointing to a specific role of these proteases for DNA maintenance 
(Fu and Markovitz, 1998; Lu et al., 2003; Liu et al., 2004). It is conceivable that Lon 
proteases affect mitochondrial DNA (mtDNA) stability by complete proteolysis or by 
processing of a regulatory protein. The autocatalytic maturation of newly imported Pim1 
subunits in yeast illustrates that Lon proteases, like the m-AAA protease (see below), can 
indeed act as a processing peptidase. 
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 A second ATP-dependent protease, the ClpXP protease, is present in the matrix of 
mammalian mitochondria (De Sagarra et al., 1999; Santagata et al., 1999). This hetero-
oligomeric protease is built up of proteolytic ClpP subunits with serine peptidase activity and 
of ClpX subunits, which exert ATPase and, most likely, chaperone activity and confer 
substrate specificity to the complex (Kang et al., 2002; Kang et al., 2005). Notably, yeast 
mitochondria harbour only ATPase but no proteolytic ClpP subunits suggesting non-
proteolytic functions (Van Dyck et al., 1998b). The role of Clp proteases within mitochondria 
is currently not understood. The ClpP-mediated turnover of a misfolded model substrate and 
the increased expression of ClpP under cellular stress in mammalian cells suggest a similar 
role of mitochondrial Clp and Lon proteases for protein quality control (Zhao et al., 2002). 
 Members of a third class of ATP-dependent proteases, the AAA proteases (AAA: 
ATPases associated with a variety of cellular activities), are present within the inner 
membrane of mitochondria and expose their catalytic sites either to the matrix or the 
intermembrane space (Fig. 1) (Langer, 2000). AAA proteases conduct protein quality 
surveillance in the inner membrane and exert crucial functions during mitochondrial 
biogenesis. They are discussed in detail below. 
 
1.1.3  Oligopeptidases 
 Oligopeptidases are, with few exceptions, the most poorly characterised mitochondrial 
proteases. Their existence was suggested by the observation that polypeptides can be 
completely degraded to amino acids within mitochondria (Desautels and Goldberg, 1982; 
Young et al., 2001). As ATP-dependent proteases are known to degrade proteins processively 
to peptides, proteolysis was expected to be completed by other proteins with oligopeptidase 
activity (Fig. 1). Several proteins with oligopetidase activity in vitro have been identified, 
mostly localised in the intermembrane space. However, evidence for their in vivo function is 
scarce. Yeast mutant cells lacking mitochondrial oligopeptidases show usually no or only 
mild phenotypes, most likely due to the redundant activity of various enzymes (Garcia-
Alvarez et al., 1987; Büchler et al., 1994; Kambacheld et al., 2005). Moreover, mitochondria 
contain a peptide export system which allows the efficient extrusion of peptides and prevents 
their accumulation in case of an impaired proteolysis. The ABC-transporter protein Mdl1 has 
been linked to this transport process (Fig. 1) (Young et al., 2001). Nevertheless, a quantitative 
assessment of mitochondrial peptide export and the mass-spectrometric identification of 
peptides released from yeast mitochondria provided first evidence for the function of 
oligopeptidases in vivo (Kambacheld et al., 2005). Two oligopeptidases were found to cleave 
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peptides generated by the i-AAA protease in the intermembrane space (Fig. 1) (Kambacheld 
et al., 2005): the thimet oligopeptidase Prd1 (or saccharolysin) and a second metallopeptidase 
Mop112/Cym1 (or PreP1 and PreP2 in Arabidopsis thaliana and PreP in human) (Jonson et 
al., 2004; Kambacheld et al., 2005; Falkevall et al., 2006, Glaser et al., 2006). Peptides 
degraded by this group of peptidases also include various mitochondrial targeting signals 
cleaved off by specific processing peptidases (Stahl et al., 2002; Moberg et al., 2003; 
Kambacheld et al., 2005). Interestingly, the yeast oligopeptidases Prd1 and Mop112 also 
mediate the proteolytic breakdown of peptides, which were initially generated in the matrix 
and then transported into the intermembrane space (Kambacheld et al., 2005). They thus can 
contribute to the complete degradation of proteins localised in another mitochondrial 
subcompartment. Several enzymes with proposed oligopeptidase activity have also been 
identified in the matrix space including the bleomycin hydrolase Lap3. It is a cysteine 
peptidase which is localised both in the cytosol and the mitochondrial matrix space in yeast 
(Kambouris et al., 1992; Enenkel and Wolf, 1993; Magdolen et al., 1993; Huh et al., 2003; 
Sickmann et al., 2003). A functional characterisation of the in vivo function of matrix-
localised oligopeptidases, however, is still awaited. It is likely that they act in concert with 
ATP-dependent proteases in the proteolysis of matrix proteins and are thus part of a similar 
pathway as present in the intermembrane space (Fig. 1). 
 
1.1.4  Other mitochondrial proteases 
 A number of additional proteases are present within mitochondria but their functional 
classification into the above mentioned categories remains unclear. The metallopeptidase 
Oma1 has been identified in a genome-wide screen for mitochondrial peptidases in yeast and 
was localised to the inner membrane of mitochondria with its catalytic site facing the matrix 
space (Käser et al., 2003). Oma1 is a member of a conserved and widespread family of 
membrane-integrated metallopeptidases and was shown to cleave a misfolded polytopic 
membrane protein at multiple sites (Käser et al., 2003). It therefore exerts a function similar 
to the m-AAA protease for quality control of inner membrane proteins and has been proposed 
to be part of a salvage system under conditions of limited AAA protease activity. 
 HtrA2 (Omi, Prss25) is localised in the intermembrane space of mammalian 
mitochondria (Suzuki et al., 2001; Hegde et al., 2002). It is a member of a conserved family 
of oligomeric serine peptidases, which were functionally linked to protein quality control in 
various organisms (Clausen et al., 2002; Kim and Kim, 2005). Mitochondrial HtrA2 has been 
identified as a pro-apoptotic XIAP-binding protein in the cytosol and was demonstrated to be 
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released from mitochondria in apoptotic cells (Suzuki et al., 2001; Hegde et al., 2002; Martins 
et al., 2002; van Loo et al., 2002; Verhagen et al., 2002). A pro-apoptotic function of HtrA2, 
however, was recently challenged as targeted deletion of HtrA2 in mice did not impair the 
rate of apoptosis, but led to a selective loss of neurons in the striatum (Martins et al., 2004). 
Consistently, a missense mutation inactivating HtrA2 in mice causes a neuromuscular 
disorder (Jones et al., 2003). The molecular basis of these phenotypes, as the function of 
HtrA2 within mitochondria, is currently not understood. Murine embryonic fibroblasts 
lacking HtrA2 exhibit an increased sensitivity to stress-induced cell death (Martins et al., 
2004). It is therefore conceivable that, in analogy to homologous bacterial proteases, HtrA2 
conducts protein quality control and protects mitochondrial activities under stress conditions 
(Clausen et al., 2002; Kim and Kim, 2005). Evidence for a processing activity of HtrA2 was 
recently provided analysing cleavage of the β-amyloid precursor protein in vivo and in vitro 
(Park et al., 2006). 
 
1.2  AAA proteases 
1.2.1  Domain structure and assembly of AAA proteases 
 AAA proteases are integral parts of the mitochondrial inner membrane and their 
catalytic domains are facing either the matrix or the intermembrane space (Langer, 2000). 
Accordingly, they were termed m-AAA protease, active on the matrix side, and i-AAA 
protease, active on the intermembrane side (Fig. 2). AAA proteases form large complexes 
with a native molecular mass of ~1 MDa, which are composed of closely related or identical 
subunits of 70-80 kDa (Arlt et al., 1996; Leonhard et al., 1996; Klanner et al., 2001; Atorino 
et al., 2003; Urantowka et al., 2005). An N-terminal mitochondrial sorting signal targets the 
nuclearly encoded subunits to mitochondria. While m-AAA protease subunits are anchored to 
the inner membrane by two transmembrane segments present in the N-terminal part, i-AAA 
protease subunits span the inner membrane only once (Fig. 2). Accordingly, catalytic domains 
following the membrane-embedded domains are exposed to the intermembrane or matrix 
space. The AAA domain contains Walker A and Walker B motifs involved in ATP binding 
and hydrolysis, respectively, and the so-called second region of homology (SRH) (Hanson 
and Whiteheart, 2005). Two conserved arginine residues in this region protrude into the 
catalytic site of adjacent subunits and thereby stimulate ATP hydrolysis (Hanson and 
Whiteheart, 2005). Mutational alterations of these arginine fingers in bacterial and 
mitochondrial m-AAA protease subunits impaired ATPase activity (Karata et al., 1999; 
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Karata et al., 2001; Korbel et al., 2004). Therefore, assembly of AAA protease subunits is a 
prerequisite for ATP-dependent proteolysis. AAA proteases belong to the M41 family of 
metallopeptidases characterised by the consensus metal-binding motif HExxH (x represents a 
variable amino acid residue) (Rawlings and Barrett, 1995). Mutation of the glutamate residue 
within the proteolytic centre inhibits protein degradation by AAA proteases (Arlt et al., 1996; 
Guélin et al., 1996; Leonhard et al., 1996; Weber et al., 1996; Atorino et al., 2003). Notably, 
proteolytic activity is only completely abolished if all subunits harbour mutations in their 
proteolytic centres. Hetero-oligomeric mutant m-AAA proteases still containing wild type 
subunits exhibit residual activity and are capable of processing protein substrates (Arlt et al., 
1998). 
 
 
 
 
Figure 2. Mitochondrial AAA proteases. 
(A) Domain structure of AAA protease subunits. Subunits of i- and m-AAA protease complexes 
harbour one or two transmembrane domains (TM), respectively. Conserved sequence motifs within 
domains are indicated with grey boxes. MTS, mitochondrial targeting sequence; ND, N-terminal 
domain; AAA, AAA domain; PD, proteolytic domain; NH, N-terminal helices; WA, Walker A-motif; 
WB, Walker B-motif; SRH, second region of homology; HEXGH, proteolytic centre; CH, C-terminal 
helices. 
(B) Membrane topology of AAA proteases. The stoichiometry and arrangement of mitochondrial 
AAA protease subunits within a complex is still speculative. IMS, intermembrane space; IM, inner 
membrane; M, matrix space. 
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 For two homologous eubacterial FtsH proteases, the crystal structure of the soluble 
cytosolic region containing the catalytic domains has recently been solved (Bieniossek et al., 
2006; Suno et al., 2006). They form a hexameric structure which adopts a flat-cylinder-like 
shape and consists of two structurally separate rings composed of the proteolytic domains and 
the AAA domains, respectively (Fig. 3). The proteolytic centres are located within an inner 
cavity of the hexameric molecule and can be accessed via a narrow central pore formed by the 
AAA domains facing the membrane. A similar hexameric and ring-like assembly can also be 
suggested for mitochondrial AAA proteases. 
 
 
 
 
Figure 3. Substrate engagement by the yeast i-AAA protease. 
A lattice-like arrangement of the substrate binding regions CH (C-terminal helices) and NH (N-
terminal helices) at the surface of the proteolytic cylinder of an AAA protease. Helices homologous to 
CH and NH of yeast Yme1 are marked in red in the crystal structure of Thermotoga maritima FtsH 
(Bieniossek et al., 2006). Only three subunits are shown. AAA, AAA domain; PD, proteolytic domain; 
IM, inner membrane. 
 
 Both the m- and the i-AAA protease recognise and degrade non-native and non-
assembled polypeptides to peptides (Fig. 4A) (Arlt et al., 1996; Leonhard et al., 1996). These 
proteases exhibit degenerate substrate specificity and, similar to molecular chaperone 
proteins, recognise the folding state of solvent-exposed domains of membrane proteins 
(Leonhard et al., 1999). Studies on the i-AAA protease subunit Yme1 of yeast allowed the 
identification of two helical binding regions, which form a lattice-like structure at the surface 
of the proteolytic cylinder and mediate the initial encounter of substrate proteins with the 
protease (Fig. 3) (Leonhard et al., 1999; Graef et al., 2007): helices C-terminal of the 
proteolytic domain (CH) and N-terminal helices of the AAA domain (NH), which are located 
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in close proximity to the membrane surfaces and highly negatively charged. Thus, substrate 
proteins initially interact with the i-AAA protease at the outer surface of the proteolytic 
cylinder, before they enter the proteolytic chamber (Graef et al., 2007). Evidence for substrate 
translocation into a proteolytic chamber through the central pore of mitochondrial AAA 
proteases has been obtained by mutational analysis of a conserved loop motif YVG (aromatic-
hydrophobic-glycine) in Yme1 (Graef and Langer, 2006), which has been localised to the 
central pore of other hexameric AAA+ ring complexes (Wang et al., 2001). Furthermore, 
AAA protease-mediated degradation of inner membrane proteins involves the extraction of 
the substrate from the membrane bilayer (Leonhard et al., 2000). Recently, the ability of the 
m-AAA protease to mediate vectorial membrane dislocation of proteins in an ATP-dependent 
reaction has been directly demonstrated (see below) (Tatsuta et al., 2007). This membrane 
extraction of substrate proteins is likely to be facilitated by the membrane-embedded parts of 
AAA protease subunits which might form a pore-like structure or provide at least a more 
hydrophilic environment (Korbel et al., 2004). 
 The yeast m-AAA protease assembles with the prohibin complex into a large 
supercomplex (Steglich et al., 1999). Two ubiquitous and highly conserved subunits, Phb1 
and Phb2, assemble into a multimeric complex, which is exposed to the intermembrane space 
and anchored N-terminally to the inner membrane (Steglich et al., 1999; Nijtmans et al., 
2000; Artal-Sanz et al., 2003). Prohibitins appear to modulate proteolysis by the m-AAA 
protease, since deletion of prohibitins in yeast results in accelerated protein degradation by the 
m-AAA protease (Steglich et al., 1999). However, the molecular mechanism of how 
prohibitins exert this function is not understood. 
 
1.2.2  Functions of AAA proteases within mitochondria 
 AAA proteases in the inner mitochondrial membrane exert essential housekeeping 
functions like protein quality control (Fig. 4A) and have crucial roles in mitochondrial 
biogenesis. Therefore, their deletion or inactivation causes severe pleiotropic phenotypes in 
various organisms, which are best characterised in the yeast Saccharomyces cerevisiae. Here, 
all observed defects can be attributed to a loss of proteolytic activity as identical phenotypes 
were observed after deletion of an AAA protease subunit or after inactivation of the 
proteolytic sites of all subunits of AAA protease complexes (Leonhard et al., 1996; Weber et 
al., 1996; Arlt et al., 1998). Notably, yeast cells deficient in both the m- and the i-AAA 
protease are not viable (Lemaire et al., 2000; Leonhard et al., 2000). 
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Figure 4. Versatile functions of AAA proteases within mitochondria. 
A) Protein turnover. AAA proteases conduct protein quality surveillance and degrade excess and 
damaged proteins to peptides after their dislocation from the membrane. 
B) Protein processing. AAA proteases can cleave mitochondrial proteins resulting in their activation. 
This is exemplified by the maturation of newly imported MrpL32 by yeast and mammalian m-AAA 
proteases, but additional substrates are likely to exist.  
C) ATP-dependent membrane dislocation. Independent of its proteolytic activity, the m-AAA protease 
mediates the vectorial dislocation of Ccp1 precursor proteins to allow intramembrane cleavage by 
rhomboid. It is conceivable that this activity is required for the correct sorting of additional 
mitochondrial proteins residing in the inner membrane or the intermembrane space. 
D) Protein import into mitochondria. The yeast i-AAA protease is required for the import of 
heterologously expressed PNPase into the mitochondrial intermembrane space. The role of the 
proteolytic activity of the i-AAA protease in this process is currently not understood. OM, outer 
membrane; IMS, intermembrane space; IM, inner membrane; M, matrix space; TOM, translocase of 
the outer membrane; TIM, translocase of the inner membrane; MTS, mitochondrial targeting 
sequence. 
 
 The yeast i-AAA protease is a homo-oligomeric complex of Yme1 subunits (Leonhard 
et al., 1996). In the absence of a functional i-AAA protease, yeast cells are characterised by a 
respiratory deficiency at high temperature, an inability to grow on rich glucose medium at low 
temperature, an increased rate of mtDNA escape to the nucleus (Thorsness and Fox, 1993; 
Thorsness et al., 1993), and a petite-negative phenotype, i.e. strongly impaired growth in the 
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absence of mtDNA (Weber et al., 1995). Moreover, ∆yme1 cells exhibit an accumulation of 
punctate mitochondria with grossly swollen compartments pointing to a potential role of 
Yme1 in maintaining normal mitochondrial morphology (Campbell et al., 1994). However, it 
remains an open question if these phenotypes are caused by the accumulation of misfolded 
polypeptides or the impaired proteolysis of specific substrate proteins. Only a limited number 
of protein quality control substrates of the yeast i-AAA protease has been identified including 
non-assembled Cox2 (Nakai et al., 1995; Pearce and Sherman, 1995; Weber et al., 1996), 
unassembled prohibitin subunits Phb1 and Phb2 (Kambacheld et al., 2005), as well as 
external NADH dehydrogenase (Nde1) (Augustin et al., 2005). In addition to protein quality 
surveillance (Fig. 4A), a novel function has recently been associated with the i-AAA protease. 
Polynucleotide phosphorylase (PNPase) has been localised to the mitochondrial 
intermembrane space in mammals and was shown to be required for the maintenance of 
mitochondrial homeostasis (Chen et al., 2006). Import of mammalian PNPase into yeast 
mitochondria critically depends on the presence of the i-AAA protease Yme1 in mitochondria 
(Rainey et al., 2006). Yme1 binds to the precursor form of PNPase and mediates its 
translocation across the outer membrane, but does not degrade it suggesting a non-proteolytic 
function (Fig. 4D). 
 In yeast, the m-AAA protease is hetero-oligomeric and composed of two closely 
related subunits, Yta10 (Afg3) and Yta12 (Rca1), which assemble in an ATP-dependent 
manner into m-AAA protease complexes (Arlt et al., 1996). Yeast cells lacking either subunit 
or expressing proteolytically inactive variants of both subunits are respiratory deficient 
(Guélin et al., 1994; Tauer et al., 1994; Tzagoloff et al., 1994; Arlt et al., 1998) and lack 
assembled respiratory chain and ATP-synthase complexes in the inner membrane (Paul and 
Tzagoloff, 1995; Arlt et al., 1998; Galluhn and Langer, 2004). As substrates, non-assembled, 
mitochondrially encoded respiratory chain subunits of complexes III, IV and V (Cob, Cox1, 
Cox3, Atp6, Atp8, Atp9) were found to be degraded by the yeast m-AAA protease (Arlt et al., 
1996; Guélin et al., 1996). In addition to these integral membrane proteins, the m-AAA 
protease has also been demonstrated to degrade peripheral membrane proteins such as Atp7 
(Korbel et al., 2004). Recently, the processing of specific substrate proteins with regulatory 
functions has been recognised as a second housekeeping function of the m-AAA protease 
(Fig. 4B). Specific substrates for proteolytic cleavage include the ribosomal subunit MrpL32 
(Nolden et al., 2005) and cytochrome c peroxidase (Ccp1), a heme-binding ROS scavenger in 
the intermembrane space (Esser et al., 2002; Tatsuta et al., 2007). These findings have 
provided a rationale for cellular defects associated with an m-AAA protease-deficiency in 
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yeast. Moreover, they allowed the identification of ATP-dependent membrane dislocation as a 
novel non-proteolytic function of AAA proteases (Fig. 4C). 
 
1.2.3  Proteolytic processing by AAA proteases  
 In order to purify specific substrate proteins biochemically, an m-AAA protease 
variant harbouring point mutations in the proteolytic centres was employed as substrate-trap 
(Nolden et al., 2005). This approach has led to the identification of MrpL32, a conserved 
nuclearly encoded subunit of mitochondrial ribosomes (Grohmann et al., 1991). Surprisingly, 
the m-AAA protease does not affect the stability of this protein, but cleaves off the N-terminal 
targeting sequence upon import into mitochondria (Fig. 5A) (Nolden et al., 2005). MrpL32 
processing is a prerequisite for its assembly into ribosomes, which is thus completed in close 
proximity to the inner membrane. An impaired translation within mitochondria rationalises 
the loss of the respiratory competence of m-AAA protease-deficient yeast cells, as essential 
subunits of the respiratory chain are encoded by the mitochondrial DNA (Foury et al., 1998). 
That the processing of MrpL32 indeed represents a key function of the m-AAA protease in 
yeast is demonstrated by a complementation experiment. Expression of an MrpL32 variant, 
which harbours an unrelated presequence and is matured by MPP, maintains respiratory 
growth of m-AAA protease-deficient cells (Nolden et al., 2005). Therefore, it can be 
concluded that cellular defects associated with an inactivation of the yeast m-AAA protease 
are largely explained by an impaired processing of a matrix protein rather than the deleterious 
effects of accumulating non-native membrane proteins in mitochondria. 
 Another substrate whose processing depends on the yeast m-AAA protease is the 
ROS-scavenger protein Ccp1 (Fig. 5B). A bipartite presequence targets this nuclearly encoded 
protein into the intermembrane space and is cleaved off by the consecutive action of m-AAA 
and rhomboid proteases in the inner membrane (Esser et al., 2002). Strikingly, although 
strictly dependent on the presence of the m-AAA protease, maturation of Ccp1 by the 
rhomboid protease Pcp1 was observed in yeast cells harbouring a proteolytically inactive 
variant of the m-AAA protease (Tatsuta et al., 2007). In contrast, Ccp1 cleavage by rhomboid 
was abolished if mutations were introduced into the AAA domains of m-AAA protease 
subunits. Subsequent experiments revealed that the m-AAA protease is required to mediate 
the ATP-dependent vectorial dislocation of Ccp1 from the membrane bilayer (Fig. 5B) 
(Tatsuta et al., 2007). This activity most likely ensures the correct positioning of Ccp1 relative 
to the membrane to allow intramembrane cleavage by Pcp1. It appears that the general  
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Figure 5. Protein processing by the yeast m-AAA protease. 
A) Processing of MrpL32, a subunit of mitochondrial ribosomes. Newly imported MrpL32 is matured 
by the m-AAA protease, most likely accompanied by a conformational change. This allows its 
assembly with pre-assembled ribosomal particles at the inner surface of the inner membrane. The 
presequence of MrpL32 is either degraded within mitochondria or released from the organelle 
(Kambacheld et al., 2005).  
B) Processing of cytochrome c peroxidase (Ccp1), a ROS scavenger in the intermembrane space. Ccp1 
is targeted to mitochondria by a bipartite presequence which is cleaved off in a two-step process by the 
m-AAA protease and rhomboid (Pcp1). The first hydrophobic stretch triggers lateral sorting of the 
precursor protein in the inner membrane. The m-AAA protease mediates the ATP-dependent vectorial 
dislocation and positions the precursor protein within the lipid bilayer for intramembrane cleavage by 
rhomboid. Mature Ccp1 is released as a soluble protein into the intermembrane space. OM, outer 
membrane; IMS, intermembrane space; IM, inner membrane; M, matrix space; TOM, translocase of 
the outer membrane; TIM, translocase of the inner membrane; OXA, membrane insertion machinery 
containing Oxa1. 
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activity of the m-AAA protease, namely to extract non-native substrate proteins from the 
membrane bilayer for proteolysis is recruited to ensure the biogenesis of Ccp1. Maturation of 
Ccp1 within mitochondria thus represents the first non-proteolytic function of the m-AAA 
protease within mitochondrial biogenesis. It is tempting to speculate that additional substrates 
of the m-AAA protease exist whose biogenesis depend on the ATP-dependent dislocase rather 
than the proteolytic activity of the m-AAA protease. 
 
1.2.4  Mammalian AAA proteases 
 The presence of AAA proteases with their catalytic domains exposed to opposite 
membrane surfaces is conserved in mammals. AAA protease subunits with a high degree of 
homology to Yta10, Yta12, and Yme1 of yeast have been identified in humans and mice 
(Fig. 6) and several complementation studies in yeast have demonstrated a functional 
conservation of m- and i-AAA proteases (Shah et al., 2000; Atorino et al., 2003; Nolden et 
al., 2005). 
 A mammalian homologue of yeast Yme1 has been found in humans and mice, named 
YME1L1 (Coppola et al., 2000; Shah et al., 2000). Expression of human YME1L1 restores 
respiratory growth of ∆yme1 yeast cells at high temperature identifying it as the human i-
AAA protease (Shah et al., 2000). Thus, the i-AAA protease in mammalian mitochondria 
apparently represents a homo-oligomeric assembly like in yeast. In contrast, next to nothing is 
known about its substrates and exact function in mammals and the generation of a Yme1l1-
deficient mouse line is awaited. 
 In case of the m-AAA protease, three potential subunits have been identified in 
humans and mice, termed Afg3l1, Afg3l2, and paraplegin (Casari et al., 1998; Shah et al., 
1998; Banfi et al., 1999). They are all mitochondrially localised and ubiquitously present in 
mammalian tissues. However, Afg3l1 which is highly homologous to Afg3l2 is only 
expressed in mice, whereas it is encoded by a pseudogene in humans (Kremmidiotis et al., 
2001). Both in human and murine mitochondria, paraplegin assembles with Afg3l2 into a 
hetero-oligomeric complex which can functionally substitute for the yeast m-AAA protease 
when expressed in yeast (Atorino et al., 2003; Nolden et al., 2005). The assembly and 
function of Afg3l1 has not been analysed. Remarkably, paraplegin was initially identified by 
its association with a neurodegenerative disease which also provided first insights into the role 
of m-AAA proteases in mammalian mitochondria. Mutations in the gene encoding paraplegin 
(spastic-paraplegia-gene 7/SPG7) are causative for an autosomal recessive form of hereditary 
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spastic paraplegia (HSP) (Casari et al., 1998). It is noteworthy that up to date disease-causing 
mutations have not been reported for human AFG3L2 and YME1L1. 
 
 
 
 
Figure 6. AAA protease subunits of yeast and mammals are evolutionary conserved. 
Phylogenetic relationship between mitochondrial AAA protease subunits of yeast (Yta10, Yta12, 
Yme1), mice (paraplegin, Afg3l1, Afg3l2, Yme1l1), and humans (hparaplegin, hAFG3L2, 
hYME1L1), including their sequence identity. 
 
1.3  Hereditary spastic paraplegia (HSP) 
1.3.1 HSP is a clinically and genetically heterogenous disease 
 Hereditary spastic paraplegia comprises a diverse group of neurodegenerative 
disorders whose main clinical features include progressive weakness and spasticity of the 
lower limbs, loss of the vibratory sense, and urinary urgency (Rugarli and Langer, 2006; 
Soderblom and Blackstone, 2006). The age of onset is variable, but usually lies between 10 
and 40 years of age. A further characteristic of the “pure” forms of HSP, where these 
symptoms are isolated, is a remarkable tissue-specificity: only motor neurons of the cortico-
spinal tracts and sensory neurons of the fasiculus gracilis are selectively affected by axonal 
degeneration (Rugarli and Langer, 2006; Soderblom and Blackstone, 2006). Interestingly, the 
axons of these neurons belong to the longest in the central nervous system reaching lengths of 
~1 m. The axonal degeneration in HSP starts distally at the synaptic terminals and slowly 
proceeds towards the neuronal cell bodies which are preserved. Thus, HSP is a member of a 
new category of neurological disorders and can be classified as a “dying back” axonopathy 
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(Züchner and Vance, 2005). In the “complicated” forms of HSP, patients have additional 
neurological abnormalities like cortical and cerebellar atrophy, amyotrophy, peripheral 
neuropathy, optic atrophy, deafness, short stature, and mental retardation (Harding, 1983). 
 The clinical heterogeneity of spastic paraplegias is paralleled by a genetic 
heterogeneity. The inheritance pattern can be X chromosome-linked, autosomal dominant, or 
autosomal recessive. In total, 33 genetic loci have been associated with different forms of 
HSP (SPG1 to SPG33). However, causative mutations have been identified only in 15 genes 
(Tab. 2), which can be divided into three functional categories: Firstly, genes whose products 
play a role in axonal targeting and pathfinding or myelination. These include the two X 
chromosome-linked genes SPG1 and SPG2 encoding the glycoprotein L1CAM and the 
proteolipid protein PLP1, respectively (Jouet et al., 1994; Saugier-Veber et al., 1994). 
Secondly, genes whose products are involved in axonal transport and trafficking (Crosby and 
Proukakis, 2002; Soderblom and Blackstone, 2006). The kinesin heavy chain gene KIF5A 
(SPG10) is the paradigm of this group (Reid et al., 2002). KIF5A is part of a hetero-tetrameric 
protein complex, the neuronal kinesin-I, that acts as a plus-end-directed microtubule motor 
involved in anterograde transport of membranous organelles in nerve axons (Goldstein and 
Yang, 2000). The AAA protein spastin which is encoded by SPG4 interacts with microtubules 
and regulates microtubule dynamics (Errico et al., 2002; Errico et al., 2004; Evans et al., 
2005). In addition, spastin interacts with one component of the endosomal sorting complex 
required for transport (ESCRT)-III and with the large GTPase atlastin (SPG3A), which also 
causative for HSP (Reid et al., 2005; Evans et al., 2006; Sanderson et al., 2006). Spartin 
(SPG20), maspardin (SPG21), and the recently identified protein ZFYVE27 (SPG33) have 
also been suggested to have a function in intracellular trafficking, but clear evidence is 
missing (Patel et al., 2002; Simpson et al., 2003; Mannan et al., 2006). The third functional 
group encompasses genes that have mitochondrial functions (Bross et al., 2004; Rugarli and 
Langer, 2006). Besides the m-AAA protease subunit paraplegin, mitochondrial Hsp60 (heat-
shock protein 60; also known as chaperonin) which is encoded by SPG13 has been linked to 
HSP (Hansen et al., 2002). Hsp60 mediates the folding of newly imported proteins and 
protects mitochondrial proteins from heat denaturation (Voos and Röttgers, 2002). Recently, 
the protein product of the SPG31 gene, termed REEP1 (receptor expression-enhancing 
protein 1) has been localised to mitochondria but its function is unknown (Züchner et al., 
2006). Conflicting results concerning the subcellular localisation of spartin have been 
reported (Lu et al., 2006; Robay et al., 2006). In one study, transfected and fluorescent-tagged 
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spartin was recently found to be mitochondrial and to co-localise with microtubules 
suggesting a possible role of spartin in transport of mitochondria (Lu et al., 2006). 
 
Table 2. Cloned genes which are linked to HSP. 
Locus Inheritance Protein  Function Reference 
     
SPG1 X-linked L1CAM axonal targeting and 
pathfinding, development of 
corticospinal tract 
Jouet et al., 1994 
SPG2 X-linked PLP1 myelination, axonal-glial 
interactions 
Saugier-Veber et al., 
1994 
SPG3A AD atlastin GTPase in the cis-Golgi, 
interaction with spastin, 
involved in axonal develop. 
Zhao et al., 2001 
SPG4 AD spastin microtubule dynamics, 
vesicular trafficking 
Hazan et al., 1999 
SPG6 AD NIPA1 Mg2+ transporter Rainier et al., 2003 
SPG7 AR paraplegin mitochondrial AAA 
protease 
Casari et al., 1998 
SPG8 AD strumpellin unknown Valdmanis et al., 
2007 
SPG10 AD KIF5A kinesin motor protein 
(axonal transport) 
Reid et al., 2002 
SPG11 AR spatacsin unknown Stevanin et al., 2007 
SPG13 AD Hsp60 mitochondrial chaperonin Hansen et al., 2002 
SPG17 AD seipin ER membrane protein Windpassinger et al., 
2004 
SPG20 AR spartin microtubule-mediated 
trafficking of mitochondria? 
Patel et al., 2002 
SPG21 AR maspardin vesicular trafficking? Simpson et al., 2003 
SPG31 AD REEP1 mitochondrial membrane 
protein 
Züchner et al., 2006 
SPG33 AD ZFYVE27 spastin-binding protein Mannan et al., 2006 
     
AD, autosomal dominant; AR, autosomal recessive; X-linked, X chromosome-linked 
 
1.3.2 HSP due to lack of paraplegin 
 Mutations in the SPG7 gene encoding paraplegin account for ~10% of recessive and 
sporadic cases of HSP (Casari and Rugarli, 2001). Analysis of the paraplegin mutations that 
were identified in human HSP patients suggests a complete loss of paraplegin function 
(McDermott et al., 2001; Wilkinson et al., 2004). What are the consequences of a paraplegin 
deficiency on mitochondrial activities in HSP patients? Primary fibroblasts from HSP patients 
showed defects in the assembly and activity of complex I of the respiratory chain, 
accompanied by decreased ATP levels (Atorino et al., 2003). An impaired activity of 
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complex I can lead to an elevated production of reactive oxygen species (Barrientos and 
Moraes, 1999; Li et al., 2003). Consistently, an increased sensitivity of HSP fibroblasts 
towards oxidative stress was detected (Atorino et al., 2003). 
 Recently, a paraplegin-deficient mouse line has been generated which recapitulates 
central features of the human disease and thus can serve as a valuable model to further 
understand the molecular basis of mitochondrial dysfunction in HSP (Ferreirinha et al., 2004). 
Similar to HSP patients, the long axons of paraplegin-deficient mice were specifically 
affected and found to contain enlarged and structurally abnormal mitochondria in the distal 
regions. These changes in mitochondrial morphology represented the first detectable defect 
whose appearance was followed by axonal swelling and finally progressive degeneration 
(Ferreirinha et al., 2004). Thus, the mammalian m-AAA protease might also play a role in the 
regulation of mitochondrial dynamics. Further studies revealed that, similar to m-AAA 
protease-deficient yeast cells, processing of murine MrpL32 and concomitantly mitochondrial 
translation were impaired in the absence of paraplegin (Nolden et al., 2005). When co-
expressed with murine paraplegin and Afg3l2 in yeast, murine MrpL32 was matured 
identifying it as the first in vivo substrate of the mammalian m-AAA protease (Nolden et al., 
2005). Since essential respiratory chain subunits are mitochondrially encoded (Anderson et 
al., 1981), mitochondrial-protein-synthesis defects should result in oxidative-phosphorylation 
deficiencies. However, the activities of respiratory chain complexes were not significantly 
affected and only moderately defective ATP synthesis became apparent in spinal cord 
mitochondria of old paraplegin-deficient mice (Ferreirinha et al., 2004). 
 
1.3.3 A possible mechanism for axonal degeneration in HSP 
 Taken together, significant progress has been made in the recent years to unravel the 
pathogenetic mechanism of HSP due to a loss of paraplegin. However, it remains an open 
question whether accumulating non-native polypeptides, an impaired mitochondrial 
translation, or the impaired processing of another mitochondrial protein in the absence of 
paraplegin results in axonal degeneration. One can envision the following general model, 
which can also be reconciled with the genetic heterogeneity of this neurological disorder. 
Axons depend on active anterograde transport for the supply of protein and lipid constituents, 
which are synthesised in the neuronal cell body and on retrograde transport for the 
degradation and replacement of old and damaged material (Hirokawa and Takemura, 2005). 
Mitochondria are also transported in an anterograde manner mediated by kinesin motor 
proteins to the distal regions of axons (Hollenbeck and Saxton, 2005). Neurons with long 
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axons as those of the corticospinal tracts can be considered to be particularly vulnerable to 
defects in axonal trafficking as indicated by the axonal length-dependance in HSP. Thus, 
deficiencies in proteins directly involved in axonal transport such as KIF5A or in 
mitochondrial proteins like paraplegin and Hsp60 could both result in the absence of 
functional mitochondria from the synapses triggering degeneration. Consistently, it has been 
demonstrated that reduced mitochondria content leads to the loss of dendritic spines and 
synapses (Li et al., 2004). In the absence of paraplegin, synaptic mitochondria undergo 
morphological changes and accumulate which, in combination with a limited energy supply, 
might further affect axonal transport and eventually clog the axon. In line with this scenario, a 
delayed retrograde transport was indeed observed in motor neurons of paraplegin-deficient 
mice (Ferreirinha et al., 2004). 
 
1.4 Mitochondrial dynamics 
1.4.1 Mitochondrial fusion in yeast and mammals 
 Mitochondria are highly dynamic organelles whose morphology depends on the tissue, 
on the physiological condition of the cell, and in particular on the functional status of 
mitochondria (Okamoto and Shaw, 2005). This dynamic behaviour is crucial for a number of 
cellular processes, such as apoptosis, the inheritance of mtDNA, defence against oxidative 
stress, and development through spermatogenesis (Hales and Fuller, 1997; Chen and Chan, 
2005; Chen and Butow, 2005; Cereghetti and Scorrano, 2006). Mitochondrial morphology is 
regulated by opposing but balanced fusion and fission events which maintain the normal 
mitochondrial network (Okamoto and Shaw, 2005). Loss of fusion results in mitochondrial 
fragmentation due to ongoing fission events. Conversely, loss of fission leads to the formation 
of elongated and highly interconnected mitochondria. The central components of the 
mitochondrial fusion and fission machineries have been identified, but the molecular 
mechanisms of both processes are not completely understood. Most proteins involved are 
conserved in yeast, flies, mice, and humans indicating that the fundamental mechanisms 
controlling mitochondrial dynamics have been maintained during evolution. 
 Mitochondrial fusion includes the fusion of the outer and the inner membrane of two 
organelles in a coordinated manner. Three proteins are essential for fusion in yeast and 
interact with each other to form a fusion complex: the two dynamin-related GTPases Fzo1 
and Mgm1 as well as Ugo1 (Sesaki et al., 2003b; Wong et al., 2003; Sesaki and Jensen, 
2004). Fzo1 is integrated into the outer membrane exposing its functional domains to the 
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cytoplasm (Hermann et al., 1998; Rapaport et al., 1998; Fritz et al., 2001). Mgm1, on the 
other hand, resides in the intermembrane space but is present in two forms both of which are 
required for fusion (Wong et al., 2000; Herlan et al., 2003; Sesaki et al., 2003b; Wong et al., 
2003): the large (l-) isoform, which is integrated into the inner membrane, and the short (s-) 
isoform, which is peripherally associated with inner and/or outer membrane and generated by 
proteolytic processing of the l-form, as discussed below. The third player, Ugo1, is also 
embedded into the outer membrane and exposes its N-terminal domain to the cytoplasm and 
the C-terminal domain to the intermembrane space (Sesaki and Jensen, 2001). Ugo1 has been 
shown to bind to both Fzo1 and Mgm1 via its N- and C-terminal domains thus linking the 
fusion components of the outer and inner membrane and possibly the fusion events of both 
membranes (Sesaki and Jensen, 2004). Outer- and inner-membrane fusion events are tightly 
coupled in vivo, but could be separated by the reconstitution of fusion in vitro (Meeusen et al., 
2004). Furthermore, these in vitro studies revealed that Fzo1 is required for outer membrane 
fusion, whereas inner membrane fusion depends on Mgm1 (Meeusen et al., 2004; Meeusen et 
al., 2006). For both mitochondrial membranes, trans interactions of either Fzo1 or Mgm1 
mediate tethering of opposing membranes and subsequent fusion. 
 Two homologues of Fzo1 have been identified in humans, called mitofusin (Mfn) 1 
and 2, whereas OPA1 is the homologue of Mgm1 (Alexander et al., 2000; Delettre et al., 
2000; Santel and Fuller, 2001; Rojo et al., 2002). Interestingly, Ugo1 does not have an 
obvious counterpart in mammals. The localisation of mitofusins and OPA1 in the outer 
membrane and intermembrane space, respectively, and their topology has been conserved in 
mammals (Rojo et al., 2002; Griparic et al., 2004). In addition, different isoforms of OPA1 
are also present in mammalian mitochondria. The essential role of mitofusins and OPA1 in 
mitochondrial fusion has been established through the generation of knockout mice and by 
knockdown experiments using RNA intereference (RNAi). The absence of either Mfn1 or 
Mfn2 causes embryonic lethality in mice and isolated mouse embryonic fibroblasts only 
exhibit greatly reduced levels of mitochondrial fusion leading to a highly fragmented 
mitochondrial population (Chen et al., 2003; Chen et al., 2005). This indicates that Mfn1 and 
Mfn2 apparently play similar roles in mitochondrial fusion, which was supported by the 
finding that they can form both homo- and hetero-oligomeric complexes all competent for 
fusion (Chen et al., 2003; Eura et al., 2003; Chen et al., 2005). Similarly, depletion of OPA1 
from mammalian cells also results in mitochondrial fragmentation due to loss of fusion 
(Olichon et al., 2003; Cipolat et al., 2004; Griparic et al., 2004; Chen et al., 2005). 
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1.4.2 Regulation of mitochondrial fusion by proteolytic processes 
 In yeast, two components of the mitochondrial fusion machinery, Fzo1 and Mgm1, are 
under proteolytic control. In the case of Fzo1, the maintenance of mitochondrial morphology 
depends on the tight control of its steady state concentration which is regulated by 
degradation of Fzo1 via two independent proteolytic pathways. On one hand, Fzo1 turnover 
can be induced by cell cycle arrest with the mating factor alpha which leads to mitochondrial 
fragmentation (Neutzner and Youle, 2005). This induced degradation of Fzo1 is mediated by 
the ubiquitin-proteasome system (UPS) (Escobar-Henriques et al., 2006), the central 
proteolytic system in the cytosol of eukaryotic cells (Ciechanover, 2005). On the other hand, 
Fzo1 is degraded in vegetatively growing yeast cells in a constitutive manner which depends 
on the F-box protein Mdm30 (Escobar-Henriques et al., 2006). In the absence of Mdm30, the 
steady state concentration of Fzo1 is increased and yeast cells accumulate aggregated and 
fragmented mitochondria (Fritz et al., 2003). F-box proteins often assemble into Skp1-Cdc53-
F-box (SCF) E3 ubiquitin ligase complexes which ensure ubiquitin-dependent degradation by 
the 26S proteasome (Willems et al., 2004; Petroski and Deshaies, 2005). However, Mdm30-
dependent turnover of Fzo1 does not involve SCF complexes or the UPS, but rather proceeds 
along an alternative proteolytic pathway which remains to be identified (Escobar-Henriques et 
al., 2006). 
 In contrast to control of Fzo1, Mgm1 is not subject to complete degradation but is 
proteolytically processed at its N-terminus yielding two isoforms within the mitochondrial 
intermembrane space: the large (l-) and the short (s-) isoform. Both Mgm1 isoforms are 
required for mitochondrial fusion and their balanced formation appears to be crucial for 
mitochondrial morphology (Herlan et al., 2003). According to the alternative topogenesis 
model, the ratio of both isoforms is dictated by the level of matrix ATP (Herlan et al., 2004). 
The Mgm1 protein contains two N-terminal transmembrane segments of which the first one 
serves as a stop-transfer signal during mitochondrial import of the pre-protein. At low ATP 
levels, the subsequent removal of the MTS by MPP and lateral membrane insertion result in l-
Mgm1, which is anchored to the inner membrane. At high ATP levels, however, Mgm1 can 
be pulled further into the matrix by the ATP-dependent mitochondrial import motor until the 
second hydrophobic segment reaches the inner membrane. Thereby, a second cleavage site 
within this segment gets accessible for the rhomboid protease Pcp1 in the inner membrane. 
Pcp1-mediated cleavage generates s-Mgm1 (Herlan et al., 2003; McQuibban et al., 2003; 
Sesaki et al., 2003a), which is peripherally associated with the inner and/or outer membrane. 
This mechanism may link the bioenergetic state of mitochondria and their morphology. 
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Furthermore, it would allow separating damaged, non-functional mitochondria from the intact 
mitochondrial network by preventing fusion due to impaired formation of s-Mgm1. 
 
1.4.3 OPA1 and optic atrophy 
 Mammalian OPA1 has been originally identified by mutations causative for autosomal 
dominant optic atrophy (ADOA) type I, the most common form of inherited optic neuropathy 
(Alexander et al., 2000; Delettre et al., 2000). A degeneration of retinal ganglion cells leading 
to atrophy of the optic nerve is the underlying defect in this disease (Delettre et al., 2002). 
Thus, optic atrophy is also characterised by an intriguing tissue-specificity, although the 
OPA1 mRNA and protein are widely distributed in mammalian tissues including various 
brain areas (Alexander et al., 2000; Delettre et al., 2000; Misaka et al., 2002; Olichon et al., 
2002; Aijaz et al., 2004; Bette et al., 2005). Interestingly, mutations in Mfn2 cause a different 
neuropathy, called Charcot-Marie-Tooth type 2A (CMT2A), whose hallmarks are muscle 
weakness and sensory loss in the distal limbs (Züchner et al., 2004). 
 
 
 
 
Figure 7. Domain structure of OPA1. 
Schematic representation of the domain structure of splice variant 8 of human OPA1, which contains 
the complete sequence (1015 amino acids) and all three hydrophobic stretches called TM1, TM2a, and 
TM2b, indicated with black boxes (upper panel). OPA1 splice variants differ from each other by the 
presence or absence of protein segments encoded by alternatively spliced exons 4, 4b, and 5b, which 
are indicated by grey boxes (lower panel). Amino acid positions of the hydrophobic stretches and the 
alternative protein segments are given. The cleavage site of the mitochondrial processing peptidase 
(MPP) and the putative cleavage site of the m-AAA protease (m-AAA), as determined by Ishihara et 
al., 2006, are marked by arrows. In this study, the L1 and S3 isoforms were purified from HeLa cells 
expressing FLAG-tagged rat OPA1 splice variant 7, which lacks TM2a, and used for protein 
sequencing. MTS, mitochondrial targeting sequence; TM, transmembrane domain; CC, coiled-coil 
domain; GTPase, GTPase domain; Middle, middle domain; GED, GTPase effector domain. 
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 OPA1 is a key player in regulating dynamic changes of mitochondrial morphology by 
promoting mitochondrial fusion (Olichon et al., 2003; Cipolat et al., 2004). Accordingly, 
downregulation of OPA1 results in fragmentation of the mitochondrial network owing to 
ongoing fission (Olichon et al., 2003; Cipolat et al., 2004; Griparic et al., 2004; Chen et al., 
2005). In addition, cells depleted of OPA1 show an aberrant cristae structure (Olichon et al., 
2003; Griparic et al., 2004), which is reminiscent of the role of yeast Mgm1 in maintenance of 
cristae morphology (Sesaki et al., 2003b; Amutha et al., 2004; Meeusen et al., 2006). Further 
phenotypes that have been linked to loss of OPA1 are reduction of mitochondrial membrane 
potential, defects in mitochondrial respiration, accelerated release of cytochrome c and 
concomitantly increased propensity for apoptosis (Olichon et al., 2003; Lee et al., 2004; 
Arnoult et al., 2005; Chen et al., 2005). Thus, OPA1 seems to have additional functions in 
mitochondria which are independent from mitochondrial fusion. Indeed, evidence has been 
obtained for a direct role of OPA1 in the control of cristae remodelling during apoptosis and 
release of cytochrome c which is sequestered in the intra-cristae regions (Cipolat et al., 2006; 
Frezza et al., 2006). 
 OPA1 is a dynamin-like GTPase which resides in the mitochondrial intermembrane 
space (Olichon et al., 2002; Satoh et al., 2003; Griparic et al., 2004) and features the 
following domain structure (Fig. 7): an N-terminal mitochondrial targeting sequence is 
followed by one transmembrane segment (TM1) and two further hydrophobic stretches 
(TM2a and TM2b). A coiled-coil region (or heptad repeat) is located immediately in front of 
the GTPase domain containing the consensus GTP binding sites. The GTPase domain is 
followed by a middle domain and a C-terminal coiled-coil domain, known as the GTPase 
effector domain, which both are generally involved in oligomerisation and regulation of 
GTPase activity (Praefcke and McMahon, 2004). The mRNAs transcribed from the OPA1 
gene are subject to extensive alternative splicing resulting in eight different splice variants 
(Delettre et al., 2001; Satoh et al., 2003). The alternative splicing involves the exons 4, 4b, 
and 5b which encode protein segments of the N-terminal region between the first 
transmembrane domain and the GTPase domain. Therefore, OPA1 splice variants differ in the 
presence or absence of the two additional hydrophobic stretches TM2a and TM2b. In 
addition, the different splice variants are not uniformly expressed in human tissues and appear 
to have distinct roles in mitochondria such as mitochondrial fusion and apoptosis (Delettre et 
al., 2001; Olichon et al., 2006). Several protein isoforms of OPA1 can be detected in human 
cells, e.g. five different isoforms are apparently present in HeLa cells (Olichon et al., 2003; 
Ishihara et al., 2006; Olichon et al., 2006), which have been designated L1 and L2 for the two 
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larger isoforms and S3, S4, and S5 for the three smaller isoforms (Fig. 21B) (Duvezin-Caubet 
et al., 2006). The large and small OPA1 isoforms differ in their membrane association. 
Whereas the L-isoforms are anchored to the inner membrane, S-isoforms are only peripherally 
attached to the membrane (Duvezin-Caubet et al., 2006). 
 It has, however, remained unclear to which extent the different OPA1 isoforms are 
generated by alternative splicing and/or proteolytic processing similar to yeast Mgm1. 
Evidence for the involvement of proteolysis has recently been obtained by the observation 
that upon dissipation of the mitochondrial membrane potential the L-isoforms were converted 
into S-isoforms (Duvezin-Caubet et al., 2006; Ishihara et al., 2006). This induced conversion 
was abolished in the presence of protease inhibitors indicating proteolytic cleavage. 
Moreover, this apparent OPA1 processing was accompanied by mitochondrial fragmentation 
thus linking mitochondrial dysfunction to changes in mitochondrial morphology (Duvezin-
Caubet et al., 2006; Ishihara et al., 2006). Large OPA1 isoforms are generated upon 
mitochondrial import by MPP (Ishihara et al., 2006). However, the protease mediating further 
OPA1 cleavage has not been unambiguously identified, yet. Due to the homology of Mgm1 
and OPA1, the rhomboid protease PARL (presenilin-associated rhomboid-like) (Pellegrini et 
al., 2001), the mammalian homologue of yeast Pcp1, has been implicated in OPA1 
processing. PARL can functionally replace yeast Pcp1 and mediate processing of Ccp1 and 
Mgm1 (McQuibban et al., 2003). Furthermore, the analysis of PARL-deficient mice revealed 
a protective role of PARL against mitochondria-dependent apoptosis in a pathway which also 
depends on OPA1 (Cipolat et al., 2006). In support of proteolysis by PARL, it was found to 
interact with OPA1 and to be involved in the generation of small amounts of a soluble 
intermembrane space form of OPA1. Deletion of PARL, however, did not significantly impair 
the pattern of OPA1 isoforms (Cipolat et al., 2006). The mammalian m-AAA protease has 
also been linked to OPA1 processing, since over-expression of its subunit paraplegin in HeLa 
cells led to an increased accumulation of S-isoforms (Ishihara et al., 2006). Vice versa, OPA1 
processing was slightly inhibited upon downregulation of paraplegin (Ishihara et al., 2006). 
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1.5 Aims of the thesis 
 
 AAA proteases in the mitochondrial inner membrane are evolutionary conserved 
components of the protein quality control system and play crucial regulatory roles during 
organellar biogenesis. Mutations in the mammalian m-AAA protease subunit paraplegin are 
causative for hereditary spastic paraplegia (HSP) in humans and in the mouse model of this 
disorder. However, the molecular basis of cell-specific axonal degeneration in HSP patients 
lacking paraplegin is poorly understood. Mammalian paraplegin has been shown to assemble 
with its homologue Afg3l2 into a hetero-oligomeric m-AAA protease complex, but the 
assembly status of Afg3l2 in the absence of paraplegin has not been assessed. Moreover, 
murine mitochondria contain a third putative m-AAA protease subunit, termed Afg3l1, whose 
function remains elusive. 
 Due to these considerations, initial experiments were aiming at analysing the complex 
formation of human AFG3L2 using mitochondria isolated from paraplegin-deficient HSP 
fibroblasts. Previous studies have shown that the yeast S. cerevisiae can serve as a model 
system for the biochemical and functional characterisation of mammalian proteins. Therefore, 
human AFG3L2 and murine m-AAA protease subunits were heterologously expressed in 
yeast cells lacking the endogenous m-AAA protease. This should provide further insights into 
the assembly of human AFG3L2 and allow the identification of the number and subunit 
composition of murine m-AAA protease complexes which potentially can be formed. In 
addition, these experiments should clarify the role of murine Afg3l1. 
 Mutations in OPA1, a component of the mitochondrial fusion machinery, lead to 
another neurodegenerative disorder called autosomal dominant optic atrophy. Mammalian 
mitochondria contain several protein isoforms of OPA1, but it is unclear to which extent they 
are derived from alternative splicing and/or proteolytic processing. Paraplegin has recently 
been linked to OPA1 cleavage, but an involvement of the m-AAA protease in this process is 
still a matter of debate. Therefore, another aim of this thesis was the reconstitution of OPA1 
processing in yeast upon co-expression of individual OPA1 splice variants and mammalian m-
AAA protease subunits. This should help to determine the role of proteolytic processing by 
the mammalian m-AAA protease in the generation of OPA1 isoforms. 
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2 Material and Methods 
 
2.1 Expression plasmids and cloning procedures 
 For expression of human m-AAA protease subunits in yeast, constructs consisting of 
the mitochondrial targeting sequence (MTS) of Yta10 (amino acids 1-63 or 1-61) and the 
assumed mature forms of hparaplegin (amino acids 59-795) or hAFG3L2 (amino acids 36-
798), respectively, were excised from the CEN plasmids YCplac111 or pRS316 and cloned 
into the multicopy plasmids YEplac181 or YEplac112 (Gietz and Sugino, 1988) under the 
control of the ADH1 promoter (720 bp) as previously described (Koppen, 2002). In order to 
facilitate immunodetection, a hemagglutinin (HA) epitope was added to the C-terminus of 
hparaplegin, whereas a c-Myc epitope was used for hAFG3L2. In case of the murine m-AAA 
protease subunits, the putative mature forms of paraplegin (amino acids 44-781), Afg3l1 
(amino acids 25-789), and Afg3l2 (amino acids 36-802) were also fused to the MTS of Yta10 
(amino acids 1-61). The corresponding DNA sequences were amplified from either genomic 
DNA of wild-type yeast cells or murine cDNA and restriction sites were introduced by 
polymerase chain reaction (PCR) using the oligonucleotides listed in Tab. 4. Subsequently, a 
SbfI/BamHI DNA fragment containing the YTA10 promoter (480 bp) and bp 1-183 of YTA10 
and a BamHI/EcoRI DNA fragment containing bp 130-2343 of paraplegin were cloned into 
the corresponding restriction sites of the multicopy plasmid YEplac181. Similarly, a 
HindIII/BamHI DNA fragment of the YTA10 promoter and MTS and a BamHI/KpnI DNA 
fragment containing bp 73-2367 of Afg3l1 were cloned into the multicopy vector YEplac195 
(Gietz and Sugino, 1988). For cloning of the Afg3l2 expression construct into YEplac112, a 
XmaI/HindIII DNA fragment consisting of the YTA10 promoter and MTS and a HindIII/KpnI 
DNA fragment containing bp 106-2406 of Afg3l2 were used. A c-Myc or an HA epitope were 
attached to the C-terminus of either Afg3l1 or Afg3l2 to allow immunodetection of the 
respective hybrid proteins Yta10 (1-61)-Afg3l1 (25-789)-Myc or Yta10 (1-61)-Afg3l2 (36-
802)-HA.  
 m-AAA protease subunits were inactivated by substitution of catalytically active 
glutamate residues within the proteolytic centres by glutamine residues using the Quick 
Change site-directed mutagenesis kit (Stratagene). Degenerated oligonucleotides used are 
listed in Tab. 4. The respective codons of the human and murine expression constructs were 
mutated as follows: GAA to CAG for hparaplegin (amino acid 575), GAA to CAA for 
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hAFG3L2 (amino acid 575) and murine Afg3l2 (amino acid 574), and GAG to CAG for 
murine paraplegin (amino acid 575) and Afg3l1 (amino acid 567). Mutagenesis was always 
verified by DNA sequencing.  
 
Table 3. List of plasmids used in this study. 
Plasmid  Reference 
YEplac181ADH1-Yta10 (1-63)-hparaplegin (59-795) Koppen, 2002 
YEplac181ADH1-Yta10 (1-63)-hparapleginE575Q (59-795) this study 
YEplac112ADH1-Yta10 (1-61)-hAFG3L2 (36-798)-Myc Koppen, 2002 
YEplac112ADH1-Yta10 (1-61)-hAFG3L2E575Q (36-798)-Myc this study 
YEplac181YTA10-Yta10 (1-61)-paraplegin (44-781) this study 
YEplac181YTA10-Yta10 (1-61)-parapleginE575Q (44-781) this study 
YEplac195YTA10-Yta10 (1-61)-Afg3l1 (25-789)-Myc this study 
YEplac195YTA10-Yta10 (1-61)-Afg3l1E567Q (25-789)-Myc this study 
YEplac112YTA10-Yta10 (1-61)-Afg3l2 (36-802)-HA this study 
YEplac112YTA10-Yta10 (1-61)-Afg3l2E574Q (36-802)-HA this study 
pYES2-OPA1-Sp.1, -Sp.4, -Sp.7, and -Sp.8 (URA3) Duvezin-Caubet et al., 2007 
pYES2-OPA1-Sp.1, -Sp.4, -Sp.7, and -Sp.8 (ura3::TRP1) this study 
pUT11 Cross, 1997 
pGEM4-Yme2F114S∆C15+1 (-Yme2∆C) Korbel et al., 2004 
pGEM4-Atp7 Korbel et al., 2004 
pFA6a-kanMX6 Longtine et al., 1998 
 
 Plasmids for expression of human OPA1 splice variants (Sp.) 1, 4, 7, and 8 were 
described previously (Duvezin-Caubet et al., 2007). The OPA1 splice variant 8 encodes the 
polymorphism A210V (Yao et al., 2006). In order to change the URA3 selection marker of the 
pYES2-OPA1-Sp.X (X: 1, 4, 7, or 8) plasmid series to TRP1, the ‘marker swap’ plasmid 
pUT11 was employed. By using the restriction endonuclease SmaI, a disrupting DNA 
fragment of ~4 kb was generated which contains the TRP1 gene and flanking regions 
homologous to the URA3 gene (Cross, 1997). Wild-type yeast cells harbouring pYES2-
OPA1-Sp.X were transformed with this SmaI DNA fragment to allow homologous 
recombination resulting in pYES2-OPA1-Sp.X (ura3::TRP1). After selection of Trp1+ but 
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Ura3- yeast cells, the pYES2-OPA1-Sp.X (ura3::TRP1) plasmids were re-isolated and used 
for further transformations. 
 
Table 4. List of oligonucleotides used in this study. 
Oligonu-
cleotide Description Sequence 
TL209 Deletion of YTA12 5’-ACTATACCGGCTAACTGGAAAGAACAGAAAC GCAAAATTGATGAACGTACGCTGCAGGTCGAC-3’ 
TL210 Deletion of YTA12 5’-GTCACCTGTCTCGTCCGAAAATGGTTTTGTCA AATCGCTATCATCATCGATGAATTCGAGCTCG-3’ 
TL1048 3’-hparapleginE575Q 5’-GGCGTGGCCCGACTGATGAAACGCAACCAC-3’ 
TL1049 5’-hparapleginE575Q 5’-GTGGTTGCGTTTCATCAGTCGGGCCACGCC-3’ 
TL1050 3’-hAFG3L2E575Q 5’-CCGCATGGCCTGCTTGGTGGTATGCCACAG-3’ 
TL1051 5’-hAFG3L2E575Q 5’-CTGTGGCATACCACCAAGCAGGCCATGCGG-3’ 
TL1616 5’-SbfI-YTA10 promoter and MTS 
5’-TTTTTCCTGCAGGGTGTGTCCAATTACGCGCAC 
GT-3’ 
TL1617 3’-BamHI-YTA10  promoter and MTS 
5’-AAAAGGATCCTATTTGGGTAGAACGGTGTATT 
GTG-3’ 
TL1618 5’-HindIII-YTA10 promoter and MTS 
5’-TTTTTAAGCTTGTGTGTCCAATTACGCGCACGT 
TGGG-3’ 
TL1619 5’-XmaI-YTA10 promoter and MTS 
5’-TCCCCCCGGGGTGTGTCCAATTACGCGCACGT 
TGG-3’ 
TL1620 3’-HindIII-YTA10  promoter and MTS 
5’-AAAAAAGCTTTATTTGGGTAGAACGGTGTATT 
GTGTT-3’ 
TL1621 5’-HindIII-Afg3l2 5’-TTTTAAGCTTCTCCGTACGCTCTATCAATATGC TACTG-3’ 
TL1622 3’-KpnI-Afg3l2 5’-AAAAGGTACCTCAAGCGTAATCTGGAACATCG TATGG-3’ 
TL1642 5’-BamHI-paraplegin 5’-TTTTGGATCCGCGGCCCGCGGGACTCCGGTTG-3’ 
TL1643 3’-EcoRI-paraplegin 5’-AAAAGAATTCCTAGGGAGCCGGAGCCTCCTCC TCCCCTG-3’ 
TL1644 5’-BamHI-Afg3l1 5’-TTTTGGATCCGGCGGATGCGCAGGGAGCGGCG GGAC-3’ 
TL1645 3’-KpnI-Afg3l1 5’-AAAAGGTACCCTACAGATCCTCCTCAGAAATC AGCTTTTG-3’ 
TL2061 5’-Afg3l2E574Q 5’-CGGTGGCTTACCACCAAGCAGGCCATGCGG-3’ 
TL2062 3’-Afg3l2E574Q 5’-CCGCATGGCCTGCTTGGTGGTAAGCCACCG-3’ 
TL2501 5’-parapleginE575Q 5’-GGTCGCCTTCCATCAGTCTGGCCATGCC-3’ 
TL2502 3’-parapleginE575Q 5’-GGCATGGCCAGACTGATGGAAGGCGACC-3’ 
TL2503 5’-Afg3l1E567Q 5’-CTGTAGCCTACCACCAGGCTGGGCATGCAG-3’ 
TL2504 3’-Afg3l1E567Q 5’-CTGCATGCCCAGCCTGGTGGTAGGCTACAG-3’ 
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 The plasmids pGEM4-Atp7 and pGEM4-Yme2F114S∆C15+1 (-Yme2∆C) for SP6-
polymerase-driven expression in vitro were described previously (Korbel et al., 2004). 
 
2.2 Yeast strains and growth conditions 
 All S. cerevisiae strains used in this study are derivatives of W303 (Rothstein and 
Sherman, 1980; genotype: MATa/α ade2-1 his3-11,15 leu2,112 trp1-1 ura3-52 can1-100) and 
listed in Tab. 5. The strain ∆yta10∆yta12 (YKO200) was obtained by deletion of YTA12 in 
the strain ∆yta10 (YGS101) (Arlt et al., 1998) by PCR-targeted homologous recombination 
using the kanMX6 deletion cassette and the oligonucleotides TL209 and TL210 (Longtine et 
al., 1998). ∆yta10∆yta12 strains expressing human or murine m-AAA proteases (see Tab. 3) 
were generated by transformation of YKO200 cells with the plasmids YEplac181ADH1-Yta10 
(1-63)-hparaplegin (59-795), YEplac112ADH1-Yta10 (1-61)-hAFG3L2 (36-798)-Myc, 
YEplac181YTA10-Yta10 (1-61)-paraplegin (44-781), YEplac195YTA10-Yta10 (1-61)-Afg3l1 (25-
789)-Myc, and YEplac112YTA10-Yta10 (1-61)-Afg3l2 (36-802)-HA or plasmids encoding the 
respective proteolytic site variants. To obtain yeast strains harbouring human OPA1 splice 
variants 1, 4, 7, or 8, W303 MATa cells, YKO200 cells, or YKO200 cells expressing 
mammalian m-AAA protease subunits were transformed with the pYES2-OPA1-Sp.X 
(URA3) plasmid series. For co-expression of OPA1 splice variants in ∆yta10∆yta12 cells 
containing YEplac195YTA10-Yta10 (1-61)-Afg3l1 (25-789)-Myc, the pYES2-OPA1-Sp.X 
(ura3::TRP1) plasmids were employed. ∆pcp1 and ∆phb1 strains expressing the OPA1 splice 
variants were generated by transformation of either YTT407 cells (T. Tatsuta, unpublished) or 
YGS410 cells (Steglich et al., 1999) with pYES2-OPA1-Sp.X (URA3). All transformations 
were carried out using the lithium acetate method described by (Gietz et al., 1995). 
 Yeast cells were grown according to standard procedures at 30°C either in YP medium 
or synthetic minimal medium supplemented with the required auxotrophs (Sherman, 2002; 
Tatsuta and Langer, 2007). 2% (w/v) glucose or, for isolation of mitochondria, 2% (w/v) 
galactose and 0.5% (w/v) lactate or, for examining respiratory growth, 3% (w/v) glycerol 
were added as carbon sources. In the latter case, 5 x 104 yeast cells were spotted onto 
glycerol-containing YP plates. To induce GAL1 promoter-driven OPA1 expression, yeast 
cells harbouring pYES2-OPA1-Sp.X plasmids were grown in minimal medium containing 
1.5% (w/v) galactose and 0.5% (w/v) glucose. 
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Table 5. List of yeast strains used*. All YKO strains were generated in this study. 
Name Description Genotype  Plasmids 
WT Wild-type W303 MATa  
YKO200 ∆yta10∆yta12 
W303 MATα  
yta10::HIS3MX6 
yta12::kanMX6 
 
YKO201 ∆yta10∆yta12  + hparaplegin YKO200 
YEplac181ADH1-Yta10 (1-63)-hparaplegin 
(59-795) 
YKO203 ∆yta10∆yta12  + hAFG3L2 YKO200 
YEplac112ADH1-Yta10 (1-61)-hAFG3L2 
(36-798)-Myc 
YKO204 ∆yta10∆yta12  + hAFG3L2EQ YKO200 
YEplac112ADH1-Yta10 (1-61)-
hAFG3L2E575Q (36-798)-Myc 
YKO205 
∆yta10∆yta12 
+ hparaplegin 
+ hAFG3L2 
YKO200 
YEplac181ADH1-Yta10 (1-63)-hparaplegin 
(59-795); YEplac112ADH1-Yta10 (1-61)-
hAFG3L2 (36-798)-Myc 
YKO206 
∆yta10∆yta12  
+ hparapleginEQ
+ hAFG3L2 
YKO200 
YEplac181ADH1-Yta10 (1-63)-hpara-
pleginE575Q (59-795); YEplac112ADH1-
Yta10 (1-61)-hAFG3L2 (36-798)-Myc  
YKO207 
∆yta10∆yta12  
+ hparaplegin 
+ hAFG3L2EQ
YKO200 
YEplac181ADH1-Yta10 (1-63)-hparaplegin 
(59-795); YEplac112ADH1-Yta10 (1-61)-
hAFG3L2E575Q (36-798)-Myc 
YKO208 
∆yta10∆yta12  
+ hparapleginEQ
+ hAFG3L2EQ
YKO200 
YEplac181ADH1-Yta10 (1-63)-hparaple-
ginE575Q (59-795); YEplac112ADH1-Yta10 
(1-61)-hAFG3L2E575Q (36-798)-Myc 
YKO209 ∆yta10∆yta12  + paraplegin YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781)  
YKO211 ∆yta10∆yta12  + Afg3l1 YKO200 
YEplac195YTA10-Yta10 (1-61)-Afg3l1 (25-
789)-Myc  
YKO212 ∆yta10∆yta12  + Afg3l1EQ YKO200 
YEplac195YTA10-Yta10 (1-61)-Afg3l1E567Q 
(25-789)-Myc 
YKO213 ∆yta10∆yta12  + Afg3l2 YKO200 
YEplac112YTA10-Yta10 (1-61)-Afg3l2 (36-
802)-HA 
YKO214 ∆yta10∆yta12  + Afg3l2EQ YKO200 
YEplac112YTA10-Yta10 (1-61)-Afg3l2E574Q 
(36-802)-HA 
YKO215 
∆yta10∆yta12  
+ paraplegin 
+ Afg3l1 
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781); YEplac195YTA10-Yta10 (1-61)-
Afg3l1 (25-789)-Myc 
YKO216 
∆yta10∆yta12  
+ parapleginEQ
+ Afg3l1 
YKO200 
YEplac181YTA10-Yta10 (1-61)-
parapleginE575Q (44-781); YEplac195YTA10-
Yta10 (1-61)-Afg3l1 (25-789)-Myc 
YKO217 
∆yta10∆yta12  
+ paraplegin 
+ Afg3l1EQ
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781); YEplac195YTA10-Yta10 (1-61)-
Afg3l1E567Q (25-789)-Myc 
YKO218 
∆yta10∆yta12  
+ parapleginEQ
+ Afg3l1EQ
YKO200 
YEplac181YTA10-Yta10 (1-61)-
parapleginE575Q (44-781); YEplac195YTA10-
Yta10 (1-61)-Afg3l1E567Q (25-789)-Myc 
YKO219 
∆yta10∆yta12  
+ paraplegin 
+ Afg3l2 
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781); YEplac112YTA10-Yta10 (1-61)-
Afg3l2 (36-802)-HA 
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Name Description Genotype  Plasmids 
YKO220 
∆yta10∆yta12  
+ parapleginEQ
+ Afg3l2 
YKO200 
YEplac181YTA10-Yta10 (1-61)-
parapleginE575Q (44-781); YEplac112YTA10-
Yta10 (1-61)-Afg3l2 (36-802)-HA 
YKO221 
∆yta10∆yta12  
+ paraplegin 
+ Afg3l2EQ
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781); YEplac112YTA10-Yta10 (1-61)-
Afg3l2E574Q (36-802)-HA 
YKO222 
∆yta10∆yta12  
+ parapleginEQ
+ Afg3l2EQ
YKO200 
YEplac181YTA10-Yta10 (1-61)-
parapleginE575Q (44-781); YEplac112YTA10-
Yta10 (1-61)-Afg3l2E574Q (36-802)-HA 
YKO400 WT + OPA1-Sp4 W303 MATa pYES2-OPA1-Sp4 (URA3) 
YKO401 ∆yta10∆yta12 + OPA1-Sp4 YKO200 pYES2-OPA1-Sp4 (URA3) 
YKO402 ∆pcp1 + OPA1-Sp4 
W303 MATα 
pcp1::kanMX6 pYES2-OPA1-Sp4 (URA3) 
YKO404 
∆yta10∆yta12  
+ paraplegin 
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781) 
pYES2-OPA1-Sp4 (URA3) 
YKO405 
∆yta10∆yta12  
+ Afg3l1 
+ OPA1-Sp4 
YKO200 
YEplac195YTA10-Yta10 (1-61)-Afg3l1 (25-
789)-Myc 
pYES2-OPA1-Sp4 (ura3::TRP1) 
YKO406 
∆yta10∆yta12  
+ Afg3l1EQ
+ OPA1-Sp4 
YKO200 
YEplac195YTA10-Yta10 (1-61)-Afg3l1E567Q 
(25-789)-Myc 
pYES2-OPA1-Sp4 (ura3::TRP1) 
YKO407 
∆yta10∆yta12  
+ Afg3l2 
+ OPA1-Sp4 
YKO200 
YEplac112YTA10-Yta10 (1-61)-Afg3l2 (36-
802)-HA 
pYES2-OPA1-Sp4 (URA3) 
YKO408 
∆yta10∆yta12  
+ Afg3l2EQ 
+ OPA1-Sp4 
YKO200 
YEplac112YTA10-Yta10 (1-61)-Afg3l2E574Q 
(36-802)-HA 
pYES2-OPA1-Sp4 (URA3) 
YKO409 
∆yta10∆yta12  
+ paraplegin 
+ Afg3l1
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781); YEplac195YTA10-Yta10 (1-61)-
Afg3l1 (25-789)-Myc;  
pYES2-OPA1-Sp4 (ura3::TRP1) 
YKO410 
∆yta10∆yta12  
+ parapleginEQ
+ Afg3l1
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-
parapleginE575Q (44-781); YEplac195YTA10-
Yta10 (1-61)-Afg3l1 (25-789)-Myc; 
pYES2-OPA1-Sp4 (ura3::TRP1) 
YKO411 
∆yta10∆yta12  
+ paraplegin 
+ Afg3l1EQ 
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781); YEplac195YTA10-Yta10 (1-61)-
Afg3l1E567Q (25-789)-Myc;  
pYES2-OPA1-Sp4 (ura3::TRP1) 
YKO412 
∆yta10∆yta12  
+ parapleginEQ
+ Afg3l1EQ 
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-
parapleginE575Q (44-781); YEplac195YTA10-
Yta10 (1-61)-Afg3l1E567Q (25-789)-Myc; 
pYES2-OPA1-Sp4 (ura3::TRP1) 
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Name Description Genotype  Plasmids 
YKO413 
∆yta10∆yta12  
+ paraplegin 
+ Afg3l2
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781); YEplac112YTA10-Yta10 (1-61)-
Afg3l2 (36-802)-HA;  
pYES2-OPA1-Sp4 (URA3) 
YKO414 
∆yta10∆yta12  
+ parapleginEQ
+ Afg3l2
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-
parapleginE575Q (44-781); YEplac112YTA10-
Yta10 (1-61)-Afg3l2 (36-802)-HA;  
pYES2-OPA1-Sp4 (URA3) 
YKO415 
∆yta10∆yta12  
+ paraplegin 
+ Afg3l2EQ 
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-paraplegin 
(44-781); YEplac112YTA10-Yta10 (1-61)-
Afg3l2E574Q (36-802)-HA;  
pYES2-OPA1-Sp4 (URA3) 
YKO416 
∆yta10∆yta12  
+ parapleginEQ
+ Afg3l2EQ 
+ OPA1-Sp4 
YKO200 
YEplac181YTA10-Yta10 (1-61)-
parapleginE575Q (44-781); YEplac112YTA10-
Yta10 (1-61)-Afg3l2E574Q (36-802)-HA;  
pYES2-OPA1-Sp4 (URA3) 
YKO470 
∆yta10∆yta12  
+ hAFG3L2 
+ OPA1-Sp4 
YKO200 
YEplac112ADH1-Yta10 (1-61)-hAFG3L2 
(36-798)-Myc; 
pYES2-OPA1-Sp4 (URA3) 
YKO471 
∆yta10∆yta12  
+ hAFG3L2EQ 
+ OPA1-Sp4 
YKO200 
YEplac112ADH1-Yta10 (1-61)-
hAFG3L2E575Q (36-798)-Myc; 
pYES2-OPA1-Sp4 (URA3) 
YKO477 ∆phb1 + OPA1-Sp4 
W303 MATα  
phb1::HIS3MX6 pYES2-OPA1-Sp4 (URA3) 
*This list only contains the strains expressing OPA1 splice variant 4 (OPA1-Sp.4). The corresponding strain 
names for OPA1 splice variants 1, 7, and 8 are as follows: YKO417-YKO433, YKO468, YKO469, and YKO476 
for OPA1-Sp.1; YKO434-450, YKO472, YKO473, and YKO478 for OPA1-Sp.7; YKO451-YKO469, YKO474, 
YKO475, and YKO479 for OPA1-Sp.8. 
 
 
2.3 Cell culture 
 Primary human fibroblasts are derived from a control individual and an HSP patient 
who is homozygous for a 9.5 kb deletion in the SPG7 gene encoding hparaplegin (De Michele 
et al., 1998; Atorino et al., 2003). Fibroblasts were cultured in minimal essential medium 
supplemented with 2 mM L-glutamine, 200 U/ml penicillin, 200 mg/ml streptomycin, and 
20% fetal bovine serum at 37°C in 95% humidified air and 5% CO2. For HeLa cells, minimal 
essential medium with Earle’s salts supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin, 100 mg/ml streptomycin, 1 mM sodium pyruvate, 1x non-essential amino acids, 
and 10% fetal bovine serum was used. 
 
Material and Methods 41
2.4 Preparation of total extracts from S. cerevisiae and HeLa 
cells 
 In order to prepare total cell extracts from yeast cells expressing human OPA1 splice 
variants, alkaline lysis was carried out according to (Yaffe and Schatz, 1984). 1 OD600 unit 
yeast cells was sedimented by centrifugation for 2 min at 16,000 g and washed once with 
H2O. Subsequently, the cell pellet was resuspended in 500 µl H2O and 75 µl alkaline lysis 
buffer [1.85 M NaOH, 7.4% (v/v) β-mercaptoethanol, 10 mM PMSF, 5% (v/v) ethanol] were 
added. After incubation for 10 min at 4°C, the sample was subjected to TCA precipitation 
(Tatsuta and Langer, 2007) and analysed by SDS-PAGE (Laemmli, 1970) and Western blot 
(Towbin et al., 1979). For SDS-PAGE, precipitated cellular proteins corresponding to 
0.25 OD600 units yeast cells were loaded for cells expressing OPA1 splice variants 4, 7, and 8, 
whereas proteins of 1 OD600 unit yeast cells were used in case of OPA1 splice variant 1. 
 HeLa cells were resuspended in SDS-PAGE sample buffer [1.6% (w/v) SDS, 4% (v/v) 
β-mercaptoethanol, 50 mM Tris-HCl pH 6.8, 8% (w/v) glycerol, 0,005% (w/v) bromphenol 
blue]. After addition of 1 µl of the nuclease benzonase (25 U/µl, Novagen), the sample was 
mixed for 30 min at 1,400 rpm and RT and analysed as described above. 
 
2.5 Preparation of cellular membranes from S. cerevisiae 
 For the fast preparation of cellular membrane fractions including mitochondrial 
fractions, yeast cells were lysed using glass beads. 10 OD600 units of a yeast culture were 
centrifuged for 5 min at 3,000 g and RT. The yeast cells were then resuspended in 300 µl ice-
cold SHKCl buffer (0,6 M sorbitol, 50 mM HEPES/KOH pH 7.4, 80 mM KCl, 2 mM PMSF) 
and glass beads (∅ 0,5 mm) equivalent to a volume of 200 µl were added. The sample was 
mixed four times for 30 s with a Vortex mixer and each time cooled on ice for another 30 s. 
Upon the addition of 400 µl SHKCl buffer, glass beads and non-lysed cells were removed by 
centrifugation for 3 min at 500 g and 4°C. The cellular membrane fraction was separated from 
the soluble supernatant by centrifugation for 10 min at 16,000 g and 4°C. In addition, 50 µl of 
the supernatant containing the cytosolic fraction were subjected to TCA precipitation (Tatsuta 
and Langer, 2007) and together with the total membrane fraction immunochemically analysed 
after SDS-PAGE (Laemmli, 1970) and Western blot (Towbin et al., 1979). The presence of 
mitochondrial membranes in the cellular membrane fraction was verified by 
immunodecoration with an antibody recognising the mitochondrial ADP/ATP carrier Aac2 
(Tab. 6). 
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2.6 Alkaline extraction of mitochondrial membranes 
 The membrane insertion of mitochondrial proteins can be examined using alkaline 
extraction of membranes in a sodium carbonate buffer (Fujiki et al., 1982). This extraction 
allows the separation of integral membrane proteins from soluble proteins and proteins 
peripherally associated with mitochondrial membranes by centrifugation. These latter proteins 
can be recovered from the supernatant fraction, whereas integral membrane proteins remain in 
the insoluble pellet fraction. Isolated mitochondria (100 µg mitochondrial protein) were 
resuspended in 1 ml 100 mM sodium carbonate (pH 11.5) and incubated for 30 min at 4°C. A 
sample of 500 µl (total) was withdrawn and TCA-precipitated (Tatsuta and Langer, 2007). 
The remaining 500 µl were subjected to centrifugation for 30 min at 125,000 g and 4°C. The 
resulting insoluble pellet fraction was resuspended in 500 µl 100 mM sodium carbonate 
(pH 11.5) and like the supernatant fraction supplemented with TCA. Precipitated proteins of 
the total, the supernatant, and the pellet were analysed by SDS-PAGE (Laemmli, 1970) and 
Western blot (Towbin et al., 1979). The separation of integral membrane proteins from 
soluble proteins was surveyed by immunodetection using antibodies directed against the 
multi-spanning inner membrane protein Aac2 and the soluble matrix protein Mge1 (Tab. 6). 
 
2.7 Isolation of mitochondria from human fibroblasts 
 Mitochondria of human primary fibroblasts from a control individual or a paraplegin-
deficient HSP patient were isolated by differential centrifugation of fibroblast homogenates. 
Human fibroblasts were washed in PBS and resuspended in 5 ml isotonic homogenisation 
buffer (250 mM sucrose, 5 mM Tris-HCl pH 7.5, 0.1 mM PMSF). The cell suspension was 
homogenised by 35 strokes in a Dounce glass-homogeniser. Nuclei and unbroken cells were 
removed by centrifugation for 10 min at 4,500 g and 4°C. The supernatant was centrifuged for 
20 min at 16,000 g and 4°C to collect the mitochondria. Subsequently, the mitochondrial 
pellet was washed and resuspended with homogenisation buffer supplemented with 1 mM 
EDTA (pH 8.0). Finally, the protein concentration of the suspension was determined using the 
Bradford assay according to manufacturer’s instruction (Bio-Rad). Mitochondria were diluted, 
frozen as 100 µg aliquots in liquid nitrogen, and stored at -80°C. 
 
 
Material and Methods 43
2.8 Blue native polyacrylamide gel electrophoresis (BN-PAGE) 
 BN-PAGE is a method to analyse native protein complexes of mitochondrial 
membranes (Schägger, 2001; Reisinger and Eichacker, 2006). It is based on the usage of an 
anionic dye (Coomassie blue G-250), which is added after the solubilisation of mitochondria 
and binds to the surface of proteins. Thereby, a negative net charge is introduced into the 
protein complexes allowing an electrophoretic separation. A high resolution according to the 
mass of the protein complexes is achieved by the decreasing pore size of an acrylamide-
gradient gel. The gradient gels used in this study were composed of a separation gel with a 
linear gradient of 3-13% polyacrylamide [3-13% (w/v) acrylamide, 0.09-0.4% (w/v) 
bisacrylamide, 0-20% (w/v) glycerol, 0.5 M ε-amino-n-caproic acid, 25 mM imidazole-HCl 
pH 7.0, 0.1% (w/v) APS, 0.1% (v/v) TEMED] and a stacking gel [3% (w/v) acrylamide, 
0.09% (w/v) bisacrylamide, 0.5 M ε-amino-n-caproic acid, 25 mM imidazole-HCl pH 7.0, 
0.1% (w/v) APS, 0.1% (v/v) TEMED]. Mitochondrial proteins (150 µg) isolated from yeast or 
human primary fibroblasts were solubilised by shaking (15 min; 1,400 rpm; 4°C) at a 
concentration of 5 mg/ml in 1% (w/v) digitonin, 30 mM Tris-HCl pH 7.4, 4 mM Mg-acetate, 
5 mM ε-amino-n-caproic acid, 50 mM NaCl, 1 mM ATP. After a clarifying spin for 30 min at 
125,000 g and 4°C, mitochondrial extracts were supplemented with 2 µl 50% (w/v) glycerol 
and 1 µl sample buffer [5% (w/v) Coomassie blue G-250 in 0.5 M ε-amino-n-caproic acid] 
and loaded onto the polyacrylamide-gradient gel. The electrophoretic separation was carried 
out in Mini-Protean-3-gel chambers (Bio-Rad) at 4°C [deep blue cathode buffer B: 50 mM 
Tricine, 7.5 mM imidazole, 0.02% (w/v) Coomassie blue G-250; anode buffer: 25 mM 
imidazole-HCl pH 7.0] using a constant voltage of 50 V and a current of 15 mA for ~30 min, 
followed by 300 V and 15 mA for ~30 min. Subsequently, the deep blue cathode buffer B was 
exchanged for a cathode buffer of identical composition but lacking Coomassie blue G-250 
and the separation was continued at 300 V and 15 mA. Finally, the proteins were transferred 
from the gradient gel onto a PVDF membrane for 2 h at 200 mA. Thyroglobulin (669 kDa) 
and apoferritin (443 kDa) were used for calibration. Protein complexes containing hAFG3L2 
were detected by immunodecoration with a specific antiserum (Tab. 6). 
 
2.9 Gel filtration analysis of mitochondrial extracts from yeast 
 Gel filtration analysis (size exclusion chromatography) using a Superose 6 column and 
the Äkta Purifier-LC system (GE Healthcare) was employed to analyse the complex 
formation of mammalian m-AAA protease subunits and to determine their native molecular 
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mass. Isolated yeast mitochondria (900 µg mitochondrial protein) were solubilised by shaking 
(15 min; 1,400 rpm; 4°C) at a concentration of 5 mg/ml in 1% (w/v) digitonin, 30 mM Tris-
HCl pH 7.4, 4 mM Mg-acetate, 150 mM K-acetate pH 7.4, 1 mM PMSF, 1 mM ATP. Non-
solubilised or aggregated material was removed by centrifugation for 30 min at 125,000 g and 
4°C and the supernatant was loaded onto a Superose 6 column, which was equilibrated with 
digitonin-containing buffer lacking PMSF. The flow rate was set to 0.3 ml/min. Eluted 
proteins were collected in 500 µl fractions, TCA-precipitated (Tatsuta and Langer, 2007), and 
analysed by SDS-PAGE (Laemmli, 1970) and Western blot (Towbin et al., 1979). Proteins 
present in eluate fractions were quantified by laser densitometry (Kodak Image Station 440) 
and normalised to the amount of the respective protein in the total eluate. The calibration of 
the Superose 6 column was carried out with the following marker proteins: Hsp60 (840 kDa), 
apoferritin (443 kDa), alcohol dehydrogenase (150 kDa), and bovine serum albumine (66 
kDa). 
 
2.10 Degradation of newly imported, radiolabelled polypeptides in 
isolated yeast mitochondria 
 The SP6-polymerase-driven in vitro transcription of pGEM4-Atp7 and pGEM4-
Yme2∆C, the cell free synthesis of radiolabelled precursor proteins, and the subsequent 
analysis of their degradation upon import into isolated yeast mitochondria were performed as 
previously described except for the following changes (Tatsuta and Langer, 2007). For 
mitochondrial import, the import buffer was supplemented with 5 mM NADH, 2.5 mM ATP, 
10 mM creatine phosphate, 100 µg/ml creatine kinase, and 0.5 mg/ml isolated yeast 
mitochondria. After incubation for 3 min at 25°C, the reticulocyte lysate (Promega) 
containing radiolabelled precursor proteins was added to the import reaction at a final 
concentration of 2% (v/v), followed by incubation for 10 min at 25°C. Mitochondrial import 
was stopped by the addition of 0.5 µM valinomycin. After removal of non-imported precursor 
proteins by trypsin treatment (Tatsuta and Langer, 2007), the import reaction was divided into 
5 aliquots of 60 µl (corresponding to 30 µg mitochondrial protein), which were incubated for 
0, 5, 10, 20, and 30 min at 37°C to allow proteolysis. Mitochondria were re-isolated by 
centrifugation for 5 min at 16,000 g and 4°C and washed once with SHKCl. The samples 
were analysed by autoradiography after SDS-PAGE (Laemmli, 1970) and Western blot 
(Towbin et al., 1979). For the quantification of radiolabelled proteins, a phosphorimaging 
plate (BAS-SR 127, Fuji) was used and the phosphorescence signals were detected with a 
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reader (Molecular Imager, Bio-Rad) and quantified (Quantity One, Bio-Rad). The integrity of 
the mitochondria was monitored by immunodetection with antisera specific for the 
intermembrane space protein Ccp1 and the matrix protein Mge1 (Tab. 6). 
 
2.11 Co-immunoprecipitation 
 Co-immunoprecipitation experiments were performed to investigate a direct 
interaction between murine m-AAA protease subunits following expression in yeast. In order 
to couple antibodies to Protein A Sepharose (PAS) beads (GE Healthcare), 5 mg PAS beads 
were equilibrated with washing buffer [0.5% (w/v) digitonin, 30 mM Tris-HCl pH 7.4, 4 mM 
Mg-acetate, 150 mM K-acetate pH 7.4, 1 mM PMSF, 1 mM ATP] and then incubated with 
15 µl of c-Myc-specific or 10 µl of HA-specific antisera (Tab. 6) for 1.5 h at 4°C under gentle 
shaking in 400 µl washing buffer. Subsequently, the PAS beads with coupled antibodies were 
washed once with washing buffer and used for co-immunoprecipitation. 
 Isolated yeast mitochondria (400 µg mitochondrial protein) harbouring murine m-
AAA protease subunits were solubilised by shaking (15 min; 1,400 rpm; 4°C) at a 
concentration of 1 mg/ml in lysis buffer [2% (w/v) digitonin, 30 mM Tris-HCl pH 7.4, 4 mM 
Mg-acetate, 150 mM K-acetate pH 7.4, 1 mM PMSF, 1 mM ATP supplemented with EDTA-
free protease inhibitor cocktail (Roche)]. After centrifugation for 15 min at 125,000 g and 
4°C, 300 µl of the supernatant were loaded onto the prepared PAS beads (5 mg) with coupled 
c-Myc- or HA-specific antibodies and incubated under gentle shaking for 2.5 h at 4°C. The 
PAS beads were then washed twice with washing buffer and once with 10 mM Tris-HCl 
pH 7.4. Antibody-antigen complexes were eluted from the PAS beads with SDS-PAGE 
sample buffer and analysed by SDS-PAGE (Laemmli, 1970) and Western blot (Towbin et al., 
1979). 10% of the mitochondrial extract obtained by solubilisation and centrifugation were 
used as input control and analysed in parallel. 
 
2.12 Immunological detection of proteins 
 Nitrocellulose or PVDF membranes were incubated after protein transfer for at least 
30 min at RT in blocking solution [5% (w/v) milk powder in TBS buffer (10 mM Tris/HCl 
pH 7.4, 150 mM NaCl)]. This was followed by immunodecoration for 60-120 min with a 
specific antiserum (Tab. 6) diluted in 5% (w/v) milk powder in TBS buffer. Upon removal of 
the antiserum, the membranes were washed for 10 min with TBS, TBS supplemented with 
0.05% (v/v) Triton X-100, and again with TBS, respectively. To recognise bound antibodies, 
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horseradish peroxidase-conjugated antibodies specific for immunoglobulins G of rabbit, 
mouse, or rat were employed in a dilution of 1:10,000 in 5% (w/v) milk powder in TBS. 
Membranes were incubated for 60 min with these solutions and subsequently washed twice 
for 10 min with TBS. The bound peroxidase was detected after incubating the membranes 
with 2 ml of a 1:1 mixture of chemoluminiscence reagents [solution 1: 10 ml 1 M Tris-HCl 
pH 8.5, 1 ml luminol (44 µg/ml in DMSO), 440 µl p-coumaric acid (15 mg/ml in DMSO), 
88.56 ml H2O; solution 2: 10 ml Tris-HCl pH 8.5, 60 µl 30% hydrogen peroxide, 89.94 ml 
H20]. Subsequently, the membranes were exposed to light-sensitive X-ray films (Super RX, 
Fuji). 
 
Table 6: Antibodies used in this study are listed in the order of their appearance. 
Antibody Antigen Dilution Reference 
α-hAFG3L2 amino acids 413-828 of human AFG3L2 1:2000 Atorino et al., 2003 
α-pMrpL32  
peptide corresponding to amino 
acids 45-59 of MrpL32 from 
S. cerevisiae 
1:1000 Nolden et al., 2005 
α-mMrpL32  
peptide corresponding to amino 
acids 131-145 of MrpL32 from 
S. cerevisiae 
1:500 Nolden et al., 2005 
α-Mge1 C-terminal peptide of Mge1 from S. cerevisiae 1:10000 Schneider et al., 1994 
α-Ccp1 purified protein, cytochrome c peroxidase from S. cerevisiae 1:1000  
α-Tom40 C-terminal peptide of Tom40 from S. cerevisiae 1:20000  
α-paraplegin* 
peptide corresponding to amino 
acids 121-139 of murine 
paraplegin 
1:100 Koppen et al., 2007 
α-Myc (9B11) 
peptide corresponding to amino 
acids 410-419 of human c-Myc 
(EQKLISEEDL) 
1:1000 Cell Signalling Technology 
α-HA (3F10) 
synthetic peptide corresponding 
to amino acids 76-111 of X47 
hemagglutinin 1 (recognises the 
sequence YPYDVPDYA) 
1:1000 Roche 
α-Aac2 
C-terminal peptide of the 
ADP/ATP carrier from 
S. cerevisiae 
1:10000  
α-OPA1 amino acids 708-830 of human OPA1 1:500 BD biosciences 
p, precursor; m, mature form; *, this antiserum raised against an epitope of murine paraplegin also recognises 
human paraplegin. 
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2.13 Miscellaneous 
 The following procedures used in this study have been described previously: 
isolation of mitochondria from yeast (Tatsuta and Langer, 2007); molecular biology and 
genetics methods (Sambrook and Russell, 2001). 
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3 Results 
 
3.1 Identification of the human AFG3L2 complex, a novel homo-
oligomeric m-AAA protease 
 
 Human paraplegin (hparaplegin) and AFG3L2 (hAFG3L2) assemble into a hetero-
oligomeric m-AAA protease, which was identified in mitochondria of human primary 
fibroblasts by co-immunoprecipitation experiments and gel filtration analysis (Atorino et al., 
2003). Complementation studies in the yeast S. cerevisiae assigned functional activity to this 
complex, as it could substitute for the endogenous m-AAA protease (Atorino et al., 2003). 
The formation of this hetero-oligomeric assembly is impaired in HSP patients lacking 
hparaplegin. Therefore, initial experiments were aiming at the analysis of the assembly status 
of the remaining m-AAA protease subunit hAFG3L2 in mitochondria of hparaplegin-deficient 
HSP fibroblasts. In parallel, hAFG3L2 was heterologously expressed in yeast in order to 
investigate its activity and function in the absence of hparaplegin. 
 
3.1.1 A homo-oligomeric hAFG3L2 complex in HSP fibroblasts and 
upon expression in yeast 
To assess the assembly status of hAFG3L2, mitochondria were isolated from control 
and HSP fibroblasts, solubilised in digitonin and subjected to blue-native gel electrophoresis 
(BN-PAGE) (Schägger, 2001; Reisinger and Eichacker, 2006). The complete absence of 
hparaplegin in HSP fibroblasts was verified by SDS-PAGE and immunoblotting of isolated 
mitochondria using a hparaplegin-specific antiserum (Fig. 8A). In mitochondria of control 
fibroblasts, hAFG3L2 was detected with specific antibodies in a high molecular mass 
complex of ~900 kDa (Fig. 8A). Surprisingly, the loss of hparaplegin in mitochondria of HSP 
patients did not impair the formation of this complex, which showed a similar size as the 
putative hetero-oligomeric m-AAA protease observed in control mitochondria (Fig. 8A). This 
finding is in contrast to previous results showing that hAFG3L2 is only present in a complex 
with a native molecular mass of ~250 kDa in hparaplegin-deficient HSP fibroblasts (Atorino 
et al., 2003). This apparent discrepancy, however, can be explained by the usage of the milder 
detergent digitonin in this work instead of the previously used NP-40. 
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Figure 8. hAFG3L2 forms a homo-oligomeric m-AAA protease complex in HSP fibroblasts and 
upon expression in the yeast S. cerevisiae. 
(A) A homo-oligomeric hAFG3L2 complex in mitochondria isolated from HSP fibroblasts. 
Mitochondria from control fibroblasts and hparaplegin-deficient HSP fibroblasts were either subjected 
to SDS-PAGE (50 µg mitochondrial protein; upper panel) or solubilised in digitonin and analysed by 
BN-PAGE (150 µg mitochondrial protein; lower panel), followed by immunoblotting using 
hparaplegin- (upper panel) and hAFG3L2-specific (upper and lower panel) antisera. For control, yeast 
∆yta10∆yta12 mitochondria containing hAFG3L2 were fractionated by BN-PAGE in parallel. 
Thyroglobulin (669 kDa) and apoferritin (443 kDa) were used for calibration. 
(B) Homo-oligomeric hAFG3L2 complexes in ∆yta10∆yta12 mitochondria. hAFG3L2 or 
hAFG3L2E575Q (hAFG3L2EQ) were expressed in ∆yta10∆yta12 cells and mitochondria were isolated. 
After solubilisation in digitonin-containing buffer, mitochondrial extracts (900 µg mitochondrial 
protein) were fractionated by Superose 6 sizing chromatography. Eluate fractions were TCA-
precipitated and analysed by SDS-PAGE and immunoblotting using antibodies specific for the C-
terminal c-Myc-epitope of hAFG3L2. hAFG3L2 (filled squares) or hAFG3L2E575Q (hAFG3L2EQ; filled 
circles) present in eluate fractions were quantified by laser densitometry and are given as percent of 
the respective protein in the total eluate. A smaller hAFG3L2-containing complex, marked with an 
asterisk, most likely results from partial dissociation of the large complex. The following marker 
proteins were used for calibration: 1, Hsp60 (840 kDa); 2, apoferritin (443 kDa); 3, alcohol 
dehydrogenase (150 kDa); 4, bovine serum albumine (66 kDa). 
 
 The complex formation of hAFG3L2 in the absence of hparaplegin could be due to a 
homo-oligomerisation or to its assembly with another AAA protease subunit. To distinguish 
between these possibilities, plasmid-borne hAFG3L2 was expressed under the control of the 
yeast ADH1 promoter in ∆yta10∆yta12 yeast cells lacking any m-AAA protease subunit. 
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Mitochondrial targeting of hAFG3L2 was ensured by replacing its putative mitochondrial 
targeting sequence (amino acids 1-35) with the sorting signal of Yta10 (amino acids 1-61). 
Expression and mitochondrial localisation of the resulting hybrid protein were confirmed 
previously (Koppen, 2002). Mitochondria were isolated from these cells and digitonin extracts 
were again analysed by BN-PAGE. When expressed in S. cerevisiae, hAFG3L2 assembled 
into a complex of ~900 kDa corresponding in size to the hAFG3L2 containing complex 
observed in mitochondria of HSP fibroblasts (Fig. 8A). 
 To substantiate these findings and to determine the native molecular mass of the 
hAFG3L2 complex by an additional method, digitonin-solubilised mitochondria of 
∆yta10∆yta12 yeast cells expressing C-terminally c-Myc-tagged hAFG3L2 were loaded onto 
a Superose 6 gel filtration column and eluate fractions were analysed after TCA precipitation 
by Western blot analysis using an antibody directed against the c-Myc epitope. hAFG3L2 was 
detected in eluate fractions corresponding to a native molecular mass of ~850 kDa confirming 
the results obtained by BN-PAGE (Fig. 8B). In addition, hAFG3L2 was found to be part of an 
additional smaller complex of ~370 kDa which could represent an assembly intermediate of 
the hAFG3L2 complex or may be caused by a partial disassembly of the high molecular mass 
complex upon solubilisation of mitochondrial membranes (Fig. 8B). 
 Taken together, hAFG3L2 assembles with hparaplegin and, in addition, can form a 
homo-oligomeric complex. Moreover, this hAFG3L2 complex shows a similar size as hetero-
oligomeric m-AAA proteases in humans and yeast, consisting of either hparaplegin and 
hAFG3L2 or Yta10 and Yta12, respectively (Arlt et al., 1996; Atorino et al., 2003). 
 
3.1.2 The hAFG3L2 complex can substitute for the yeast m-AAA 
protease 
 To determine if the homo-oligomeric hAFG3L2 complex is functionally active, it was 
tested if hAFG3L2 expression can complement the growth phenotype of ∆yta10∆yta12 cells. 
Yeast cells lacking the m-AAA protease are respiratory deficient and cannot grow on non-
fermentable carbon sources like glycerol (Fig. 9) (Guélin et al., 1994; Tauer et al., 1994; 
Tzagoloff et al., 1994; Arlt et al., 1998). Upon expression of hAFG3L2, growth on glycerol-
containing medium (YPG) was comparable to wild-type cells, thus the respiratory 
competence of ∆yta10∆yta12 cells was restored (Fig 9). 
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Figure 9. Maintenance of respiratory growth of ∆yta10∆yta12 yeast cells by hAFG3L2. 
Wild-type (WT) cells, ∆yta10∆yta12 cells, and ∆yta10∆yta12 cells expressing hAFG3L2 or the 
proteolytically inactive variant hAFG3L2E575Q (hAFG3L2EQ), were grown on fermentable (YPD) and 
non-fermentable (YPG) carbon sources at 30°C. 
 
 In order to assess if the proteolytic activity of hAFG3L2 is responsible for the 
observed respiratory growth, a point mutation which was shown to inactivate AAA protease 
subunits of yeast was introduced into its proteolytic centre (Arlt et al., 1996; Guélin et al., 
1996; Leonhard et al., 1996). Glutamate residue 575 of the consensus metal-binding motif 
was replaced by glutamine and the mutant variant of hAFG3L2 (hAFG3L2E575Q) was 
expressed in ∆yta10∆yta12 cells. To rule out the possibility that this mutation impairs the 
assembly of hAFG3L2 into a high molecular mass complex, mitochondria were isolated from 
the respective strain and analysed as above by Superose 6 gel filtration after solubilisation in 
digitonin. As observed for hAFG3L2, its variant harbouring the proteolytic site mutation was 
detected as part of a complex of ~850 kDa (Fig. 8B). Therefore, this mutation does not 
interfere with the formation of the hAFG3L2 complex. However, growth of ∆yta10∆yta12 
cells expressing hAFG3L2E575Q on glycerol-containing medium was completely abolished 
(Fig. 9). 
 In summary, these experiments reveal that human AFG3L2 confers respiratory 
competence to ∆yta10∆yta12 yeast cells, which apparently is dependent on proteolysis by 
hAFG3L2. Thus, hAFG3L2 alone can substitute for the yeast m-AAA protease showing that 
the homo-oligomeric assembly constitutes a functionally active complex. This contradicts 
previous findings that only co-expression of hparaplegin together with hAFG3L2 can 
complement the respiratory growth phenotype of ∆yta10∆yta12 cells (Atorino et al., 2003). 
As another ∆yta10∆yta12 yeast strain was used in that study, it is likely that strain-specific 
differences account for the observed discrepancy. 
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3.1.3 Proteolysis by homo-oligomeric hAFG3L2 complexes 
a) hAFG3L2 can mediate processing of MrpL32 and Ccp1 
 The experiments described suggest proteolytic activity of the homo-oligomeric 
hAFG3L2 complex, since proteolysis by the m-AAA protease is required for maintenance of 
the respiratory competence of yeast cells (Arlt et al., 1998). This notion is further supported 
by the effect of the mutation of the glutamate residue in the proteolytic centre of hAFG3L2 
preventing suppression of the growth phenotype of ∆yta10∆yta12 cells (Fig. 9). To obtain 
direct evidence for the proteolytic activity of hAFG3L2, the processing of two mitochondrial 
preproteins, the ribosomal subunit MrpL32 and cytochrome c peroxidase (Ccp1), which are 
both cleaved by the yeast m-AAA protease upon import into mitochondria, was examined 
(Esser et al., 2002; Nolden et al., 2005). 
 
 
 
 
Figure 10. Processing of yeast MrpL32 and Ccp1 by hAFG3L2. 
Protein processing was analysed in wild-type (WT) cells, ∆yta10∆yta12 cells, and ∆yta10∆yta12 cells 
expressing either hAFG3L2 or hAFG3L2E575Q (hAFG3L2EQ) by SDS-PAGE. (A) Maturation of 
MrpL32 (L32) was monitored in isolated mitochondria (30 µg mitochondrial protein) by 
immunoblotting using polyclonal antisera directed against the mature and the precursor form of 
MrpL32 and, as a loading control, against matrix-localised Mge1. (B) Ccp1 processing was examined 
in cell extracts using antisera directed against Ccp1 and, for control, the outer membrane protein 
Tom40. p, precursor; m, mature form. 
 
 The maturation of MrpL32 was monitored in isolated yeast mitochondria by Western 
blot analysis using antibodies directed against either the precursor or the mature form of 
MrpL32. Whereas wild-type mitochondria only contained mature MrpL32, its precursor 
accumulated in the absence of the m-AAA protease and processed MrpL32 could not be 
detected as previously observed (Fig. 10A) (Nolden et al., 2005). However, upon expression 
of hAFG3L2 in ∆yta10∆yta12 cells, the processing of MrpL32 was largely restored with only 
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little precursor protein remaining in mitochondria isolated from these cells (Fig. 10A). In 
contrast, expression of the mutant variant hAFG3L2E575Q resulted in the complete absence of 
mature MrpL32 from ∆yta10∆yta12 mitochondria (Fig. 10A). These findings correlate with 
the observed respiratory growth phenotypes of ∆yta10∆yta12 cells expressing either 
hAFG3L2 or proteolytically inactive hAFG3L2E575Q (Fig. 9), as the maturation of MrpL32 is 
required to allow completion of ribosomal assembly and thereby initiation of mitochondrial 
translation (Nolden et al., 2005). Mitochondrial protein synthesis in turn is a prerequisite for 
the formation of the respiratory chain complexes in the inner membrane, since in S. cerevisiae 
seven subunits are encoded by the mitochondrial genome (Foury et al., 1998). 
 To assess processing of Ccp1, a ROS scavenger in the mitochondrial intermembrane 
space, cell extracts were prepared from yeast cells and subjected to Western blot analysis with 
an antibody recognising both the precursor and the mature form of Ccp1. In contrast to wild-
type cells which accumulated the mature form, processing of Ccp1 was completely blocked in 
yeast cells lacking the m-AAA protease (Fig. 10B) (Esser et al., 2002). The expression of 
hAFG3L2 in these cells led to a partial restoration of Ccp1 maturation (Fig. 10B). In the 
presence of hAFG3L2E575Q, Ccp1 processing in ∆yta10∆yta12 cells was still impaired and 
only residual amounts of mature Ccp1 accumulated (Fig. 10B). The latter observation is in 
agreement with a recent report showing that the maturation of Ccp1 in yeast is not strictly 
dependent on the proteolytic activity of the m-AAA protease (Tatsuta et al., 2007). 
 
b) hAFG3L2 can degrade integral and peripheral non-assembled membrane proteins 
 The processing of MrpL32 and Ccp1 by hAFG3L2 provides further evidence for its 
proteolytic activity. Subsequently, it was investigated whether hAFG3L2 can also completely 
degrade misfolded and unassembled model substrates of the yeast m-AAA protease and 
thereby functions in protein quality control (Arlt et al., 1996; Leonhard et al., 2000). To this 
end, the following approach was exploited: two substrate proteins, a Yme2 derivative and 
Atp7, were synthesised in a cell-free system in the presence of 35S-methionine and imported 
into isolated ∆yta10∆yta12 mitochondria harbouring hAFG3L2 or proteolytically inactive 
hAFG3L2E575Q. Mitochondria were then incubated at 37°C and the stability of the imported 
radiolabelled proteins was followed at different time points by SDS-PAGE and 
autoradiography. 
 The first substrate, Yme2F114S∆C15+1 (in the following referred to as Yme2∆C), is 
localised in the inner membrane of mitochondria (Korbel et al., 2004). This Yme2 variant 
exposes its N-terminal domain to the matrix, but lacks its C-terminal intermembrane space 
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domain leading to the destabilisation of Yme2∆C and subsequent degradation by the m-AAA 
protease (Fig. 11A) (Korbel et al., 2004). Degradation of newly imported Yme2∆C is largely 
inhibited in ∆yta10∆yta12 mitochondria, but was observed in the presence of hAFG3L2, 
although with slightly slower kinetics compared to wild-type mitochondria (Fig. 11A). In 
∆yta10∆yta12 mitochondria harbouring hAFG3L2, ~40% of imported Yme2∆C could be 
detected after 30 min at 37°C, whereas only ~20% were still present in wild-type 
mitochondria at the same time point. On the other hand, the expression of hAFG3L2E575Q in 
∆yta10∆yta12 mitochondria had no effect on the degradation of Yme2∆C confirming the 
dependence of the observed degradation on the integrity of the proteolytic centre of hAFG3L2 
(Fig. 11A). 
 
 
 
 
Figure 11. Degradation of non-assembled membrane proteins by hAFG3L2 expressed in yeast. 
Radiolabelled Yme2∆C (A) or Atp7 (B) were imported for 10 min at 25°C into mitochondria isolated 
from yeast strains used in Fig. 10. The stability of newly imported proteins at 37°C was determined by 
SDS-PAGE and autoradiography. The average of three independent experiments (± SEM) is shown. 
Filled squares, wild-type; filled triangles, ∆yta10∆yta12; open triangles, ∆yta10∆yta12 + hAFG3L2; 
open squares, ∆yta10∆yta12 + hAFG3L2E575Q. 
 
 Atp7 was chosen as an example for a peripheral membrane protein, whose degradation 
is mediated by the m-AAA protease (Korbel et al., 2004). Atp7 is a stalk subunit of the F1FO-
ATP synthase and peripherally associated with the inner surface of the mitochondrial inner 
membrane (Ackerman and Tzagoloff, 2005). Radiolabelled Atp7 was rapidly degraded after 
import into wild-type mitochondria, but was partially stabilised in ∆yta10∆yta12 
mitochondria. Apparently, another, yet unidentified mitochondrial protease can mediate the 
degradation of Atp7 in the absence of the m-AAA protease (Fig. 11B) (Korbel et al., 2004). 
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hAFG3L2 was found to significantly accelerate the degradation of Atp7 in ∆yta10∆yta12 
mitochondria with ~30% of newly imported protein present after 30 min, while ~60% of Atp7 
were still detected without hAFG3L2 (Fig. 11B). However, similar to the results for Yme2∆C, 
degradation by hAFG3L2 was not as efficient as observed for the yeast m-AAA protease 
resulting in less than 10% of imported Atp7 detectable after 30 min (Fig. 11B). In contrast, 
Atp7 remained rather stable in ∆yta10∆yta12 mitochondria harbouring proteolytically inactive 
hAFG3L2E575Q and its degradation kinetics was indistinguishable from ∆yta10∆yta12 
mitochondria (Fig. 11B). 
 Thus, hAFG3L2 also possesses the ability to mediate the complete turnover of both 
integral and peripheral membrane proteins. Taken together, it can be concluded, that the 
homo-oligomeric hAFG3L2 complex is proteolytically active and can substitute for two 
activities of the yeast m-AAA protease, protein quality surveillance in the inner membrane 
and protein processing, respectively. In each case, mutating the proteolytic centre of 
hAFG3L2 rendered it inactive towards its proteolytic substrates. 
 
3.1.4 hAFG3L2 is active upon homo-oligomerisation and assembly with 
hparaplegin 
 The growth phenotype of the ∆yta10∆yta12 yeast strain YKO200 used in this work 
could be suppressed by expression of human AFG3L2 alone (Fig. 9), whereas previous 
experiments with another m-AAA protease-deficient yeast strain indicated that the respiratory 
competence is only restored upon co-expression of human paraplegin (Atorino et al., 2003). 
Therefore, the effect of hparaplegin expression and co-expression with hAFG3L2 on 
respiratory growth of ∆yta10∆yta12 cells was re-examined in the YKO200 strain. For 
expression of plasmid-borne hparaplegin in yeast, the mitochondrial targeting sequence of 
Yta10 (amino acids 1-63) was fused to the putative mature form of hparaplegin (amino acids 
59-795). ADH1 promoter-driven expression and correct targeting of the corresponding hybrid 
protein has already been confirmed (Koppen, 2002). 
 When hparaplegin was expressed in m-AAA protease-deficient YKO200 cells, growth 
on glycerol-containing medium was still prevented (Fig. 12), which is in line with the 
previous observation that hparaplegin does not build up homo-oligomeric high molecular 
mass complexes (Koppen, 2002). Co-expression of hparaplegin together with hAFG3L2 
resulted in respiratory growth of ∆yta10∆yta12 cells, which was indistinguishable from cells 
expressing only hAFG3L2 (Fig. 12). However, it remained open if the observed respiratory 
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activity is conferred only by homo-oligomeric hAFG3L2 complexes or by hetero-oligomeric 
complexes containing hparaplegin. To discriminate between these two possibilities, 
proteolytically inactive variants of hparaplegin (hparapleginE575Q) and hAFG3L2 
(hAFG3L2E575Q) were co-expressed. Studies on the yeast m-AAA protease have demonstrated 
that the hetero-oligomeric protease complex is still active and maintains respiratory growth if 
it is composed of proteolytically active and inactive subunits, whereas it is completely 
inactivated when all subunits harbour mutations in their proteolytic centre (Arlt et al., 1998). 
Consistently, co-expression of hparapleginE575Q and hAFG3L2 in ∆yta10∆yta12 cells did not 
impair respiratory growth (Fig. 12). As it cannot be excluded that active homo-oligomeric 
hAFG3L2 complexes are still formed under these conditions, hAFG3L2E575Q was also 
expressed in combination with hparaplegin. In contrast to ∆yta10∆yta12 cells expressing only 
hAFG3L2E575Q, cells co-expressing hparaplegin showed a partial restoration of growth on 
glycerol-containing medium, which was abolished if both human m-AAA protease subunits 
were inactivated (Fig. 12). 
 
 
 
 
Figure 12. Respiratory growth of ∆yta10∆yta12 cells co-expressing hparaplegin and hAFG3L2. 
Wild-type (WT) cells, ∆yta10∆yta12 cells, and ∆yta10∆yta12 cells expressing either hparaplegin, 
hAFG3L2, or the proteolytically inactive variant hAFG3L2E575Q (hAFG3L2EQ) were spotted on 
glucose- (YPD) and glycerol-containing media (YPG) and grown at 30°C. To examine respiratory 
activity of ∆yta10∆yta12 cells harbouring hetero-oligomeric complexes, hparaplegin, hAFG3L2, or 
their mutant variants hparapleginE575Q (hparaEQ) and hAFG3L2EQ were co-expressed in all four 
possible combinations (hpara+/-EQ/hAFG3L2+/-EQ) and cells were grown as described above. 
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 Thus, human paraplegin and AFG3L2 can assemble into a hetero-oligomeric m-AAA 
protease complex with proteolytic activity also in the YKO200 strain, thereby maintaining 
respiratory competence. These results, therefore, confirm the previously observed interaction 
of hparaplegin and hAFG3L2 upon expression in yeast (Atorino et al., 2003). Similar to the 
yeast m-AAA protease, the hetero-oligomeric complex still exerts proteolytic activity when it 
consist of catalytically active and inactive subunits, which is contrary to the former 
observation that the catalytic activity of both subunits is essential (Atorino et al., 2003). 
Furthermore, the limited respiratory growth of ∆yta10∆yta12 cells containing hparaplegin and 
hAFG3L2E575Q, compared to expression of hAFG3L2 with proteolytically active or inactive 
hparaplegin, suggests that upon co-expression in yeast both subunits are not quantitatively 
assembled with each other. Rather, the homo-oligomeric hAFG3L2 complex and the hetero-
oligomeric assembly might co-exist. Alternatively, the proteolytic activity of the hetero-
oligomeric complex could be different depending on if either the hparaplegin or the hAFG3L2 
subunits harbour a mutation in the proteolytic site. Last but not least, these observations could 
also reflect a general limited activity of hparaplegin subunits upon assembly into hetero-
oligomeric complexes in yeast. 
 
 Notably, human AFG3L2 has been identified to be part of two potential proteolytic 
complexes in human mitochondria and when expressed in yeast, either by its assembly with 
hparaplegin into a hetero-oligomeric m-AAA protease or by its homo-oligomerisation 
resulting in a hAFG3L2 complex. 
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3.2 Murine m-AAA protease subunits assemble into protease 
complexes with variable subunit composition 
 
 The proteolytic system of the inner mitochondrial membrane is conserved in mammals 
as demonstrated by complementation studies in yeast (Shah et al., 2000; Atorino et al., 2003; 
Nolden et al., 2005). Putative m-AAA subunits sharing a high degree of sequence homology 
with their human counterparts have also been identified in mice. Interestingly, a mouse line 
with a paraplegin deficiency reproducing central features of HSP has been generated 
(Ferreirinha et al., 2004). Thus, mice can serve as a valid model to study the molecular basis 
of the human disease necessitating a detailed understanding of the number and subunit 
composition of murine m-AAA protease complexes. This is underlined by the results for the 
human m-AAA protease subunit hAFG3L2 which displays variability in its assembly. 
Furthermore, in addition to paraplegin and Afg3l2, a third putative m-AAA protease subunit, 
termed Afg3l1, is expressed in mice, whereas it is encoded by a pseuodgene in humans 
(Kremmidiotis et al., 2001). A sequence comparison of Afg3l1 and Afg3l2 shows 68% amino 
acid identity between both murine proteins suggesting similar activities. However, the 
assembly of murine m-AAA protease subunits into proteolytic complexes and their functions 
have not been analysed, yet. Especially, the role of the additional putative subunit Afg3l1 
remains to be established. Heterologous expression in S. cerevisiae has been proven to be a 
powerful tool for studying assembly and proteolytic activity of m-AAA protease subunits. 
Hence, murine paraplegin, Afg3l1, and Afg3l2 were introduced into ∆yta10∆yta12 yeast cells 
in order to perform complementation analysis as well as biochemical and functional 
characterisation. 
 
3.2.1 Murine m-AAA protease subunits show mitochondrial localisation 
and correct membrane insertion when expressed in yeast 
 For expression in yeast, the sorting signal of Yta10 (amino acids 1-61) was fused to 
the assumed mature forms of murine paraplegin (amino acids 44-781), Afg3l1 (amino acids 
25-789), and Afg3l2 (amino acids 36-802) to ensure mitochondrial targeting. The DNA 
sequences coding for these hybrid proteins were cloned into multicopy vectors under the 
control of the YTA10 promoter. After transformation of ∆yta10∆yta12 cells with the obtained 
plasmids, expression and mitochondrial localisation of the hybrid proteins were examined by 
Western blot analysis of cellular membrane fractions using antisera specific for paraplegin or 
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the C-terminal c-Myc and hemagglutinin (HA) epitopes of Afg3l1 and Afg3l2, respectively. 
All three murine m-AAA protease subunits were exclusively detected in the membrane 
fraction containing mitochondrial membranes as shown by the presence of the mitochondrial 
ADP/ATP carrier Aac2 (Fig 13). 
 
 
 
 
Figure 13. Murine m-AAA protease subunits co-localise with mitochondrial membranes in yeast. 
∆yta10∆yta12 yeast cells expressing either paraplegin and Afg3l1 (A) or Afg3l2 (B) were lysed and 
separated by centrifugation into a supernatant fraction (S) and a pellet fraction (P) containing cellular 
membranes. Fractions were analysed by SDS-PAGE and immunoblotting using specific antisera for 
paraplegin, the c-Myc epitope of Afg3l1, the HA epitope of Afg3l2, or, as a marker for mitochondrial 
membranes, an antibody directed against the integral inner membrane protein Aac2. To confirm the 
specificity of the antibodies, ∆yta10∆yta12 cells were subjected to Western blot analysis in parallel. 
 
 To confirm membrane insertion of the hybrid proteins, alkaline extraction at pH 11.5 
was performed with mitochondria isolated from  ∆yta10∆yta12 cells containing paraplegin, 
Afg3l1, and Afg3l2. All three murine m-AAA protease subunits remained in the insoluble 
pellet fraction and thus behaved like the integral inner membrane protein Aac2 containing 
three transmembrane domains (Fig. 14). In contrast, the matrix protein Mge1 lacking any 
transmembrane domain was exclusively recovered from the soluble fraction (Fig. 14). From 
these experiments, one can conclude that the paraplegin-, Afg3l1-, and Afg3l2-hybrid proteins 
expressed in yeast localise to mitochondrial membranes. 
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Figure 14. Murine m-AAA protease subunits expressed in yeast are integral membrane proteins. 
Mitochondria (100 µg mitochondrial protein) isolated from ∆yta10∆yta12 cells co-expressing 
paraplegin and Afg3l2 (A) or expressing Afg3l1 (B) were treated with 100 mM sodium carbonate 
(pH 11.5) (T) and subjected to ultracentrifugation. The obtained soluble (S) and insoluble (P) fractions 
were analysed by SDS-PAGE and immunoblotting using specific antibodies described in Fig. 13. 
Antibodies directed against the integral inner membrane protein Aac2 and the soluble matrix protein 
Mge1 were used as controls. 
 
3.2.2 Murine Afg3l1 and Afg3l2 can assemble into homo-oligomeric 
complexes able to substitute for the yeast m-AAA protease 
 By expression in yeast cells lacking any m-AAA protease subunit, hAFG3L2 was 
found to assemble into a homo-oligomeric and proteolytically active complex (see chapter 
3.1.2). To investigate if murine m-AAA protease subunits also possess the ability to homo-
oligomerise and substitute for the yeast m-AAA protease, paraplegin, Afg3l1, and Afg3l2 
were individually expressed in ∆yta10∆yta12 cells and respiratory growth was examined 
(Fig. 15). Whereas expression of paraplegin did not suppress the respiratory deficiency, 
expression of either Afg3l1 or Afg3l2 completely restored the growth of ∆yta10∆yta12 cells 
on glycerol-containing medium, compared to wild-type cells (Fig. 15). This indicates that 
Afg3l1 and Afg3l2 indeed can build up homo-oligomeric complexes which are functionally 
active and confer respiratory competence. To further support the notion of proteolytic activity 
of both proteins upon assembly, the catalytic glutamate residues in the metal binding sites of 
Afg3l1 and Afg3l2 were changed to glutamine using site directed mutagenesis. Consistently, 
expression of the corresponding proteolytically inactive variants Afg3l1E567Q or Afg3l2E574Q in 
∆yta10∆yta12 cells did not allow respiratory growth (Fig. 15). 
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Figure 15. Respiratory growth of ∆yta10∆yta12 cells expressing murine m-AAA protease 
subunits. 
Wild-type (WT) cells, ∆yta10∆yta12 cells, and ∆yta10∆yta12 cells expressing either paraplegin, 
Afg3l1 (Afg3lX), Afg3l2 (Afg3lX), or their mutant variants Afg3l1E567Q or Afg3l2E574Q (Afg3lXEQ) 
were grown at 30°C on glucose- (YPD) or glycerol-containing media (YPG) to examine the 
respiratory competence of the cells. To assess the activity of hetero-oligomeric complexes, the mutant 
variants Afg3l1E567Q or Afg3l2E574Q were co-expressed with paraplegin (para/Afg3lXEQ) or with 
parapleginE575Q (paraEQ/Afg3lXEQ) in ∆yta10∆yta12 cells and cell growth was analysed as above. 
 
 In order to reveal this proposed complex formation biochemically and to determine the 
native molecular mass, mitochondria were isolated from ∆yta10∆yta12 cells expressing 
individual murine m-AAA protease subunits, solubilised in digitonin, and fractionated by 
sizing chromatography using a Superose 6 column. Eluate fractions were analysed via SDS-
PAGE and immunoblotting using specific antisera. In agreement with the results of the 
complementation analysis, murine paraplegin was only detected as part of a low molecular 
mass complex of ~300 kDa (Fig. 16). Furthermore, the gel filtration analysis confirmed that 
Afg3l2 homo-oligomerises into a high molecular mass complex. Similar to hAFG3L2, its 
native molecular mass was estimated to be ~850 kDa (Fig. 16). Murine Afg3l1, however, 
exhibited a different elution pattern and was already detected in the first eluate fractions 
corresponding to a molecular mass of >2 MDa pointing to its homo-oligomerisation (Fig. 16). 
It remains unclear whether this large Afg3l1 complex represents the correct assembly or 
rather an aggregated species. Alternatively, the interaction with other protein complexes in the 
mitochondrial inner membrane of yeast, e.g. the prohibitin complex, could account for the 
observed elution profile of Afg3l1. 
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Figure 16. Homo-oligomerisation of murine Afg3l1 and Afg3l2 into high molecular mass 
complexes in ∆yta10∆yta12 mitochondria. 
Murine paraplegin, Afg3l1, or Afg3l2 were expressed in ∆yta10∆yta12 cells and mitochondria were 
isolated. After solubilisation in digitonin-containing buffer, mitochondrial extracts (900 µg 
mitochondrial protein) were subjected to Superose 6 size exclusion chromatography. Eluate fractions 
were TCA-precipitated and examined by Western blot analysis using antibodies specific for 
paraplegin, the c-Myc epitope of Afg3l1, or the HA epitope of Afg3l2. Paraplegin (filled triangles), 
Afg3l1 (filled rectangles), and Afg3l2 (filled squares) present in eluate fractions were quantified by 
laser densitometry and are given as percent of the respective protein in the total eluate. The following 
marker proteins were used for calibration: 1, Hsp60 (840 kDa); 2, apoferritin (443 kDa); 3, alcohol 
dehydrogenase (150 kDa); 4, bovine serum albumine (66 kDa). 
 
 Taken together, these findings show that assembly into a high molecular mass 
complex is restricted to Afg3l1 and Afg3l2. These homo-oligomeric Afg3l1 and Afg3l2 
complexes can apparently both conduct proteolytic functions of the yeast m-AAA protease 
resulting in respiratory competence. Furthermore, this suggests that Afg3l1 is a functional m-
AAA protease subunit in yeast and presumably as well in mice. 
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3.2.3 Murine paraplegin can assemble with either Afg3l1 or Afg3l2 into 
hetero-oligomeric protease complexes 
 Mammalian paraplegin lacks the ability to form homo-oligomeric complexes, but 
human paraplegin has been already shown to assemble into hetero-oligomeric complexes with 
human AFG3L2, both in human fibroblasts and upon co-expression in yeast (Atorino et al., 
2003). This suggests a similar complex formation of murine paraplegin with its potential 
assembly partners Afg3l1 and Afg3l2. Therefore, paraplegin was co-expressed with Afg3l1 or 
Afg3l2 in m-AAA protease-deficient yeast cells and co-immunoprecipitation experiments 
were performed to demonstrate a direct interaction of paraplegin with either protein. After 
solubilisation of mitochondria in digitonin, extracts were incubated with antibodies 
recognising the C-terminal epitope tags of Afg3l1 and Afg3l2. The two precipitates were 
subsequently analysed by SDS-PAGE and immunoblotting using an antiserum specific for 
murine paraplegin. Paraplegin could be detected in both immunoprecipitates (Fig. 17). In 
 
 
 
 
Figure 17. Direct interaction of paraplegin with Afg3l1 or Afg3l2 resulting in hetero-oligomeric  
m-AAA protease complexes. 
Mitochondria (400 µg mitochondrial protein) isolated from ∆yta10∆yta12 cells co-expressing murine 
paraplegin and either Afg3l1 (A) or Afg3l2 (B) were solubilised with digitonin. 10% of the samples 
were removed for control (input). Co-immunoprecipitations were carried out using antibodies directed 
against the c-Myc epitope (A) and the HA epitope (B) fused to the C-terminus of Afg3l1 and Afg3l2, 
respectively. Immunoprecipitates (IP) were analysed by SDS-PAGE and immunoblotting with a 
paraplegin-specific antiserum and the antibodies used for precipitation. For negative control, 
mitochondria isolated from ∆yta10∆yta12 cells harbouring only paraplegin were employed. The two 
paraplegin-specific bands observed in these mitochondria presumably correspond to the precursor (p) 
and the mature (m) form of paraplegin. A putative degradation product of Afg3l2 is marked with an 
asterisk. 
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contrast, paraplegin was not precipitated with the same antibodies when Afg3l1 and Afg3l2 
were not co-expressed verifying the specificity of the observed interaction (Fig. 17). Hence, 
one can conclude that paraplegin directly interacts with Afg3l1 and Afg3l2 resulting in the 
formation of hetero-oligomeric, high molecular mass complexes. These findings were 
confirmed by gel filtration analysis of mitochondrial extracts (data not shown). 
 
 The proteolytic activity of the paraplegin containing complexes was again assessed by 
complementation analysis in yeast. Similar to cells containing only Afg3l1 or Afg3l2, the 
respiratory growth of ∆yta10∆yta12 cells was completely restored if paraplegin was co-
expressed with either protein (data not shown). To distinguish whether this phenotype stems 
from hetero-oligomerisation with paraplegin rather than only from homo-oligomerisation of 
Afg3l1 or Afg3l2, respectively, proteolytically inactive variants of the murine subunits were 
employed as described for human paraplegin and AFG3L2 in chapter 3.1.4. Introduction of 
the proteolytic site mutation into paraplegin (parapleginE575Q) and co-expression with Afg3l1 
or Afg3l2 in ∆yta10∆yta12 cells did not affect respiratory growth, which was comparable to 
wild-type cells (data not shown). However, co-expression of paraplegin and proteolytically 
inactive Afg3l1E567Q or Afg3l2E574Q led to a partial restoration of respiratory growth, which 
was not observed when paraplegin, Afg3l1E567Q, or Afg3l2E574Q were expressed individually 
(Fig 15). This residual growth on glycerol-containing medium was lost when two 
proteolytically inactive subunits were co-expressed, either parapleginE575Q/Afg3l1E567Q or 
parapleginE575Q/Afg3l2E574Q (Fig. 15). 
 These observations indicate that hetero-oligomeric complexes composed of murine 
paraplegin and either Afg3l1 or Afg3l2 exhibit proteolytic activity, which is sufficient to 
promote respiratory competence of yeast cells lacking the m-AAA protease. In addition, they 
confirm the functional conservation of the murine proteins and support the notion that Afg3l1 
is a bona fide subunit of m-AAA proteases. The formation of a possible hetero-oligomeric 
Afg3l1/Afg3l2 complex was not investigated in ∆yta10∆yta12 cells, as Afg3l1 and Afg3l2 
both homo-oligomerise after expression in yeast, and due to the lack of a functional assay to 
distinguish between both complexes. 
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3.2.4 Proteolysis by homo- and hetero-oligomeric murine m-AAA 
protease complexes 
a) Processing of MrpL32 and Ccp1 by homo- and hetero-oligomeric complexes 
 As proteolysis by the m-AAA protease is indispensable for respiratory competence of 
yeast cells, proteolytic activity can be assigned to the murine homo- and hetero-oligomeric m-
AAA proteases (Arlt et al., 1998). The human AFG3L2 complex has been shown in this work 
to substitute for the yeast m-AAA protease in one of its housekeeping functions, namely the 
processing of certain precursor proteins after import into mitochondria (Fig. 10). In order to 
establish if the murine protease complexes show a similar activity, the processing of the 
 
 
 
 
Figure 18. Processing of yeast MrpL32 and Ccp1 by murine m-AAA proteases. 
Protein processing was analysed in ∆yta10∆yta12 cells harbouring murine m-AAA protease subunits 
as described in Fig. 15 by SDS-PAGE and immunoblotting of (A) isolated mitochondria (30 µg 
mitochondrial protein) or (B) cell extracts using (A) MrpL32 (L32)-specific antisera or (B) Ccp1-
specific antisera. p, precursor forms; m, mature forms. Mge1 and Tom40 were used to control for 
equal gel loading. 
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ribosomal subunit MrpL32 and the ROS scavenger Ccp1 was analysed in isolated 
mitochondria or cell extracts, respectively. 
 When murine paraplegin was individually expressed in ∆yta10∆yta12 cells, mature 
forms of neither MrpL32 nor Ccp1 could be detected (Fig. 18). In line with their observed 
homo-oligomerisation, both Afg3l1 and Afg3l2 could mediate processing of either substrate 
(Fig. 18). Notably, processing by Afg3l1 appeared to be slightly more efficient compared to 
Afg3l2, as no precursor forms were detected. In contrast, residual amounts of MrpL32 and 
Ccp1 preproteins were present in Afg3l2-containing ∆yta10∆yta12 cells (Fig. 18). Processing 
was largely inhibited upon expression of the mutant variants Afg3l1E567Q or Afg3l2E574Q 
(Fig. 18). However, co-expression of paraplegin with either proteolytically inactive protein 
partially restored the maturation of MrpL32 and Ccp1, which was not observed when 
paraplegin also contained the point mutation in its proteolytic centre (parapleginE575Q) 
(Fig. 18). Since the generation of mature MrpL32 is a prerequisite for mitochondrial 
translation and assembly of respiratory chain complexes (Nolden et al., 2005), this reduced 
processing of MrpL32 in the presence of hetero-oligomeric complexes is consistent with the 
observed limited respiratory growth of the respective yeast strains (Fig. 15). 
 In summary, both the homo-oligomeric Afg3l1 and Afg3l2 complexes as well as the 
hetero-oligomeric m-AAA proteases containing paraplegin can mediate the proteolytic 
removal of MrpL32 and Ccp1 presequences. 
 
b) Degradation of integral and peripheral non-assembled membrane proteins by homo-
oligomeric complexes 
 Degradation of misfolded or non-assembled membrane proteins represents another 
housekeeping function of the m-AAA protease in yeast (Arlt et al., 1996; Leonhard et al., 
2000). To investigate if the homo-oligomeric protease complex formed by murine m-AAA 
protease subunits can also mediate the complete turnover of proteins, the stability of the two 
model substrates Yme2∆C and Atp7 was monitored using the assay described in chapter 
3.1.3. 
 Degradation of newly imported Yme2∆C, an integral protein of the inner membrane, 
was observed in ∆yta10∆yta12 mitochondria containing Afg3l1 and Afg3l2, whereas it 
remained stable in the presence of paraplegin (Fig. 19A). Interestingly, Afg3l1-mediated 
degradation occurred with faster kinetics compared to Afg3l2 and was similar to turnover by 
the yeast m-AAA protease. Similar results were obtained for newly imported Atp7, a matrix-
localised and peripheral inner membrane protein (Fig. 19B). Whereas the presence of 
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paraplegin in ∆yta10∆yta12 mitochondria had no effect on degradation of Atp7, Afg3l1 and 
Afg3l2 accelerated its degradation in a similar manner, resembling the degradation kinetics 
observed in wild-type mitochondria (Fig. 19B). 
 
 
 
 
Figure 19. Degradation of non-assembled membrane proteins by homo-oligomeric Afg3l1 and 
Afg3l2 complexes. 
Radiolabelled Yme2∆C (A) or Atp7 (B) were imported for 10 min at 25°C into mitochondria isolated 
from wild-type (WT, filled squares) cells, ∆yta10∆yta12 cells (filled triangles), and ∆yta10∆yta12 
cells expressing either paraplegin (open rectangles), Afg3l1 (open triangles), or Afg3l2 (open squares). 
The stability of newly imported proteins at 37°C was determined by SDS-PAGE and autoradiography. 
 
 Hence, the homo-oligomeric Afg3l1 and Afg3l2 complexes mediate the complete 
turnover of non-assembled or misfolded substrate proteins, which are integral parts or 
peripherally associated with the matrix-exposed surface of the inner mitochondrial membrane. 
Like the human AFG3L2 complex, they can execute both housekeeping functions of the yeast 
m-AAA protease. Notably, murine paraplegin does not exhibit any activity, unless it 
assembles with Afg3l1 or Afg3l2 into a hetero-oligomeric m-AAA protease. However, 
degradation of Yme2∆C and Atp7 by paraplegin-containing complexes, though likely to 
occur, was not analysed. ∆yta10∆yta12 cells harbouring paraplegin and either Afg3l1E567Q or 
Afg3l2E574Q only showed partial restoration of respiratory growth and protein processing, 
questioning if degradation by these complexes can be visualised. 
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3.2.5 Evidence for autocatalytic processing of murine m-AAA protease 
subunits during mitochondrial import 
 For the present analysis in yeast, murine m-AAA protease subunits were expressed as 
hybrid proteins. They consist of the first 61 amino acids of Yta10 serving as a mitochondrial 
sorting signal and the putative mature forms of paraplegin, Afg3l1, or Afg3l2, whose exact N-
termini have not been determined. The presequence of Yta10 should also allow processing of 
the hybrid proteins by MPP. Interestingly, in the course of the co-immunoprecipitation 
experiments, two bands which correspond to murine paraplegin were detected in 
∆yta10∆yta12 mitochondria containing only this subunit (Fig. 17). On the other hand, only 
one form of paraplegin was observed when Afg3l1 or Afg3l2 were co-expressed (Fig. 13, 14, 
and 17). To further characterise these different paraplegin forms and to investigate if similar 
observations can be obtained for Afg3l1 and Afg3l2, mitochondria isolated from 
∆yta10∆yta12 cells expressing only one of the murine hybrid proteins were again fractionated 
by SDS-PAGE followed by immunoblotting. 
 In contrast to two protein forms of paraplegin, only one major protein form of Afg3l1 
or Afg3l2 was present in ∆yta10∆yta12 mitochondria (Fig. 20A). This observation correlates 
with the assembly of the latter two murine proteins into homo-oligomeric complexes with 
proteolytic activity. To discern a role of proteolysis, ∆yta10∆yta12 mitochondria harbouring 
the proteolytically inactive variants of paraplegin (parapleginE575Q), Afg3l1 (Afg3l1E567Q), or 
Afg3l2 (Afg3l2E574Q) were analysed in the same way. Again two bands were observed for 
paraplegin, irrespective of the integrity of the proteolytic centre (Fig. 20A). Introduction of 
the proteolytic site mutation in Afg3l1 or Afg3l2 resulted in the accumulation of an additional 
band with an apparently higher molecular weight, which was already present in low amounts 
in mitochondria containing active Afg3l2 (Fig. 20A). This suggests that for all three murine 
m-AAA protease subunits the bigger form corresponds to the precursor, whereas the smaller 
form presumably represents the mature protein lacking the presequence. Moreover, the 
proteolytic activity of Afg3l1 and Afg3l2 upon assembly coincides with the predominant 
presence of processed forms. Thus, murine m-AAA protease subunits could have a role in 
their own maturation. 
 Subsequently, this proposed processing was examined in ∆yta10∆yta12 cells co-
expressing paraplegin and either Afg3l1 or Afg3l2. In mitochondria isolated from these two 
strains, paraplegin was found to be almost completely converted to the putative mature form 
(Fig. 20B). In order to determine if this can be attributed to the proteolytic activity of the  
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Figure 20. Murine homo- and hetero-oligomeric m-AAA protease complexes are involved in the 
maturation of their subunits in yeast. 
(A) Processing of individual murine subunits in yeast. Murine paraplegin, Afg3l1, Afg3l2, or their 
proteolytically inactive variants parapleginE575Q (parapleginEQ), Afg3l1E567Q (Afg3l1EQ), and 
Afg3l2E574Q (Afg3l2EQ) were individually expressed in ∆yta10∆yta12 cells. Mitochondria isolated from 
these strains were used for SDS-PAGE and immunodetection using antibodies recognising paraplegin, 
the c-Myc epitope of Afg3l1, or the HA epitope of Afg3l2. Bands marked with an asterisk presumably 
represent degradation products of Afg3l1 and Afg3l2, respectively. p, putative precursor of murine m-
AAA protease subunits; m, putative mature form of murine m-AAA protease subunits. 
(B) Processing of paraplegin following co-expression with Afg3l1 or Afg3l2. Mitochondria isolated 
from ∆yta10∆yta12 cells harbouring paraplegin (para), parapleginE575Q (paraEQ), or all possible 
combinations of both proteins with Afg3l1 (upper panel) or Afg3l2 (lower panel, para-/+EQ/Afg3lX), or 
their mutant variants Afg3l1E567Q (upper panel) and Afg3l2E574Q (lower panel, para-/+EQ/Afg3lX-/+EQ) 
were examined as in (A) with paraplegin-specific antibodies (α-paraplegin). 
(C) Processing of Afg3l1 and Afg3l2 in the presence of paraplegin. Mitochondria were isolated from 
∆yta10∆yta12 cells containing Afg3l1, Afg3l2 (Afg3lX), or the inactive proteins Afg3l1E567Q or 
Afg3l2E574Q (Afg3lXEQ), as well as from cells co-expressing the mutant forms of both proteins with 
either paraplegin (para/Afg3lXEQ) or parapleginE575Q (paraEQ/Afg3lXEQ) and analysed as in (A) using 
antibodies directed against the C-terminal epitopes of Afg3l1 (α-Myc, upper panel) and Afg3l2 (α-
HA, lower panel). 
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respective homo-oligomeric m-AAA proteases or rather to the hetero-oligomeric assemblies 
with paraplegin, proteolytically inactive subunits were employed as described previously (see 
chapter 3.2.4). Only one predominant band for paraplegin corresponding to the putative 
mature form was detected after co-expression of parapleginE575Q and Afg3l1 or paraplegin and 
Afg3l1E567Q (Fig. 20B). However, a faint band corresponding to the putative precursor form of 
paraplegin could additionally be observed in these mitochondria and a slightly higher amount 
of precursor accumulated in mitochondria containing paraplegin and Afg3l1E567Q (Fig. 20B). 
Upon co-expression of parapleginE575Q and Afg3l1E567Q, both forms of paraplegin were 
present in a ratio indistinguishable from mitochondria containing only paraplegin or its 
mutant variant (Fig. 20B). Analysis of Afg3l1 maturation showed that co-expression of 
paraplegin concomitantly increased the amount of the putative mature form compared to 
mitochondria harbouring only Afg3l1E567Q (Fig 20C). This was not observed when 
parapleginE575Q was co-expressed with Afg3l1E567Q (Fig 20C). Notably, very similar results 
concerning the processing of paraplegin and Afg3l2 were observed when proteolytically 
active and inactive variants of Afg3l2 were co-expressed with paraplegin variants (Fig. 20B 
and C). In contrast to individual expression of paraplegin or Afg3l2E574Q, co-expression of 
both murine proteins led to an increase of their mature forms, which was dependent on the 
proteolytic activity of paraplegin (Fig. 20B and C). 
 Taken together, these findings indicate that not only homo-oligomeric Afg3l1 and 
Afg3l2 protease complexes but also hetero-oligomeric complexes with paraplegin are 
involved in the efficient processing of their subunits. This maturation correlates with the 
proteolytic activity of the different m-AAA proteases. However, significant amounts of 
mature paraplegin and Afg3l1 are present in the absence of a functional murine m-AAA 
protease suggesting either that it is not the proteolytic activity itself which is essential or that 
in yeast another protease can also mediate processing though with reduced efficiency. Finally, 
it has to be considered that this analysis was carried out with hybrid proteins of the murine m-
AAA protease subunits containing the mitochondrial targeting sequence of Yta10. It is, 
therefore, possible that these hybrid proteins are processed in a different manner than the 
murine full length proteins. 
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3.3 Mammalian homo-oligomeric m-AAA proteases mediate 
OPA1 processing in yeast 
 
 OPA1 is a dynamin-like GTPase and the mammalian homologue of yeast Mgm1 
which are both required for mitochondrial fusion (Okamoto and Shaw, 2005; Chan, 2006b). 
Notably, mutations in the OPA1 gene cause hereditary autosomal dominant optic atrophy 
(ADOA) type I (Alexander et al., 2000; Delettre et al., 2000). Up to five different isoforms of 
the OPA1 protein have been found in mammalian mitochondria indicating proteolytic 
processing of OPA1 (Olichon et al., 2003; Duvezin-Caubet et al., 2006; Ishihara et al., 2006; 
Olichon et al., 2006). However, the fact that eight alternatively spliced mRNAs transcribed 
from the OPA1 gene have been reported complicates the analysis of OPA1 processing in 
human cells and it remains unclear to which extent the different OPA1 isoforms are generated 
by alternative splicing and/or limited proteolysis (Delettre et al., 2001; Satoh et al., 2003). For 
Mgm1, it has been shown that the conversion of the large (L-) isoform to the short (S-) 
isoform is mediated by the rhomboid protease Pcp1 (Herlan et al., 2003; McQuibban et al., 
2003; Sesaki et al., 2003a). In contrast, the protease(s) responsible for processing of OPA1 
have not been unambiguously identified. Recently, cleavage of OPA1 has been linked to the 
m-AAA protease subunit paraplegin whose downregulation in human cells resulted in 
impaired OPA1 processing (Ishihara et al., 2006). Therefore, the aim of the following 
experiments was to investigate if homo- and hetero-oligomeric mammalian m-AAA proteases 
are indeed capable of cleaving OPA1 using yeast as a model. This allows the expression of a 
single human OPA1 splice variant in cells harbouring human and murine m-AAA protease 
subunits. The reconstitution of OPA1 processing in yeast could also provide insights which 
splice variants give rise to the observed five OPA1 isoforms. 
 
3.3.1 OPA1 processing can be reconstituted in yeast and is mediated 
by the endogenous m-AAA protease 
 To initially investigate if OPA1 processing can be reconstituted in yeast, human OPA1 
splice variants 1, 4, 7, and 8 were separately expressed in wild-type cells under the control of 
the galactose-inducible GAL1 promoter using the multicopy plasmid pYES2. These OPA1 
variants differ in the N-terminal region between the first transmembrane domain and the 
GTPase domain and are characterised by the presence or absence of protein segments
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Figure 21. Reconstitution of human OPA1 processing in yeast: cleavage can be mediated by the 
yeast m-AAA protease or the homo-oligomeric hAFG3L2 complex. 
(A) Schematic representation of the primary structures of the human OPA1 splice variants (Sp.) 1, 4, 
7, and 8. The N-terminal regions upstream of the GTPase domain are depicted including the 
mitochondrial targeting sequence (MTS), the first transmembrane domain (TM), protein segments 
encoded by alternatively spliced exons 4, 4b, and 5b, and a coiled-coil domain (CC). The number of 
amino acids (AA) is indicated for each splice variant on the right side. 
(B) OPA1 isoforms present in HeLa cells. A HeLa cell lysate (50 µg protein) was separated by SDS-
PAGE followed by immunodetection with an antiserum recognising human OPA1. The resulting 
different OPA1 isoforms are indicated by arrows and named L1, L2, S3, S4, and S5 according to 
(Duvezin-Caubet et al., 2006). 
(C) Processing of human OPA1 in yeast. OPA1 splice variants (Sp.) 1, 4, 7, or 8 were expressed in 
wild-type (WT) cells, ∆yta10∆yta12 cells, and ∆yta10∆yta12 cells harbouring either hAFG3L2 or its 
proteolytically inactive variant hAFG3L2E575Q (hAFG3L2EQ). Total cell extracts from these strains 
were analysed by Western blotting with anti-OPA1 antibodies. HeLa total extracts (50 µg protein) 
were used as reference and bands are labelled by arrows according to the apparent corresponding size 
of OPA1 isoforms in the HeLa cell lysate (L1, L2, S3, S4, and S5). L1’ and L2’ refer to L1 and L2, 
respectively, but show a slight mobility shift. Putative precursor proteins (P) and yeast-specific 
degradation products (d) are also indicated. 
 
encoded by exons 4, 4b, and 5b of the OPA1 gene (Fig. 21A) (Delettre et al., 2001). The 
mitochondrial localisation of OPA1 variants expressed in yeast was verified by SDS-PAGE 
and immunoblotting of cellular membrane preparations containing mitochondrial membranes 
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(data not shown). In these experiments, a specific antiserum was used which has been raised 
against a C-terminal region of human OPA1 present in all splice variants. To study OPA1 
processing, total cell extracts were prepared from wild-type cells harbouring a single OPA1 
splice variant and subjected to Western blot analysis. For comparison, HeLa cell lysates were 
analysed in parallel, which contain five different OPA1 isoforms, named L1 and L2 for the 
two larger isoforms and S3, S4, and S5 for the three smaller isoforms (Fig. 21B) (Duvezin-
Caubet et al., 2006). Moreover, mRNAs of OPA1 splice variants 1, 7, and 8 belong to the 
most abundant OPA1 mRNAs in HeLa cells (Satoh et al., 2003; Olichon et al., 2006). 
 Upon expression of OPA1 in wild-type yeast cells, several OPA1 isoforms could be 
detected for each splice variant (Fig. 21C). These forms corresponded in size to OPA1 
isoforms present in HeLa cell lysates (Fig. 21C). For splice variant 8, a band similar but not 
identical in size to isoform L1 of HeLa cells, thus named L1’, as well as bands identical in 
size to S3 and S4 of HeLa cells were observed (Fig. 21C). Expression of splice variant 7 gave 
rise to bands with a molecular weight corresponding to the isoforms L1, S3, S4, and S5 
(Fig. 21C). Expression of splice variant 4 led to the accumulation of a large isoform slightly 
bigger in size than L2 of HeLa cells, thus named L2’, and short isoforms S3, S4, and to a 
lesser extent S5 (Fig. 21C). Splice variant 1 showed a reduced expression level in yeast cells 
compared to the other three variants suggesting that it might be not as stable and subject to 
complete degradation. Nevertheless, its expression resulted in the distinct presence of L2 and 
S4 isoforms (Fig. 21C). In addition, a band larger than the OPA1 isoforms in HeLa cells was 
detected in wild-type yeast cells containing splice variants 4 and 7 (Fig. 21C). It presumably 
represents the precursor of human OPA1 accumulating due to overexpression in yeast. 
Smaller OPA1 bands present at least in case of splice variants 4, 7, and 8 are likely to be 
yeast-specific degradation products (Fig. 21C).  
 These findings show that OPA1 splice variants expressed in wild-type yeast cells 
receive proteolytic processing leading to short OPA1 isoforms, which are apparently 
indistinguishable in size from short OPA1 isoforms present in HeLa cells. Thus, OPA1 
processing was reconstituted in yeast, which can be used as a valid model for further 
investigations. The validity of this approach was confirmed by mass spectrometric analysis of 
OPA1 isoforms purified from HeLa and yeast cells (Duvezin-Caubet et al., 2007). 
Furthermore, both alternative splicing and limited proteolysis seem to contribute to the pattern 
of OPA1 isoforms, as S3, S4, and to a limited extent S5 could be generated by expression of 
splice variants 4, 7, and 8, though in different ratios. 
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 Apparently, yeast cells possess a proteolytic system in mitochondria capable of 
cleaving heterologously expressed human OPA1. In a recent study, the human m-AAA 
protease subunit paraplegin has been implicated in OPA1 cleavage in HeLa cells (Ishihara et 
al., 2006). In addition, processing of rat OPA1 splice variants1 and 7 in yeast was found to be 
dependent on the m-AAA protease composed of Yta10 and Yta12 subunits (Ishihara et al., 
2006). To confirm these observations, human OPA1 splice variants 1, 4, 7, and 8 were 
expressed in ∆yta10∆yta12 cells and processing was examined in total cell extracts. For each 
OPA1 splice variant, only two bands corresponding to the putative precursor and the large 
isoform were detected, whereas short isoforms were completely absent from ∆yta10∆yta12 
cells (Fig. 21C). This clearly indicates that the m-AAA protease is responsible for OPA1 
processing in yeast. In another study, a role of PARL, the human homologue of the yeast 
rhomboid protease Pcp1, in the generation of a soluble OPA1 isoform of lower molecular 
weight has been reported (Cipolat et al., 2006). However, OPA1 processing was not affected 
in PARL-deficient mouse cells (Cipolat et al., 2006; Duvezin-Caubet et al., 2007). Upon 
expression of OPA1 splice variants in ∆pcp1cells, a band pattern identical to that observed in 
wild-type cells was obtained for each OPA1 splice variant excluding processing by Pcp1 (data 
not shown). 
 
3.3.2 Deletion of yeast PHB1 can enhance m-AAA protease mediated 
OPA1 processing 
 In yeast, the m-AAA protease assembles with the prohibitin complex, which consists 
of Phb1 and Phb2, into a supercomplex in the inner mitochondrial membrane (Steglich et al., 
1999). A negative regulatory effect of prohibitins on m-AAA protease activity has been 
suggested, as the degradation of non-assembled membrane proteins was accelerated in the 
absence of prohibitins (Steglich et al., 1999). Therefore, experiments were carried out in order 
to investigate if the prohibitin complex has an effect on OPA1 processing by the yeast m-
AAA protease. Total cell extracts were prepared from ∆phb1 cells expressing OPA1 splice 
variants 1, 4, 7, or 8, followed by Western blot analysis with OPA1-specific antibodies. Due 
to the interdependence of Phb1 and Phb2, both proteins are absent in ∆phb1 cells (Berger and 
Yaffe, 1998). Essentially, no difference in the band pattern could be observed for OPA1 splice 
variants 1 and 7 compared to wild-type cells (Fig. 22). However, in contrast to wild-type cells, 
the L1’ isoform was not detected in ∆phb1 cells containing splice variant 8, suggesting a 
complete conversion of large OPA1 isoforms to small isoforms (Fig. 22). Similarly, the 
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amount of the L2’ isoform was strongly reduced for splice variant 4 when prohibitins were 
lacking (Fig. 22). In parallel, an increase in the S3 isoform was observed for this splice variant 
(Fig. 22). Apparently, OPA1 processing is enhanced in the absence of prohibitins, although 
their role in OPA1 cleavage is restricted only to certain OPA1 splice variants. These findings 
suggest a possible negative regulatory function of the prohibitin complex also for processing 
by the m-AAA protease. Alternatively, this increased generation of short isoforms of OPA1 
may also reflect a presumed chaperone-like function of the prohibitin complex protecting 
OPA1 from m-AAA protease mediated cleavage (Nijtmans et al., 2000). 
 
 
 
 
Figure 22. Processing of human OPA1 in ∆phb1 yeast cells lacking the prohibitin complex. 
The human OPA1 splice variants (Sp.) 1, 4, 7, and 8 were expressed in wild-type (WT), ∆phb1, or 
∆yta10∆yta12 cells. Total cell extracts were analysed as described in Fig. 15C using an antiserum 
recognising human OPA1. HeLa cell extracts (50 µg protein) were used for comparison and bands are 
labelled by arrows as described for Fig. 15C. 
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3.3.3 Proteolytic processing of OPA1 splice variants by the human 
AFG3L2 complex 
 The yeast m-AAA protease mediates proteolytic processing of human OPA1 
suggesting that mammalian m-AAA proteases have a similar activity. To examine this 
possibility for the human homo-oligomeric AFG3L2 complex, OPA1 splice variants 1, 4, 7, 
and 8 were individually expressed in ∆yta10∆yta12 cells containing either hAFG3L2 or 
proteolytically inactive hAFG3L2E575Q. The analysis of OPA1 processing by SDS-PAGE and 
immunoblotting of total cell extracts revealed that short isoforms were generated for each 
OPA1 splice variant in the presence of hAFG3L2 (Fig. 21C). Co-expression of 
hAFG3L2E575Q with one of the four OPA1 splice variants did not restore its processing in 
∆yta10∆yta12 cells demonstrating that cleavage depends on the proteolytic activity of 
hAFG3L2 (Fig. 21C). It is noteworthy, that hAFG3L2 seems to have a different preference or 
enzymatic activity for the different splice variants, as a larger amount of short isoforms was 
observed for splice variants 7 and 8 than for variants 1 and 4 (Fig. 21C). However, cleavage 
by the hAFG3L2 complex was always less efficient than observed for the yeast m-AAA 
protease and only S3 and S4 isoforms were generated, whereas S5 isoforms were lacking 
(Fig. 21C). Taken together, the homo-oligomeric m-AAA protease built up of hAFG3L2 can 
promote cleavage of human OPA1 upon reconstitution in yeast. 
 
3.3.4 Variable efficiencies of OPA1 processing by homo- and hetero-
oligomeric murine m-AAA proteases 
 The analysis of the proteolytic complexes formed by the three murine m-AAA 
protease subunits has demonstrated a high variability in the assembly of m-AAA protease 
complexes. Homo-oligomeric Afg3l1 and Afg3l2 complexes as well as hetero-oligomeric 
paraplegin/Afg3l1 and paraplegin/Afg3l2 complexes can be formed, which all exert 
proteolytic activity. To assess if these complexes can promote OPA1 cleavage or display 
varying activities, human OPA1 splice variants 1, 4, 7, and 8 were expressed in ∆yta10∆yta12 
cells containing single murine subunits or various combinations of them. Human OPA1 splice 
variants are highly homologous to their murine counterparts and thus should also be 
recognised by murine m-AAA proteases. In the case of splice variant 1, the human and the 
murine protein share 96% identity over the whole sequence and 86% identity for the N-
terminal 208 amino acids comprising the mitochondrial targeting sequence and the variable 
protein segments caused by differential splicing. 
 
Results 77
 
 
Figure 23. Processing of human OPA1 in yeast by murine homo- and hetero-oligomeric m-AAA 
protease complexes. 
The human OPA1 splice variants (Sp.) 1, 4, 7, and 8 were expressed in wild-type (WT), ∆yta10∆yta12 
cells, or ∆yta10∆yta12 cells containing either murine paraplegin (para), Afg3l1, Afg3l2, or their 
mutant variants parapleginE575Q (paraEQ), Afg3l1E567Q (Afg3l1EQ), or Afg3l2E574Q (Afg3l2EQ) or 
combinations of them. Total cell extracts were prepared from these strains and subjected to SDS-
PAGE and immunoblotting using human OPA1-specific antibodies. Cell extracts (50 µg protein) from 
HeLa cells were used as reference and bands are labelled by arrows as described for Fig. 21C. 
 
 Expression of paraplegin in these yeast cells did not compensate for the lack of the m-
AAA protease, as short isoforms of OPA1 were not detected for any splice variant (Fig. 23). 
This is in line with the observation that paraplegin, in contrast to Afg3l1 and Afg3l2, does not 
assemble into a homo-oligomeric complex with proteolytic activity. Accordingly, the short 
isoforms S3 and S4 were present for all four splice variants when either Afg3l1 or Afg3l2 
were individually expressed in ∆yta10∆yta12 cells (Fig. 23). S5 isoforms were hardly 
detectable under these conditions (Fig. 23). On the other hand, OPA1 cleavage was almost 
completely abolished when the proteolytic centres of Afg3l1 and Afg3l2 were mutated 
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(Afg3l1E567Q and Afg3l2E574Q) (Fig. 23). Hence, similar to hAFG3L2, the homo-oligomeric 
Afg3l1 and Afg3l2 complexes are capable of converting large OPA1 isoforms, derived from 
splice variants 1, 4, 7, and 8, into small isoforms due to their proteolytic activity. 
 
 
 
 
Figure 24. Different efficiencies of OPA1 processing by homo-oligomeric m-AAA proteases 
composed of hAFG3L2, murine Afg3l1, or murine Afg3l2 in yeast. 
The human OPA1 splice variants (Sp.) 1, 4, 7, and 8 were expressed in wild-type (WT) cells, 
∆yta10∆yta12 cells, or ∆yta10∆yta12 cells harbouring hAFG3L2, murine Afg3l1, or murine Afg3l2. 
Total cell extracts were analysed as described in Fig. 21C using an antiserum recognising human 
OPA1. HeLa cell lysates (50 µg protein) were used as reference and bands are labelled by arrows as 
described for Fig. 21C. 
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 This initial analysis of OPA1 processing by murine Afg3l1 and Afg3l2 complexes 
pointed to slight differences between both homo-oligomeric m-AAA proteases with respect to 
processing efficiency and the ratio of short isoforms generated. Therefore, the investigation of 
OPA1 processing was repeated with OPA1 splice variants 1, 4, 7, and 8, and total extracts 
of  ∆yta10∆yta12 cells harbouring hAFG3L2, Afg3l1, or Afg3l2 were loaded in adjacent 
lanes to facilitate a more careful analysis of the different OPA1 band patterns. For 
comparison, HeLa cell lysates and total extracts from wild-type and  ∆yta10∆yta12 cells were 
also included. For each OPA1 splice variant, the generation of short isoforms was apparently 
more pronounced in the presence of Afg3l1 when compared to hAFG3L2 and Afg3l2, which 
both showed a similar amount of short isoforms (Fig. 24). Moreover, OPA1 splice variants 1, 
7, and 8 were nearly as efficiently cleaved by Afg3l1 complexes as observed for the yeast m-
AAA protease, while splice variant 4 was cleaved even more efficiently (Fig. 24). In addition, 
expression of Afg3l1 preferentially led to the formation of S4 isoforms, whereas more of the 
isoform S3 accumulated in the presence of hAFG3L2 and Afg3l2, at least for splice variants 
4, 7, and 8 (Fig. 24). These observations support the notion that the homo-oligomeric murine 
Afg3l1 and Afg3l2 complexes differ in their substrate specificity towards OPA1 splice 
variants as exemplified by a different processing efficiency and subtle differences in the 
pattern of short isoforms. 
 Co-expression of murine paraplegin with either Afg3l1 or Afg3l2 in  ∆yta10∆yta12 
cells harbouring splice variants 1, 4, 7, or 8 did not significantly affect OPA1 processing 
compared to expression of Afg3l1 or Afg3l2 alone (data not shown). To be able to distinguish 
between OPA1 cleavage by hetero-oligomeric m-AAA protease complexes containing 
paraplegin and a contribution of the homo-oligomeric complexes, paraplegin was co-
expressed with the proteolytic site mutants Afg3l1E567Q and Afg3l2E574Q in  ∆yta10∆yta12 
cells. As described in chapter 2.4, homo-oligomeric complexes built up of mutant subunits are 
inactivate, whereas hetero-oligomeric complexes containing mutant and wild-type subunits 
are still functional due to the proteolytic activity of their paraplegin subunit. Processing of 
OPA1 splice variants 4, 7, or 8 was rather inefficient in these cells and in some cases barely 
detectable (Fig. 23). However, the accumulation of small amounts of shorter isoforms 
indicates OPA1 cleavage by paraplegin-containing m-AAA protease complexes. Furthermore, 
a preference for the generation of the respective S3 isoform could be observed for both 
hetero-oligomeric assemblies, whereas S4 isoforms were largely absent (Fig. 23). Notably, 
small OPA1 isoforms were not detected with splice variant 1 suggesting that it does not 
receive any processing by hetero-oligomeric complexes (Fig. 23). As short OPA1 isoforms 
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did not accumulate for any splice variant if both, Afg3l1 or Afg3l2, and paraplegin contained 
point mutations in their proteolytic centres, the observed processing can indeed be attributed 
to the proteolytic activity of paraplegin and thus of the hetero-oligomeric complexes (Fig. 23). 
 
 In conclusion, OPA1 splice variants 4, 7, and 8 can be processed not only by homo-
oligomeric m-AAA proteases composed of either Afg3l1 or Afg3l2 subunits, but also by 
hetero-oligomeric paraplegin/Afg3l1 and paraplegin/Afg3l2 complexes upon reconstitution in 
yeast. However, the processing efficiency of the latter is limited and lower than in the 
presence of Afg3l1 and Afg3l2 complexes. Thus, m-AAA proteases with a variable subunit 
composition are apparently able to mediate OPA1 processing with different efficiencies. 
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4 Discussion 
 
4.1 Mammalian m-AAA protease subunits assemble into 
proteolytic complexes with variable subunit composition 
 The m-AAA protease represents a hetero-oligomeric assembly in the inner 
mitochondrial membrane of yeast, which is composed of Yta10 and Yta12 subunits (Arlt et 
al., 1996). Complementation studies revealed a functional conservation of hetero-oligomeric 
m-AAA proteases in yeast and mammals, where it is built up of the subunits paraplegin and 
hAFG3L2/Afg3l2 (Atorino et al., 2003; Nolden et al., 2005). In the absence of either Yta10 
or Yta12, yeast cells lose their respiratory competence and the remaining subunit assembles 
only into a low molecular weight complex lacking proteolytic activity (Arlt et al., 1996). 
Similarly, a paraplegin deficiency leads to severe phenotypes in humans and mice including 
degeneration of long axons (Casari et al., 1998; Ferreirinha et al., 2004). However, the 
assembly status of the remaining hAFG3L2 and Afg3l2 subunits, respectively, has not been 
established. In mice, the situation is complicated by the presence of a third putative m-AAA 
protease subunit, termed Afg3l1, which has been localised to mitochondria, but whose 
assembly and function were still unclear (Kremmidiotis et al., 2001). In order to address these 
open questions, human and murine m-AAA protease subunits were separately expressed and 
co-expressed in ∆yta10∆yta12 yeast cells allowing biochemical and functional 
characterisation. 
 Upon expression in yeast, human and murine m-AAA protease subunits assembled 
into various proteolytic complexes which differ in their subunit composition. In addition to its 
assembly with human paraplegin, hAFG3L2 has the ability to homo-oligomerise into a high 
molecular mass complex when expressed in the absence of paraplegin. This hAFG3L2 
complex is functionally active and could substitute for the yeast m-AAA protease in 
maintaining respiratory growth. Homo-oligomerisation appears to be restricted to hAFG3L2, 
as human paraplegin was previously shown to be only part of low molecular weight 
complexes, which are proteolytically inactive (Koppen, 2002). Similar to hAFG3L2, murine 
Afg3l1 and Afg3l2 can homo-oligomerise in yeast and maintain respiratory activity. In line 
with the results for human paraplegin, no evidence for homo-oligomerisation was obtained for 
murine paraplegin, which only assembled into hetero-oligomeric m-AAA proteases 
containing either Afg3l1 or Afg3l2. The complementation studies in yeast thus reveal that 
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murine m-AAA protease subunits can build up at least four distinct complexes with proteo-
lytic activity: homo-oligomeric Afg3l1 and Afg3l2 complexes or hetero-oligomeric para-
plegin/Afg3l1 and paraplegin/Afg3l2 complexes (Fig. 25). 
 
 
 
 
Figure 25. Isoenzymes of the murine m-AAA protease. 
Evidence for five isoenzymes of the murine m-AAA protease with different subunit composition was 
obtained by coimmunoprecipitation and immunodepletion experiments using brain and liver 
mitochondria as well as by yeast complementation studies. The existence of an m-AAA protease 
complex containing paraplegin, Afg3l1, and Afg3l2 is speculative. Only two subunits, hAFG3L2 and 
hparaplegin, are expressed in human mitochondria and assemble into homo-oligomeric hAFG3L2 or 
hetero-oligomeric hparaplegin/hAFG3L2 complexes. 
 
 The formation of homo-oligomeric proteolytic complexes by hAFG3L2 as well as by 
murine Afg3l1 and Afg3l2 raises the question why paraplegin subunits do not have the ability 
to homo-oligomerise. Crystal structures of FtsH, the bacterial AAA protease, have revealed 
that intersubunit contacts in the hexamer mainly occur between the proteolytic domains of the 
FtsH monomers (Bieniossek et al., 2006; Suno et al., 2006). Despite the high degree of 
sequence conservation, significant variations between m-AAA protease subunits exist in C-
terminal regions. It is therefore conceivable that sequence differences of AAA proteases in 
this region determine their ability for homo-oligomerisation. In addition, a role in 
oligomerisation of FtsH from Escherichia coli and the yeast m-AAA protease has been 
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attributed to the N-terminal domain of the respective subunits, which contains the two 
transmembrane segments (Akiyama et al., 1995; Makino et al., 1999; Korbel et al., 2004). 
This domain is less conserved between the mammalian m-AAA protease subunits than the 
catalytic domains suggesting that sequence differences in paraplegin subunits could contribute 
or even account for the observed oligomeric status. Besides, it has to be considered that the 
mammalian m-AAA protease subunits were expressed in yeast as hybrid proteins containing 
the MTS of Yta10 fused to the putative mature forms of the subunits. Thus, a negative effect 
on the assembly and activity of human and murine paraplegin subunits due to the absence of 
critical residues at the extreme N-terminus cannot be ruled out. 
 Do m-AAA proteases with variable subunit composition exist in mammalian cells? 
Evidence for this versatile assembly has been obtained by the analysis of mitochondria 
isolated from murine liver and brain. Co-immunoprecipitation experiments of murine wild-
type mitochondria have revealed that paraplegin, Afg3l1, and Afg3l2 directly interact with 
each other (Koppen et al., 2007). The formation of three independent complexes containing 
two types of subunits each, either paraplegin and Afg3l1, paraplegin and Afg3l2, or Afg3l1 
and Afg3l2, can rationalise the observed interactions (Fig. 25). However, three different types 
of subunits may also be part of one m-AAA protease complex, although direct evidence for 
such an isoenzyme is still missing (Fig. 25). The formation of a hetero-oligomeric 
Afg3l1/Afg3l2 complex has been demonstrated using liver and brain mitochondria from 
paraplegin-deficient mice (Koppen et al., 2007). Both subunits were found to directly interact 
with each other in co-immunoprecipitation experiments resulting in the formation of a high 
molecular weight complex. In line with these observations, the steady state concentrations of 
Afg3l1 and Afg3l2 were not altered in the absence of paraplegin (Koppen et al., 2007). Taken 
together, different m-AAA protease isoenzymes can be formed in murine mitochondria. 
Moreover, results from both yeast and mouse establish Afg3l1 as a bona fide subunit of m-
AAA proteases which can assemble into homo- and hetero-oligomeric complexes both 
exerting proteolytic activity. 
 The formation of m-AAA protease isoenzymes differing in their subunit composition 
raises the question if they co-exist with each other in the inner membrane of mammalian 
mitochondria. Proteomic studies have demonstrated a large variability in the protein 
composition of mitochondria isolated from different murine and rat tissues (Mootha et al., 
2003; Forner et al., 2006). Consistently, Afg3l2 was found to be ~10-fold and paraplegin ~4-
fold more abundant in murine brain mitochondria than in liver mitochondria compared to the 
relative abundance of Afg3l1 in these tissues (Koppen et al., 2007). Differences in the relative 
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abundance of m-AAA protease subunits were also reflected in immunodepletion experiments. 
Paraplegin and Afg3l1 could be almost completely immunodepleted from mitochondrial 
extracts of wild-type brain with Afg3l2-specific antibodies (Koppen et al., 2007). Thus, the 
three murine proteins assemble with each other in a virtually quantative manner. In contrast, a 
large fraction of paraplegin and Afg3l2 was still present in the depleted supernatant when 
Afg3l1-specific antibodies were employed indicating that Afg3l1 is apparently present at 
lower molecular concentrations than those of paraplegin and Afg3l2 in murine brain (Koppen 
et al., 2007). The different results of these immmunodepletion experiments therefore point to 
the co-existence of at least two different m-AAA proteases in brain mitochondria: 
paraplegin/Afg3l2 complexes and less abundant Afg3l1 complexes containing paraplegin, 
Afg3l2, or both. Using brain mitochondria isolated from paraplegin-deficient mice, Afg3l1 
could be nearly entirely immunodepleted with antibodies directed against Afg3l2, which was 
not observed vice versa (Koppen et al., 2007). This strongly suggests that, in the absence of 
paraplegin, a hetero-oligomeric Afg3l1/Afg3l2 complex and a predominant homo-oligomeric 
Afg3l2 are present in murine brain. The existence of homo-oligomeric m-AAA proteases in 
mammalian mitochondria was further substantiated in this study by the identification of a 
hAFG3L2 complex in mitochondria of HSP fibroblasts lacking human paraplegin. However, 
it remains elusive if both the hetero-oligomeric paraplegin/hAFG3L2 and the homo-
oligomeric hAFG3L2 complex co-exist in human mitochondria, since immunodepletion 
experiments could not be performed. 
 In summary, these data demonstrate the versatile assembly of mammalian m-AAA 
protease subunits into proteolytic complexes with variable composition apparently depending 
on subunit availability, which is determined by the tissue-specific expression of different 
subunits. The absence of one m-AAA protease subunit does not lead to a complete loss of 
proteolytic complexes. Instead, different isoenzymes of the m-AAA protease can be formed as 
exemplified by a paraplegin deficiency in HSP patients and the corresponding mouse model. 
 
4.2 Mammalian m-AAA proteases have conserved and over-
lapping functions in mitochondria 
 Different human and murine m-AAA protease isoenzymes are functionally active as 
they could substitute for the yeast m-AAA protease in complementation studies. This holds 
true for the homo-oligomeric assemblies of hAFG3L2, Afg3l1, and Afg3l2 as well as for the 
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hetero-oligomeric isoenzymes containing paraplegin and demonstrates functional con-
servation of m-AAA proteases from yeast, mouse, and humans. 
 The homo-oligomeric hAFG3L2 complex was shown to exert proteolytic activity in 
yeast. Like the yeast m-AAA protease, it could recognise and degrade misfolded polypeptides 
that are either integrated into the inner membrane or peripherally associated with its matrix-
exposed surface. Moreover, the precursor form of the ribosomal subunit MrpL32 was cleaved 
by hAFG3L2 which is required for its activation and the concomitant initiation of 
mitochondrial translation (Nolden et al., 2005). Thus, the hAFG3L2 complex can substitute 
for crucial housekeeping functions of the yeast m-AAA protease. An additional non-
proteolytic function of the yeast enzyme during mitochondrial biogenesis has recently been 
identified. Removal of the bipartite presequence of the ROS-scavenger Ccp1 by the 
consecutive action of the m-AAA protease and the rhomboid protease Pcp1 requires its ATP-
dependent dislocation from the inner membrane by the m-AAA protease (Tatsuta et al., 
2007). The proteolytic activity of the m-AAA protease is dispensable as maturation of Ccp1 
by Pcp1 was observed in yeast cells harbouring a proteolytically inactive m-AAA protease 
(Tatsuta et al., 2007). Ccp1 processing in m-AAA protease-deficient yeast cells was also 
restored in the presence of proteolytically active and inactive hAFG3L2 complexes. This 
indicates that hAFG3L2 can mediate membrane dislocation and functionally interact with the 
yeast rhomboid protease. Notably, similar observations regarding protein degradation, 
processing, and membrane dislocation were also made for murine Afg3l1 or Afg3l2 but not 
for paraplegin, demonstrating conserved activities of homo-oligomeric complexes. 
Furthermore, complementation studies in yeast point to overlapping substrate specificities of 
these homo-oligomeric assemblies with hetero-oligomeric m-AAA proteases containing 
paraplegin. Indeed, hetero-oligomeric complexes of Afg3l1, Afg3l2, and hAFG3L2 with 
paraplegin mediated processing of MrpL32 and Ccp1 in ∆yta10∆yta12 yeast cells as shown in 
this and previous studies (Koppen, 2002; Nolden et al., 2005). 
 Hence, it can be concluded that heterologously expressed mammalian m-AAA 
protease complexes, either homo- or hetero-oligomeric, maintain mitochondrial housekeeping 
functions in yeast like protein quality control, protein processing, and membrane dislocation 
demonstrating conserved and overlapping substrate specificities. 
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4.3 Mammalian homo-oligomeric m-AAA protease complexes 
mediate OPA1 processing reconstituted in yeast 
 The dynamin-like GTPase OPA1 is a central component of the mitochondrial fusion 
machinery in mammals (Chan, 2006b). Eight alternatively spliced mRNAs are transcribed 
from the OPA1 gene resulting in the accumulation of several large (L-) and short (S-) 
isoforms of the OPA1 protein in mitochondria. The shorter OPA1 isoforms are generated by 
proteolytic processing of the larger isoforms (Duvezin-Caubet et al., 2006; Ishihara et al., 
2006). To support the notion of OPA1 cleavage and to identify the protease(s) involved, yeast 
was employed as a model system in this study. This offered the advantage to express OPA1 
splice variants individually and to use ∆yta10∆yta12 yeast cells harbouring mammalian m-
AAA protease subunits. Hence, homo- and hetero-oligomeric m-AAA proteases with different 
subunit composition could be assessed for their ability to mediate human OPA1 processing in 
yeast. 
 Upon expression of single human OPA1 splice variants in yeast, OPA1 was 
recognised and cleaved by yeast and mammalian m-AAA proteases. Several lines of evidence 
support the validity of the yeast model for studying OPA1 processing. For all four splice 
variants, the OPA1 isoforms obtained after expression in yeast were similar in size to those 
detected in HeLa cells demonstrating that OPA1 was specifically processed and not 
completely degraded by the m-AAA protease. In particular, similar OPA1 isoforms could be 
observed when splice variants 1 and 4 were expressed in yeast cells harbouring a functional 
m-AAA protease or after transfection of HeLa cells (Olichon et al., 2006). The OPA1 
isoforms obtained for splice variants 1 and 7 in yeast are also comparable to those reported by 
Ishihara et al., 2006, upon expression of the corresponding splice variants from rat in HeLa 
cells. Last but not least, the mass spectrometric analysis of OPA1 isoforms purified from 
either HeLa cells or wild-type yeast cells containing OPA1 splice variants 7 or 8 showed a 
consistent peptide pattern for large and small isoforms (Duvezin-Caubet et al., 2007). 
Therefore, it can be concluded that OPA1 is processed in a similar manner in yeast and human 
mitochondria. 
 Expression of a single OPA1 splice variant in yeast cells gave rise to several S- and L-
isoforms of OPA1 directly demonstrating the proteolytic conversion of OPA1 to short 
isoforms. In wild-type yeast cells, the respective large isoforms of OPA1 splice variants 4, 7, 
and 8 were found to be converted mainly to S3 and S4 isoforms. Additionally, the OPA1 
splice variants 4 and 7 were processed to the S5 isoform, whereas expression of splice 
variant 1 almost exclusively resulted in the generation of the S4 isoform. Thus, both 
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alternative splicing and proteolytic processing apparently contribute to the pattern of OPA1 
isoforms as observed in HeLa cells. This was confirmed by mass spectrometric analysis of 
purified OPA1 isoforms from HeLa cells, which revealed that some isoforms could be derived 
from several OPA1 splice variants (Duvezin-Caubet et al., 2007). In the absence of Yta10 and 
Yta12, short isoforms were not generated upon expression of OPA1 splice variants indicating 
that the yeast m-AAA protease cleaves OPA1. This is consistent with a recent report about m-
AAA protease-mediated processing of rat OPA1 in yeast (Ishihara et al., 2006). The 
observation that the generation of L-isoforms is not affected is in agreement with the removal 
of the OPA1 presequence upon import into mitochondria by MPP (Ishihara et al., 2006). In 
summary, these data suggest that S-isoforms of OPA1 are generated by m-AAA protease-
mediated processing of L1- and L2-isoforms, which both originate from different splice 
variants. 
 Furthermore, OPA1 processing by homo- and hetero-oligomeric mammalian m-AAA 
proteases was reconstituted in yeast. The mammalian m-AAA protease has previously been 
linked to proteolytic processing of OPA1, since RNAi-mediated downregulation of human 
paraplegin in HeLa cells led to a modestly impaired processing of endogenous and over-
expressed rat OPA1 (Ishihara et al., 2006). Upon co-transfection of rat OPA1 and human 
paraplegin, an increased accumulation of S-isoforms as well as a direct interaction of both 
over-expressed proteins has been observed in HeLa cells (Ishihara et al., 2006). However, the 
over-expression of hAFG3L2 had no effect on processing of rat OPA1. In apparent contrast to 
these results, cleavage of OPA1 was not affected in fibroblasts of paraplegin-deficient mice 
under steady-state conditions and after dissipation of the membrane potential, respectively 
(Duvezin-Caubet et al., 2007). Moreover, upon reconstitution in yeast, homo-oligomeric m-
AAA proteases composed of murine Afg3l1, Afg3l2, or human AFG3L2 mediated processing 
of all four OPA1 splice variants analysed in this study. Thus, OPA1 processing in yeast can 
occur independently of murine paraplegin. Expression of paraplegin did not restore OPA1 
processing in m-AAA protease-deficient yeast cells, which is in line with the observation that 
this subunit lacks the ability to homo-oligomerise. Paraplegin could cleave OPA1 only when 
assembled into hetero-oligomeric m-AAA protease complexes containing Afg3l1 or Afg3l2. 
These findings in yeast provide a rationale for the normal pattern of OPA1 isoforms in 
paraplegin-deficient mice, since Afg3l1 and Afg3l2 can apparently substitute for the loss of 
paraplegin, which is not essential for OPA1 processing. The complete lack of short OPA1 
isoforms in the presence of proteolytically inactive mammalian m-AAA proteases, either 
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homo- or hetero-oligomeric, further supports the notion that OPA1 processing depends on the 
proteolytic activity of m-AAA proteases. 
 
 
 
 
Figure 26. Model of OPA1 processing in mammalian mitochondria. 
The newly imported precursor of OPA1 (P-OPA1) is matured by the mitochondrial processing 
peptidase (MPP) leading to the large isoform of OPA1 (L-OPA1). This isoform is integrated into the 
inner membrane (IM) and can receive further proteolytic processing mediated by the m-AAA protease, 
which can occur independently of paraplegin. Finally, short OPA1 isoforms (S-OPA1) are released 
into the intermembrane space (IMS), where they are associated with the inner membrane. The first 
transmembrane domain (TM1) is present in all OPA1 splice variants, whereas the presence of one or 
two additional hydrophobic stretches, termed TM2a and TM2b, varies between different splice 
variants. Only one additional hydrophobic segment is depicted here (TM2). m-AAA protease-
mediated OPA1 processing occurs in close proximity to TM2a or TM2b (Duvezin-Caubet et al., 
2007). OM, outer membrane; M, matrix space; MTS, mitochondrial targeting sequence; TOM, 
translocase of the outer membrane; TIM, translocase of the inner membrane. 
 
 The mammalian rhomboid protease PARL, the homologue of yeast Pcp1, has also 
been suggested to be involved in OPA1 processing, as both proteins were co-
immunoprecipiated in murine mitochondria (Cipolat et al., 2006). PARL regulates OPA1-
dependent cristae remodelling and plays a protective role against cytochrome c release and 
apoptosis. In this context, PARL was found to be responsible for the generation of low 
amounts of a soluble OPA1 isoform (Cipolat et al., 2006). OPA1 processing, however, was 
not significantly impaired upon RNAi-mediated downregulation in HeLa cells or in PARL-
deficient mouse cells (Cipolat et al., 2006; Ishihara et al., 2006; Duvezin-Caubet et al., 2007). 
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Consistently, neither the absence of yeast Pcp1 nor the presence of human PARL had an 
effect on processing of several OPA1 splice variants in the reconstituted yeast system 
(Duvezin-Caubet et al., 2007). Overexpression of PARL in m-AAA protease-deficient yeast 
cells did not lead to the generation of short OPA1 isoforms either. These results indicate that 
PARL is dispensable for OPA1 processing in mammals and that at most a small fraction of S-
isoforms is generated by rhomboid. 
 In summary, OPA1 biogenesis and proteolytic processing in mammalian mitochondria 
apparently proceed according to the following model (Fig. 26): Upon import into 
mitochondria via the TOM and TIM complexes, the matrix targeting signal of the OPA1 
precursor is cleaved off by MPP resulting in the L-isoform of OPA1, which is embedded into 
the inner membrane by its first transmembrane domain (Olichon et al., 2002). Further 
proteolytic processing is mediated by the m-AAA protease, either homo-or hetero-oligomeric, 
and generates S-isoforms, which are released into the intermembrane space, but stay 
peripherally associated with the inner membrane (Duvezin-Caubet et al., 2006). This cleavage 
occurs after the first transmembrane domain and most likely involves the m-AAA protease-
driven and ATP-dependent dislocation of this OPA1 segment from the membrane bilayer to 
allow proteolysis on the matrix side. However, a role of the Hsp70 import motor in this 
dislocation process cannot be excluded at the moment. Moreover, there is so far no evidence 
for a functional interplay between the m-AAA protease and the rhomboid protease as shown 
for the maturation of Ccp1 in yeast.  
 
4.4 OPA1 processing provides first evidence for different 
substrate specificities of m-AAA protease isoenzymes 
 The efficiency of OPA1 processing and the resulting pattern of short isoforms in yeast 
were dependent on the splice variant and the subunit composition of the mammalian m-AAA 
protease. In particular, homo-oligomeric m-AAA proteases converted OPA1 more efficiently 
to short isoforms than observed for hetero-oligomeric m-AAA proteases containing 
paraplegin. Regarding the homo-oligomeric enzymes, Afg3l1 complexes mediated OPA1 
processing more efficiently than human AFG3L2 and murine Afg3l2 complexes. In addition, 
the presence of Afg3l1 complexes preferentially led to S4 isoforms, whereas S3 isoforms 
were predominantly generated by hAFG3L2 and Afg3l2 complexes and paraplegin-
containing, hetero-oligomeric m-AAA proteases. These results provide first evidence for a 
varying substrate specificity of m-AAA proteases with different subunit composition and 
 
Discussion 90
suggest that certain short isoforms of OPA1 are potentially generated by certain m-AAA 
protease assemblies. However, additional factors might influence OPA1 recognition and 
processing in mammalian cells. For instance, the yeast prohibitin complex apparently had a 
weak inhibitory effect on m-AAA protease-mediated cleavage of some OPA1 splice variants 
in the reconstituted system. As a supercomplex consisting of the m-AAA protease and the 
prohibitin complex has also been identified in mammalian mitochondria (M. Metodiev and T. 
Langer, unpublished observation), an influence of prohibitins on OPA1 processing can be 
envisioned. 
 Potential limitations of the reconstituted system have to be considered. It is possible 
that the hybrid proteins containing mammalian m-AAA protease subunits are not fully active 
in the heterologous environment. Especially, this might be the case for mammalian paraplegin 
which does not homo-oligomerise and on its own exert proteolytic activity in yeast. 
Moreover, the observed decreased efficiency of OPA1 processing by paraplegin-containing 
m-AAA proteases is based on the analysis of paraplegin/Afg3l1E567Q and para-
plegin/Afg3l2E574Q complexes. Thus, this limited OPA1 cleavage could be attributed to a 
potential negative effect of proteolytic site mutations in the Afg3l1 and Afg3l2 subunits on 
the proteolytic activity of paraplegin. 
 Different efficiencies of OPA1 cleavage by mammalian m-AAA proteases in yeast 
could be on one hand explained by different binding specificities to OPA1. On the other hand, 
it is conceivable that m-AAA protease-mediated OPA1 processing involves the ATP-
dependent membrane dislocation of OPA1 segments from the inner membrane to facilitate 
cleavage on the matrix side. Thus, differences in the ATPase activities of m-AAA proteases 
with variable subunit composition could account for the different efficiencies of OPA1 
cleavage or the preferential formation of certain short isoforms. In case of the yeast m-AAA 
protease, a correlation of the efficiency of Ccp1 processing with the ATPase activities of m-
AAA protease variants has been demonstrated (Tatsuta et al., 2007). Similarly, m-AAA 
protease isoenzymes with a lower ATPase activity could promote dislocation of the first 
transmembrane and following OPA1 segments only to a lesser extent than proteolytic 
assemblies with high ATPase activity. 
 In conclusion, mammalian m-AAA protease subunits can assemble into several 
proteolytic complexes with different subunit composition mediating OPA1 processing with 
varying efficiencies. It is conceivable that this variable assembly of m-AAA proteases in 
addition to the expression of alternatively spliced OPA1 variants allows a tissue-specific 
adjustment of OPA1 isoforms needed for mitochondrial dynamics. 
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4.5 The versatile assembly of the mammalian m-AAA protease 
and its implications for the pathogenesis of HSP 
 HSP due to a paraplegin deficiency is a neurodegenerative disease, which is 
characterised by an intriguing tissue specificity. Only a subset of motor and sensory neurons 
is affected by axonal degeneration, although paraplegin is ubiquitously expressed. In the 
current model, HSP is caused ultimately by deficiencies of mitochondrial activities in axonal 
endings due to impaired axonal transport, which is of special importance for neurons with 
long axons. The variable assembly of mammalian m-AAA proteases and the varying relative 
abundance of murine m-AAA protease subunits in different tissues shed new light on the 
pathogenesis of HSP.  
 Remarkably, the lack of paraplegin per se does not cause a loss of m-AAA protease 
activity in mammalian cells. Instead, m-AAA proteases with a different subunit composition 
can be formed by the remaining m-AAA protease subunits depending on the tissue or cell 
type. In the mouse model of HSP, a hetero-oligomeric Afg3l1/Afg3l2 complex and due to the 
decreased relative abundance of Afg3l1 a predominant homo-oligomeric Afg3l2 complex are 
present in brain mitochondria. Similarly, human mitochondria isolated from HSP fibroblasts 
contain a homo-oligomeric hAFG3L2 complex in the absence of paraplegin, which is also 
expected to be present in human brain. The apparent lower molar concentration of Afg3l1 
compared to other m-AAA protease subunits in murine brain can thus also explain why a 
paraplegin-deficiency leads to similar phenotypic consequences in humans and mice, despite 
the presence of a third proteolytic subunit in mice. Taken together, these findings could at 
least partially explain the tissue specificity of mitochondrial defects causing HSP when 
paraplegin is absent. Similarly, a varying abundance of several mitochondrial translation 
factors in different tissues has also been identified to form the basis of tissue-specific 
oxidative phosphorylation defects due to mutations in EFG1, the mitochondrial translation 
factor (Antonicka et al., 2006). Another neurodegenerative disease, called Charcot-Marie-
Tooth disease type 2A (CMT2A), is caused by autosomal-dominant mutations in the 
mitofusin Mfn2 (Züchner et al., 2004). Homo- and hetero-oligomeric mitofusin complexes of 
Mfn1 and Mfn2, both mediating mitochondrial fusion, can be formed (Chen et al., 2003; Eura 
et al., 2003; Detmer and Chan, 2007). A low Mfn1 expression in specific cells has recently 
been suggested to underlie cell type-specific mitochondrial fusion defects in CMT2A as the 
ratio and number of functional mitofusin complexes is perturbed (Detmer and Chan, 2007). 
Thus, protein complexes with variable composition and tissue-specific differences in the 
 
Discussion 92
expression of their subunits may represent a general principle in mammalian cells to regulate 
mitochondrial processes in a tissue-specific manner. 
 A different substrate abundance or dependence represents another aspect of tissue 
specificity. However, the ribosomal subunit MrpL32 is currently the only known substrate of 
the mammalian m-AAA protease (Nolden et al., 2005). Defective MrpL32 processing in 
paraplegin-deficient mice leads to impaired mitochondrial protein synthesis, but it is unclear if 
this is the reason for axonal degeneration in HSP. Complementation studies in yeast have 
demonstrated the proteolytic activity of homo-oligomeric hAFG3L2 and Afg3l2 complexes 
and overlapping substrate specificity with hetero-oligomeric m-AAA proteases containing 
paraplegin. These homo-oligomeric m-AAA proteases can apparently exert important 
housekeeping functions in mitochondria challenging the view that defects in mitochondrial 
translation and/or protein quality control can sufficiently explain the development of HSP due 
to mutations in paraplegin. Consistently, the analysis of HSP fibroblasts lacking paraplegin 
has only revealed an impaired assembly of complex I but no general mitochondrial protein 
synthesis defect (Atorino et al., 2003). Mitochondrial translation was found to be reduced by 
50% in liver mitochondria of paraplegin-deficient mice (Nolden et al., 2005), but ATP 
synthesis was only modestly affected in spinal cord mitochondria of old mice (Ferreirinha et 
al., 2004). These observations could be simply explained by a reduced number of functionally 
active m-AAA proteases in the absence of paraplegin, but additionally suggest the existence 
of specific substrates of m-AAA proteases differing in their subunit composition, e.g. for 
paraplegin-containing m-AAA proteases. These paraplegin-specific substrates could be 
expressed in a tissue-specific manner providing a further rationale for cell-specific 
consequences of a loss of paraplegin in HSP. Alternatively, the impaired proteolysis of a 
specific substrate could only affect the mitochondrial functions of certain cells. 
 Apart from the identification of MrpL32, specific substrates of mammalian m-AAA 
proteases have remained elusive. However, the dynamin-like GTPase OPA1, which is 
required for mitochondrial fusion, may represent such a substrate. In mammals, OPA1 is 
proteolytically processed by m-AAA proteases with varying efficiencies depending on their 
subunit composition and the OPA1 splice variant as suggested by the results of the yeast 
model. Mutations in OPA1 lead to neurodegeneration in dominant optic atrophy type 1, which 
selectively affects retinal ganglion cells thus exhibiting a tissue-specificity different from HSP 
(Alexander et al., 2000; Delettre et al., 2000). Interestingly, optic atrophy has been found as 
an additional symptom in some paraplegin-deficient patients suffering from a complicated 
form of HSP (Casari et al., 1998). More significantly, enlarged and structurally abnormal 
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mitochondria appear at early stages at the synaptic terminals of motor axons in paraplegin-
deficient mice (Ferreirinha et al., 2004). Changes in the morphology of mitochondria are 
known to affect axonal transport of these organelles (Li et al., 2004; Chen and Chan, 2005; 
Verstreken et al., 2005). Consistently, mitochondria with aberrant morphology accumulate in 
axons of paraplegin-deficient mice further impairing axonal transport (Ferreirinha et al., 
2004). Thus, impaired OPA1 processing and, as a consequence, altered mitochondrial 
morphology might also play a role in the pathogenesis of HSP. On the contrary, OPA1 
processing is not significantly affected in paraplegin-deficient mice (Duvezin-Caubet et al., 
2007) and paraplegin-containing, hetero-oligomeric m-AAA proteases process OPA1 splice 
variants only to a minor extent in yeast. As tissue-specific differences in the expression and 
assembly of their subunits are hallmarks of mammalian m-AAA proteases, paraplegin-
containing m-AAA proteases might be crucial for OPA1 processing in specific tissues or cell 
types. 
 In view of the versatile assembly of mammalian m-AAA proteases and their potential 
differences in substrate specificity, the findings of this study further suggest that mutations in 
Afg3l1 or Afg3l2 may be linked to phenotypes different from HSP and may possibly affect 
different tissues. In line with this prediction, Afg3l2-deficient mice which recently have been 
generated exhibit a much more severe phenotype than paraplegin-deficient mice exemplified 
by a postnatal death (G. Casari, personal communication). 
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5 Abstract 
 The m-AAA protease, an ATP-dependent proteolytic complex in the mitochondrial 
inner membrane, controls protein quality and regulates ribosome assembly within 
mitochondria. Mutations in the human m-AAA protease subunit paraplegin cause hereditary 
spastic paraplegia (HSP) characterised by cell-specific axonal degeneration which is also 
observed in a paraplegin-deficient mouse model. It has been proposed that paraplegin 
mediates proteolytic processing of OPA1 which is essential for mitochondrial morphology 
and linked to dominant optic atrophy, another neurodegenerative disease in humans. 
Paraplegin assembles with homologous Afg3l2 subunits into hetero-oligomeric complexes, 
but the consequences of a loss of paraplegin for m-AAA protease assembly and function 
remain unclear. Moreover, a third putative m-AAA protease subunit, termed Afg3l1, is 
expressed in mice but its role for m-AAA protease activity has not been determined. 
 The assembly status of human AFG3L2 was monitored in paraplegin-deficient 
mitochondria from human HSP cells revealing the existence of a homo-oligomeric AFG3L2 
complex which was also formed upon heterologous expression in yeast. This AFG3L2 
complex is proteolytically active as it could substitute for the yeast m-AAA protease. In 
related complementation studies in yeast, murine m-AAA protease subunits were found to 
assemble into several proteolytic complexes with variable subunit composition in the 
mitochondrial inner membrane. Homo-oligomeric Afg3l1 and Afg3l2 complexes and hetero-
oligomeric complexes of both proteins with paraplegin could be identified. Afg3l1 was 
established as a bona fide subunit of m-AAA proteases with proteolytic activity. All 
assemblies have conserved and overlapping substrate specificities as they were able to 
maintain mitochondrial housekeeping functions in yeast. These results suggest that the lack of 
paraplegin does not lead to a complete loss of m-AAA protease activity in affected 
mitochondria. Instead, m-AAA protease complexes with a different subunit composition 
could be formed which may substitute for paraplegin-containing m-AAA proteases. First 
evidence for different substrate specificities of m-AAA proteases differing in their subunit 
composition was obtained by reconstitution of OPA1 cleavage in yeast cells harbouring 
different mammalian m-AAA protease complexes. The efficiency of OPA1 processing was 
dependent on the subunit composition of mammalian m-AAA proteases. Homo-oligomeric 
complexes composed of murine Afg3l1, Afg3l2, or human AFG3L2 cleaved OPA1 with 
higher efficiency than hetero-oligomeric complexes containing paraplegin. This also confirms 
OPA1 as a novel potential substrate of the m-AAA protease. Taken together, these findings 
reveal an unexpected variety of mammalian m-AAA proteases in the inner mitochondrial 
membrane and may help to understand the pathogenesis and tissue-specificity of HSP due to a 
loss of paraplegin. 
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AAA   ATPases associated with a variety of cellular activities 
Aβ   amyloid β−peptide 
ABC   ATP-binding cassette 
ADOA  autosomal dominant optic atrophy 
ADP   adenosine diphosphate 
APP   amyloid precursor protein 
APS   ammoniumperoxo disulfate 
ATP   adenosine triphosphate 
bp   base pairs 
BN   blue native 
cDNA   complementary DNA 
CEN   centromere 
CMT2A  Charcot-Marie-Tooth type 2A 
DMSO  dimethyl sulfoxide 
C-terminal  carboxyterminal 
C-terminus  carboxy terminus 
DNA   deoxyribonucleic acid 
EDTA   ethylene diamine tetraacetic acid 
Fig.   Figure 
g   standard gravity 
GTP   guanosine triphosphate 
h   hour(s) 
HA   hemagglutinin 
HCl   hydrochloric acid 
HEPES  N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic-acid 
HSP   hereditary spastic paraplegia 
IMP   inner membrane peptidase 
K   potassium 
kb   kilobase pairs 
KCl   potassium chloride 
kDa   kilodalton 
KOH   potassium hydroxide 
m   meter 
M   molar (mole per liter) 
mA   milliampere 
MDa   megadalton 
µg   microgram 
µl   microliter 
mg   milligram 
ml   milliliter 
Mg   magnesium 
min   minute(s) 
MIP   mitochondrial intermediate peptidase 
mM   millimolar 
MPP   mitochondrial processing peptidase 
mRNA  messenger RNA 
mtDNA  mitochondrial DNA 
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MTS   mitochondrial targeting sequence 
NaCl   sodium chloride 
NADH  nicotinamide adenine dinucleotide (reduced form) 
NaOH   sodium hydroxide 
NP-40   Nonidet P-40 
N-terminal  aminoterminal 
N-terminus  amino terminus 
OD600   optical density at a wavelength of 600 nanometer 
PAGE   polyacrylamide gel electrophoresis 
PAS   Protein A Sepharose 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PMSF   phenylmethylsulphonyl fluoride 
PVDF   polyvinylidene fluoride 
RNA   ribonucleic acid 
RNAi   RNA interference 
ROS   reactive oxygen species 
rpm   rounds per minute 
RT   room temperature 
s   second(s) 
SDS   sodium dodecyl sulfate 
SPG   spastic paraplegia gene 
SRH   second region of homology 
Tab.   Table 
TBS   Tris buffered saline 
TCA   trichloracetic acid 
TEMED  N,N,N',N'-Tetramethylethylenediamine 
TIM   translocase of the inner membrane 
TM   transmembrane domain 
TOM   translocase of the outer membrane 
Tris   2-amino-2-(hydroxymethyl)-1,3-propandiole 
U   unit(s) 
UPS   ubiquitin-proteasome system 
v/v   volume per volume 
V   volt 
WT   wild-type 
w/v   weight per voulme 
XIAP   X chromosome-linked inhibitor of apoptosis protein 
YP   yeast extract-peptone 
YPD   yeast extract-peptone with glucose 
YPG   yeast extract-peptone with glycerol 
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Teilpublikationen im Rahmen dieser Arbeit: 
 
Atorino, L., Silvestri, L., Koppen, M., Cassina, L., Ballabio, A., Marconi, R., Langer, T., 
and Casari, G. (2003) 
“Loss of m-AAA protease in mitochondria causes complex I deficiency and increased 
sensitivity to oxidative stress in hereditary spastic paraplegia.” 
Journal of Cell Biology 163: 777-787. 
 
 
Abstract: 
Mutations in paraplegin, a putative mitochondrialmetallopeptidase of the AAA family, cause 
an autosomal recessive form of hereditary spastic paraplegia (HSP). Here, we analyze the 
function of paraplegin at the cellular level and characterize the phenotypic defects of HSP 
patients’ cells lacking this protein. We demonstrate that paraplegin coassembles with a 
homologous protein, AFG3L2, in the mitochondrial inner membrane. These two proteins 
form a high molecular mass complex, which we show to be aberrant in HSP fibroblasts. The 
loss of this complex causes a reduced complex I activity in mitochondria and an increased 
sensitivity to oxidant stress, which can both be rescued by exogenous expression of wild-type 
paraplegin. Furthermore, complementation studies in yeast demonstrate functional 
conservation of the human paraplegin–AFG3L2 complex with the yeast m-AAA protease and 
assign proteolytic activity to this structure. These results shed new light on the molecular 
pathogenesis of HSP and functionally link AFG3L2 to this neurodegenerative disease. 
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Nolden, M., Ehses, S., Koppen, M., Bernacchia, A., Rugarli, E. I., and Langer, T. (2005) 
“The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly 
in mitochondria.” 
Cell 123: 277-289. 
 
 
Abstract: 
AAA proteases comprise a conserved family of membrane bound ATP-dependent proteases 
that ensures the quality control of mitochondrial inner-membrane proteins. Inactivation of 
AAA proteases causes pleiotropic phenotypes in various organisms, including respiratory 
deficiencies, mitochondrial morphology defects, and axonal degeneration in hereditary spastic 
paraplegia (HSP). The molecular basis of these defects, however, remained unclear. Here, we 
describe a regulatory role of an AAA protease for mitochondrial protein synthesis in yeast. 
The mitochondrial ribosomal protein MrpL32 is processed by the m-AAA protease, allowing 
its association with preassembled ribosomal particles and completion of ribosome assembly in 
close proximity to the inner membrane. Maturation of MrpL32 and mitochondrial protein 
synthesis are also impaired in a HSP mouse model lacking the m-AAA protease subunit 
paraplegin, demonstrating functional conservation. Our findings therefore rationalize 
mitochondrial defects associated with m-AAA protease mutants in yeast and shed new light 
on the mechanism of axonal degeneration in HSP. 
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Koppen, M.*, Metodiev, M. D.*, Casari, G., Rugarli, E. I., and Langer, T. (2007) 
“Variable and tissue-tpecific subunit composition of mitochondrial m-AAA protease 
complexes linked to hereditary spastic paraplegia.” 
Molecular and Cellular Biology 27: 758-767. 
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Abstract: 
The m-AAA protease, an ATP-dependent proteolytic complex in the mitochondrial inner 
membrane, controls protein quality and regulates ribosome assembly, thus exerting essential 
housekeeping functions within mitochondria. Mutations in the m-AAA protease subunit 
paraplegin cause axonal degeneration in hereditary spastic paraplegia (HSP), but the basis for 
the unexpected tissue specificity is not understood. Paraplegin assembles with homologous 
Afg3l2 subunits into hetero-oligomeric complexes which can substitute for yeast m-AAA 
proteases, demonstrating functional conservation. The function of a third paralogue, Afg3l1 
expressed in mouse, is unknown. Here, we analyze the assembly of paraplegin into m-AAA 
complexes and monitor consequences of paraplegin deficiency in HSP fibroblasts and in a 
mouse model for HSP. Our findings reveal variability in the assembly of m-AAA proteases in 
mitochondria in different tissues. Homo-oligomeric Afg3l1 and Afg3l2 complexes and hetero-
oligomeric assemblies of both proteins with paraplegin can be formed. Yeast 
complementation studies demonstrate the proteolytic activity of these assemblies. Paraplegin 
deficiency in HSP does not result in the loss of m-AAA protease activity in brain 
mitochondria. Rather, homo-oligomeric Afg3l2 complexes accumulate, and these complexes 
can substitute for housekeeping functions of paraplegin-containing m-AAA complexes. We 
therefore propose that the formation of m-AAA proteases with altered substrate specificities 
leads to axonal degeneration in HSP. 
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Koppen, M. and Langer, T. (2007) 
“Protein degradation within mitochondria: Versatile activities of AAA proteases and other 
peptidases.” 
Critical reviews in Biochemistry and Molecular Biology 42: 221-242. 
 
 
Abstract: 
Cell survival depends on essential processes in mitochondria. Various proteases within these 
organelles regulate mitochondrial biogenesis and ensure the complete degradation of excess 
or damaged proteins. Many of these proteases are highly conserved and ubiquitous in 
eukaryotic cells. They can be assigned to three functional classes: processing peptidases, 
which cleave off mitochondrial targeting sequences of nuclearly encoded proteins and process 
mitochondrial proteins with regulatory functions; ATP-dependent proteases, which either act 
as processing peptidases with regulatory functions or as quality control enzymes degrading 
non-native polypeptides to peptides; and oligopeptidases, which degrade these peptides and 
mitochondrial targeting sequences to amino acids. Disturbances of protein degradation within 
mitochondria cause severe phenotypes in various organisms and can lead to the induction of 
apoptotic programmes and cell-specific neurodegeneration in mammals. After an overview of 
the proteolytic system of mitochondria, we will focus on versatile functions of ATP-
dependent AAA proteases in the inner membrane. These conserved proteolytic machines 
conduct protein quality surveillance of mitochondrial inner membrane proteins, mediate 
vectorial protein dislocation from membranes, and, acting as processing enzymes, control 
ribosome assembly, mitochondrial protein synthesis, and mitochondrial fusion. Implications 
of these functions for cell-specific axonal degeneration in hereditary spastic paraplegia will be 
discussed. 
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“OPA1 processing reconstituted in yeast depends on the subunit composition of the m-AAA 
protease in mitochondria.” 
Molecular Biology of the Cell in press 
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Abstract: 
The morphology of mitochondria in mammalian cells is regulated by proteolytic cleavage of 
OPA1, a dynamin-like GTPase of the mitochondrial inner membrane. The mitochondrial 
rhomboid protease, PARL, as well as paraplegin, a subunit of the ATPdependent m-AAA 
protease, were proposed to be involved in this process. Here, we characterized individual 
OPA1 isoforms by mass spectrometry and reconstituted their processing in yeast to identify 
proteases involved in OPA1 cleavage. The yeast homolog of OPA1, Mgm1, was processed 
both by PARL and its yeast homolog Pcp1. Neither of these rhomboid proteases cleaved 
OPA1. The formation of small OPA1 isoforms was impaired in yeast cells lacking the m-
AAA protease subunits Yta10 and Yta12 and was restored upon expression of murine or 
human m-AAA proteases. OPA1 processing depended on the subunit composition of 
mammalian m-AAA proteases. Homooligomeric m-AAA protease complexes composed of 
murine Afg3l1, Afg3l2, or human AFG3L2 subunits cleaved OPA1 with higher efficiency 
than paraplegincontaining m-AAA proteases. OPA1 processing proceeded normally in murine 
cell lines lacking paraplegin or PARL. Our results provide evidence for different substrate 
specificities of m-AAA proteases composed of different subunits and reveal a striking 
evolutionary switch of proteases involved in the proteolytic processing of dynamin-like 
GTPases in mitochondria. 
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